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Research summary 
Osteosarcoma (OS) is the most common malignant primary bone tumour in dogs and 
humans. OS is an aggressive malignancy that occurs mostly in the appendicular skeleton of 
both dogs and humans. OS classification is based on its malignant stroma and formation of 
extracellular matrix into osteoblastic, chondroblastic or fibroblastic OS. The characterisation 
of an appropriate natural disease animal model to study human OS is essential to elucidate the 
pathogenesis of the disease. Several studies have established the vital role of parathyroid 
hormone-related protein (PTHrP) and its receptor (PTHR1) in bone formation and remodeling. 
In addition, these molecules play a role in the progression and metastasis of several human 
tumour types. Novel prognostic indicators are crucial to determine a better outcome for cancer 
patients. 
The current study aimed to validate canine OS as a model for the human disease by 
immunohistochemically evaluating the expression of markers known to be important in human 
OS including vimentin, alkaline phosphatase (ALP), desmin, S100, neuron-specific enolase 
(NSE), runt-related protein 2 (Runx2) and bone morphogenetic protein 4 (BMP4). In addition, 
the localisation of PTHR1 and PTHrP in canine OS tissues was investigated and their 
prognostic values were assessed. The correlation between the three histological subtypes of 
canine OS and a clinical outcome was determined. The study also examined whether there was 
any difference in the immunostaining of desmin, S100 and NSE among the three histological 
subtypes. 
The validation of canine OS as a model for human OS utilised immunostaining of 
canine OS samples with antibodies specific for vimentin, ALP, desmin, S100, NSE, Runx2 and 
BMP4 which were compared with those previously described for human OS. 
Immunohistochemistry was conducted on formalin-fixed, paraffin-embedded (FFPE) tissue 
sections from 56 dogs (Bristol-56 group) with confirmed primary OS. Vimentin, ALP, Runx2 
 xxx 
 
and BMP4 were highly expressed by all tumours, while desmin, S100, NSE had variable 
expressions. 
Before this study, there was no information about the immunostaining of PTHR1 and 
PTHrP and their prognostic values in canine OS. FFPE tissue samples from 50 dogs (Australian 
Specialised Animal Pathology laboratory (ASAP)-50 group) diagnosed with 
primary OS were immunostained with antibodies specific for PTHR1 and PTHrP. The staining 
intensity of PTHR1 and PTHrP was correlated with survival time. Both PTHR1 and PTHrP 
were detected in all OS samples (n= 50). Dogs with strongly stained OS tumours for PTHR1 
had remarkably shorter survival times (mean survival time=  61 ± 11 days, n= 21 dogs) when 
compared with those with OS showing moderate (mean survival time=  227 ± 36 days, n= 27 
dogs) or weak staining (mean survival time= 580 ± 122  days, n= 2 dogs) (P= 0.000023, log-
rank test). Moreover, univariate (P= 0.002) and multivariate (P= 0.002) Cox regression 
analyses suggested that the staining intensity of PTHR1 was an independent prognostic 
indicator for overall survival. However, PTHrP staining intensity did not correlate with survival 
time (P > 0.05). 
The association between the three histological subtypes of canine OS and clinical 
outcomes was investigated and the difference in the localisation of desmin, S100 and NSE 
among these three histological subtypes was examined. Primary canine OS tissue sections from 
106 dogs (Bristol-56 and ASAP-50) comprising osteoblastic (n= 61 dogs), chondroblastic (n= 
24 dogs) and fibroblastic (n= 21 dogs) were examined. The survival times correlated with OS 
subtypes (n= 50 dogs). Dogs with chondroblastic OS showed significantly decreased survival 
times (mean survival time= 104 ± 22 days, n= 11 dogs) in comparison to those with osteoblastic 
(mean survival time= 168 ± 33 days, n= 33 dogs) or fibroblastic OS (mean survival time= 463 
± 116 days, n= 6 dogs) (P= 0.037, log-rank test). Furthermore, the current study showed that 
the histological subtypes of OS were an independent prognostic factor for overall survival (Cox 
 xxxi 
 
regression: univariate, P= 0.037; multivariate, P= 0.030). The study’s findings also indicated 
that there was no significant correlation between the localisation of desmin, NSE or S100 and 
histological subtypes (n= 56 dogs). 
In conclusion, this project demonstrated that the localisation of vimentin, ALP, desmin, 
S100, NSE, Runx2 and BMP4 in canine OS were similar to those described previously for 
human OS and suggested that canine OS may represent a useful model for the study of the 
disease in humans. More importantly, it was also showed that increased expression of PTHR1 
antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be 
useful as a prognostic indicator in canine OS. Dogs with chondroblastic OS also had a poorer 
prognosis when compared to dogs with other subtypes. This suggests that the histological 
subtypes of canine OS have differing behaviours and could be used to categorise patients for 
risk-based assessment. Finally, the localisation of desmin, S100 and NSE were not correlated 
with the histological subtypes of canine OS. 
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Chapter 1 
1.0 Introduction 
1.1 History of osteosarcoma 
Primary bone tumours form about 0.2% of all human tumours and they can either be 
benign or malignant (Dorfman, et al. 2002). These tumours are ancient diseases and the 
discovery dates back to the fifth Egyptian era (Smith and Dawson 1924). Osteosarcoma (OS) 
is the most prevalent type of primary malignant bone tumours in humans under the age of 30 
(Cade 1955; Jeffree, et al. 1975). Brostrom (1980) mentioned that the term osteosarcoma was 
first used in 1807 by the French surgeon Alexis Boyer and the first efforts to classify bone 
tumours into benign or malignant were made in 1860 by the French surgeon Auguste Nelaton. 
Since then, a number of scientists have presented additional systematic classifications of bone 
tumours (Ewing 1939; Cade and Scarff 1947; Lichtenstein 1951; Jaffe 1958; Dahlin 1973). OS 
is also known as osteogenic sarcoma and refers to the histological hallmark of this disease, 
which is the presence of immature bone or osteoid that is produced by neoplastic bone cells 
(Lewis and Lotz 1974; Dahlin 1975).      
1.2 Bone structure and development 
Bone is a key component of the skeletal system which has dual roles of structural 
support and storing lipids and minerals (Jee 2001). Bone also helps in protecting internal 
organs, it aids in the production of blood cells and assists with movements of the body (Jee 
2001). 
In humans and many other animals, bone is categorized as either ''soft bone'', which is 
also known as cancellous or trabecular bone, or "hard bone" otherwise known as cortical bone 
(Rho, et al. 1998). Compared to cancellous bone, cortical bone is hard and dense due to 80 to 
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90% of it being calcified (Neto and Ferreira 2018). The ratio of cortical to cancellous bone 
differs with its anatomical location (Brook, et al. 2005). 
Studies have found that the quality and quantity of bone are not the same in all 
individuals, and that these characteristics vary depending on age, sex and race (Brook, et al. 
2005). Other factors such as demographic location and level of activity may affect these 
characteristics also (Rho, et al. 1998). 
Bone tissue has a complex structure. Generally, it consists of different organic and 
inorganic components such as water, collagen, non-collagenous proteins, proteoglycans and 
hydroxyapatite (Heeley and Irving 1973; Ali 1987; Boskey, et al. 2002). Organic elements are 
responsible for providing the tension characteristics (Heeley and Irving 1973; Ali 1987; 
Ginebra, et al. 2000), whereas inorganic elements are involved in providing stiffness and 
compression strength properties (Glimcher 1987; Ginebra, et al. 2000; Lucchinetti 2001). 
Bone has four types of cells (Figure 1.1) and each cell is classified according to its 
function. The first type of cell are the osteocytes, which are mature osteoblasts located in the 
bone matrix. These cells are involved in the process of bone remodelling (Miller and Jee 1992). 
Osteocytes also play a role in sending signals of formation or resorption of bone as a result of 
mechanical stress (Kuhl, et al. 2000; Kurata, et al. 2006). Osteocytes use dendritic processes to 
connect to each other, to the bone surface cells, to bone marrow (Kamioka, et al. 2001; 
Bonewald 2007) and this communication is carried out via small canals called canaliculi 
(Bonewald 2007). Cell communication by osteocytes enable them to recruit precursors of 
osteoclasts, which results in stimulating bone resorption (Baylink, et al. 1973; Zhao, et al. 2002) 
and regulating the differentiation of mesenchymal stem cells (Han, et al. 2004). The second 
type of cells are osteoblasts, which are differentiated mesenchymal cells, and are responsible 
for the formation of new bone (Currey 2002). The third type of cell are osteogenic cells that 
are an inactivated form of osteoblasts, and can only be activated by mechanical or/and chemical 
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stimulation (Miller and Jee 1992). They can be seen on the surface of bone after production of 
new bone has stopped. The final type of cells are the osteoclasts, which are produced in bone 
marrow. In the process of bone resorption, osteoclasts are involved in the degradation of 
organic matrix catalysed by enzymes such as tartrate-resistant acid phosphatase (TRAP), 
cathepsin (Cp), matrix metalloproteinase-9 (MMP-9) and demineralising the surface of the 
bone by producing acidic hydrogen (H+) and bicarbonate (HCO3−) ions (Miller and Jee 1992). 
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Figure 1.1 The four types of bone cells, their function and location. (Boundless 2018). 
Osteocytes are located in the bone matrix and are involved in the process of bone remodelling. 
Osteoblasts and osteogenic cells are located on the surface of the bone. Osteoblasts are 
responsible for the formation of new bone, while osteogenic cells can only be activated by 
mechanical or/and chemical stimulation. Osteoclasts are involved in the degradation of organic 
matrix catalysed by enzymes such as tartrate-resistant acid phosphatase (TRAP), cathepsin 
(Cp), matrix metalloproteinase-9 (MMP-9) and demineralising the surface of the bone by 
producing acidic hydrogen (H+) and bicarbonate (HCO3
−) ions. 
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1.2.1 Bone remodelling 
The remodelling of bone is a dynamic process that occurs throughout life. Normal bone 
remodelling has two main processes: bone resorption via osteoclasts followed by bone 
formation via osteoblasts (Frost 1964). After bone damage or stress placed on the bone, 
osteocytes send signals via cytokines, hormones and growth factors to osteoclasts to start bone 
resorption (Chambers 1980; Rodan and Martin 1981). Then, osteoblasts are recruited to deposit 
matrix of bone in the lacuna, followed by mineralisation (Burr, et al. 1996; Everts, et al. 2002). 
Remodelling helps the structure and mass of the bone to adapt to mechanical needs. 
Parathyroid and estrogen hormones play critical roles in regulating the remodelling rate and 
activation of bone cells (Howard, et al. 1981; Westerlind, et al. 1997). Bone remodelling is 
regulated via the receptor activator of the nuclear factor kappa-B ligand (RANKL) pathway, 
which is one of the tumour necrosis factor ligand family members (Bord, et al. 2003; Chen, et 
al. 2004). RANKL is produced by osteoblasts and binds to the surface of osteoclasts via RANK 
receptors. Conversely, osteoprotegerin (OPG), which is secreted by osteoblasts inhibits the 
activation of osteoclasts by acting as a decoy receptor for RANKL (Figure 1.2). The balance 
between the production of RANKL and the secretion of OPG is critical for the successful and 
normal remodelling of bone (Bord, et al. 2003; Chen, et al. 2004). 
During the life of the organism, bone can be affected by many abnormalities. These 
abnormalities range from fractures to bone tumours (Currey 2002; Lee 2014). Even though 
bone tumours are rare, they can be extremely aggressive (Mirabello, et al. 2009b, a) 
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Figure 1.2 Regulation of bone remodelling. Bone remodelling is regulated by receptor 
activator of nuclear factor kappa-B ligand (RANKL). RANKL is synthesised by osteoblasts 
and binds to RANK receptors located on the surface of osteoclasts. Osteoprotegerin (OPG) is 
produced by osteoblasts and it inhibits the activation of osteoclasts by acting as a decoy 
receptor for RANKL. (Modified from (Lustberg, et al. 2012)). 
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1.3 Incidence and classification of bone cancer 
Primary bone tumours are relatively uncommon, forming around 0.2% of all human 
tumours and can be classified as malignant or benign (Dorfman, et al. 2002). Benign bone 
tumours arise from bone or cartilage and are more likely seen in childhood and adolescence 
(Unni and Inwards 1996). The most common body sites that can be affected by these benign 
tumours are the proximal humerus, the distal femur and the proximal tibia (Unni and Inwards 
1996). Bone tumours arise from osteoblasts, osteoclasts, chondrocytes and soft tissue related 
to bone such as muscle and lipid (Dorfman, et al. 2002). According to the World Health 
Organization (WHO), examples of benign bone tumours are osteochondroma, enchondroma, 
chondroblastoma, osteoid osteoma, chondromyxoid fibroma, giant cell tumour and 
osteoblastoma (Dorfman, et al. 2002). 
OS and Ewing’s sarcoma are the most common types of malignant primary bone 
tumours and are mostly seen in children and adolescents (Lee 2014). Other uncommon 
malignant tumours of bone include chordoma, fibrosarcoma and angiosarcoma (Dorfman, et 
al. 2002). The aetiology of these tumours is not yet clear (Lindsey, et al. 2017). However, 
previous evidence suggests that chronic inflammation and radiation may be the cause of 
malignant bone tumours (Wei-wei, et al. 2005; Jin, et al. 2017). 
Despite not having specific clinical features, swelling, discomfort, pain, spontaneous 
fracture and limited mobility are the most common symptoms that may lead to the diagnosis 
of a malignant bone tumour (Levesque, et al. 1998; Dorfman, et al. 2002; Pan, et al. 2010). 
In 2012, 2890 new cases of primary bone cancer were diagnosed and 1410 deaths 
occurred due to this cancer in the USA alone (Siegel, et al. 2012) The most common type of 
primary bone cancer was OS with a total number of about 1000 new cases being diagnosed 
annually (Amankwah, et al. 2013). 
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Bone tumour classification is determined by the products of tumour cells and 
histological morphology (Campanacci 1999). For example, OS, osteoblastoma, 
chondrosarcoma and chondroma tumours are categorised based on the cellular production of 
an osteoid or chondroid matrix (Campanacci 1999), whereas fibrogenic tumours are 
characterised by the production of collagen matrix (Bertoni and Bacchini 1998). Alternatively, 
the diagnosis of some other bone tumours is based on the similarity to normal tissue (Bertoni 
and Bacchini 1998). For example, chordoma is diagnosed based on the comparison with the 
notochord (Bertoni and Bacchini 1998). However, there are exceptions to the previous rule of 
diagnosis. For example, Ewing's sarcoma is known to be a tumour of unidentified histogenesis 
and the diagnosis depends on cytological characteristics rather than any similarity to normal 
tissue (Bertoni and Bacchini 1998). 
Bone tumours are classified into the following groups: 
1.3.1 Cartilage tumours 
The histological features of these tumours suggest that they have a link with hyaline 
cartilage (Marco, et al. 2000) and are usually diagnosed as a primary or a conventional 
chondrosarcoma. Examples of benign cartilage tumours are chondroma, osteochondroma and 
chondroblastoma. Cartilage is produced by malignant chondrosarcomas (Marco, et al. 2000). 
1.3.2 Osteogenic tumours 
OS is the most common type of malignant osteogenic tumour (Bielack, et al. 2009; 
Yang, et al. 2018), whereas osteoblastoma and osteoid osteoma are examples of benign 
osteogenic tumours. Production of osteoid matrix via malignant tumour cells is the most 
significant feature that helps in diagnosing OS (Walaas and Kindblom 1990). OS tumours will 
be discussed extensively in section 1.4. 
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1.3.3 Rare bone tumours    
Rare groups of bone tumours include fibrogenic tumours such as fibrosarcoma, 
histiocytic tumours, notochordal tumours such as chordoma, lipogenic bone tumours, 
neurogenic bone tumours, tumours of vascular origin and tumours of unknown differentiation 
or origin such as giant cell, adamantinoma and Ewing's sarcoma (Bertoni and Bacchini 1998). 
Neoplastic cells of fibrogenic tumours produce collagen but not a mineralising matrix and high 
grade tumours of fibrogenic origin may not have any matrix at all (Fornasier, et al. 2002). 
Chondroma tumours form lobules, which are separated via fibrous bands and neoplastic cells 
that are floating singularly, as cords or sheets within the myxoid stroma (Mirra, et al. 2002). 
Haemangiomas are types of vascular tumours and are characterised by the presence of 
capillaries with thin walls and blood-filled vessels lined by a single layer of flat endothelial 
cells (Adler and Wold 2002). The morphology of Ewing’s sarcoma varies from uniform small 
round cells with round nuclei to larger cells with prominent nucleoli and it is uncommon to see 
a spindle cell morphology (Ushigome, et al. 2002). In addition, the cytoplasm of neoplastic 
cells of Ewing’s sarcoma is PAS positive for glycogen (Ushigome, et al. 2002). 
1.4 Definition of OS 
OS or so-called osteogenic sarcoma is defined as the malignancy that originates from 
bone-forming mesenchymal cells (Lewis and Lotz 1974; Dahlin 1975; Bielack, et al. 2009; 
Mohseny, et al. 2009; Xiao, et al. 2013). This tumour is also known as the “growing bone 
tumour” (Lee 2014). It has been also defined as the tumour of malignant spindle-cells in which 
tumour cells produce immature bone, or osteoid or both (Kirpensteijn, et al. 2002). OS is known 
as the primary malignant tumour of the skeleton in which tumour cells directly form immature 
bone or osteoid (Raymond, et al. 2002). As mentioned previously, the production of malignant 
osteoid is the histological hallmark of OS (Walaas and Kindblom 1990). 
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OS is the most prevalent type of primary bone cancer in both humans and dogs (Brodey 
and Riser 1969; Mirabello, Pfeiffer, et al. 2011; Kansara, et al. 2014; Yang, et al. 2018). OS 
occurs more frequently in children, adolescents, tall humans, and in large breeds of dogs 
(Mirabello, Pfeiffer, et al. 2011; Sapierzynski and Czopowicz 2017). In both species, OS 
mostly affects the ends of long bones near the metaphyseal regions (Mirabello, et al. 2009b; 
Mirabello, Pfeiffer, et al. 2011). Femur, tibia, and humerus are the locations that are most often 
affected by OS in humans (Dorfman, et al. 2002). 
The exact aetiology behind OS is still not known but there are some factors that may 
play a role in its development (Morello, et al. 2011; Ehrhart, et al. 2012). One of these factors 
is ionising radiation produced by exposure to radioisotopes such as 239Plutonium and 
241Americium (Lloyd, et al. 1993; Lloyd, et al. 1994; Muggenburg, et al. 1996) and chronic 
trauma (Riser, et al. 1972; Sinibaldi, et al. 1976). Other factors include chemicals such as 
chromium salts, methylcholanthrene (Rani and Kumar 1992), asbestos, aniline dyes (Tan, et 
al. 2009), beryllium oxide (Dutra and Largent 1950), zinc beryllium silicate (Mazabraud 1975) 
and genetic mutations such as the mutation of p53, Rb, erb-B2 and ezrin (Wadayama, et al. 
1994; Flint, et al. 2004; Kirpensteijn, et al. 2008). It has also been shown that there is an 
association between simian virus 40 (SV40) infection, and OS pathogenesis (Mendoza, et al. 
1998). Pain, swelling and limited joint movement are the most common symptoms of OS in 
humans and dogs (Dernell, et al. 2007; Messerschmitt, et al. 2009). 
OS is morphologically sub-classified into three different subtypes: fibroblastic, 
osteoblastic and chondroblastic OS (Fletcher, et al. 1994; Kirpensteijn, et al. 2002). There are 
great variations in the histological characteristics of OS from one tumour subtype to another, 
and even within the same tumour subtype. Different types of undifferentiated cells and matrix 
are frequently seen in a single OS tumour. According to  Kirpensteijn, et al. (2002), sub-
classification of OS may not give major differences in the prognosis of OS. On the other hand, 
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several studies reported that sub-classification of OS could be an indicator for prognosis in 
both humans (Paparella, et al. 2013) and dogs (Hammer, et al. 1995). Classification of OS will 
be discussed in detail in section 1.4.4. 
1.4.1 Incidence of OS 
In humans, the prevalence of sarcomas differs with age. In adults, sarcomas represent 
1% of all cancers, in children they represent 10%, and in teenagers and young adults these 
cancers represent 8% of all cancer (Amankwah, et al. 2013).  
Worldwide, the incidence of human OS is known to have a bimodal age distribution 
(Mirabello, et al. 2009b) with the highest incidence in children and young adults (0-24 years), 
and the second peak in the elderly (60+ years) (Mirabello, et al. 2009b) (Figure 1.3). In 
addition, data show that humans younger than 40 years have five-year survival rates of around 
74.9%, whereas patients older than 65 years have a worse prognosis (32.7%) (Tsuda, et al. 
2018). In dogs, the two-year survival rate for patients with localised OS is approximately 20% 
(Shoeneman, et al. 2012). 
Humans with localised OS have five-year survival rates of around 65%, whereas 
patients with metastatic OS have a much worse prognosis with a survival rate of 20% (Li and 
Ye 2014). The five-year survival rate is much worse in metastatic OS because OS mostly 
metastasizes to lungs causing lung cancer (Raymond, et al. 2002; Selvarajah and Kirpensteijn 
2010). 
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Figure 1.3 Incidence of human OS shows a bimodal age distribution. (Modified from 
(Mirabello, et al. 2009b)). The first peak of OS incidence is located in the age range of 0-24 
years. The second peak is smaller and includes people older than 60 years. This distribution of 
age at diagnosis was carried out independent of OS subtype and gender. 
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The highest incidence rates of OS in the USA were in the ages 0-24 and >60 years (see 
Table 1.1) (Mirabello, et al. 2009a). The international incidence of OS in males (about 5.4 
males in every million per year) has been confirmed to be higher than the incidence of OS in 
females in all ages (about 4 females in every million per year) (Mirabello, et al. 2009a; 
Ottaviani and Jaffe 2009). In the USA, around 1000 new cases of human OS are diagnosed 
every year (Amankwah, et al. 2013). In dogs, there are about 10,000 new cases reported 
annually in the USA (Fenger, et al. 2014). 
In Australia, the two peaks of OS incidence were in the ages of 0-24 and >60 years (see 
Table 1.1) (Mirabello, et al. 2009a). Primary bone cancer was diagnosed in 223 Australians in 
2014, and 107 died from this cancer in 2015 (Cancer.Council.Australia 2018). In Victoria, the 
incidence of primary bone cancer is 72 new cases every year (Cancer.Council.Victoria 2018). 
In Western Australia, the incidence of OS was studied from 1972 to 1996 (Blackwell, et al. 
2005). The total number of primary bone cancer cases was 263, and OS represented 35.8% of 
this total number (Blackwell, et al. 2005). 
 
Table 1.1 Incidence of human OS in the USA and Australia by age group* (Mirabello, et 
al. 2009a). 
 Age group (years) 
Country (year) Ages 0-24 Ages 25-59 Ages >60 
USA (1973–1997) 8 3.7 8.7 
Australia (1978–1997) 6.5 3.1 10.5 
           *Incidence rate per million people annually. 
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Compared to humans, the incidence of OS in dogs is high. Canine OS represents about 
85% of all canine bone cancers (Brodey, et al. 1959; Brodey and Riser 1969). This disease 
occurs more commonly in appendicular areas of the skeleton compared to axial areas 
(Sapierzynski and Czopowicz 2017). Canine OS is a disease of middle-aged to older dogs (7-
10 years) with a small peak in age range 18-24 months (Cohen, et al. 1974). Furthermore, like 
humans, male dogs have slightly higher incidence rates of OS than bitches (Brodey, et al. 1963; 
Brodey and Riser 1969). 
1.4.2 Diagnosis, treatment and prognosis of OS 
1.4.2.1 Human OS 
In humans, most OS patients have a history of swelling and pain in the affected area, 
which can be worse at night and in later stages of the disease (Song, et al. 2014). The diagnostic 
procedures of OS in humans and dogs are similar in that radiographs are taken of the abnormal 
area of the bone followed by fine needle aspiration cytology (FNAC) and a biopsy for 
histopathological investigation (Powers, et al. 1988; Barger, et al. 2005; Kundu 2014). 
Currently, microscopic histopathological investigation is the gold standard for OS 
diagnosis (Selvarajah and Kirpensteijn 2010). A histopathological examination can help in the 
cancer subtyping and classification of cancer based on the formation of osteoid matrix into 
fibroblastic, osteoblastic and chondroblastic subtypes (section 1.4.4) (Selvarajah and 
Kirpensteijn 2010). 
Although at present there are no biomarkers that can help in the hispathological 
classification of bone cancer subtypes, immunohistochemistry (IHC) and molecular diagnostic 
methods could be useful in differential diagnosis of OS (Selvarajah and Kirpensteijn 2010). 
For example, the alkaline phosphatase biomarker cannot differentiate OS from reactive bone 
lesions or from other bone cancers like multilobular osteochondrosarcoma (Selvarajah and 
Kirpensteijn 2010). In contrast, a cytoskeletal linker protein called ezrin has been found to have 
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specificity of close to 100% in distinguishing human chondroblastic OS from chondrosarcoma. 
Ezrin is expressed by chondroblastic OS irrespective of the histological grade (Selvarajah and 
Kirpensteijn 2010). 
There has been not much improvement in the treatment of OS and its prognosis in the 
last 30 years, especially for patients with metastatic OS (Chou, et al. 2009; Bishop, et al. 2016; 
Varshney, et al. 2016; Lewis, et al. 2017; Lindsey, et al. 2017). The reason behind this could 
be the unavailability of novel markers. Perhaps if there were confirmed prognostic tumour 
markers, this might assist in categorising patients for risk-based treatment. Added to the 
problem is that the complexity of OS is such that no two tumours look alike (Lau 2009). 
In a study conducted by Lau (2009), expression profiling in 34 biopsies of childhood 
OS, aimed to determine molecular signatures which may help to predict resistance of OS to 
chemotherapy. The OS samples were divided into a poor response group and a good response 
group. Initial samples were taken after diagnosis and another biopsy was taken during surgery 
after treatment with multi-agent chemotherapy (Lau 2009). It was proposed that response to 
chemotherapy could predict survival at the stage of diagnosis (Lau 2009). Because of limited 
sample size, the signature of chemo-resistance was not validated (Lau 2009). 
The current treatment strategy for human OS involves neoadjuvant chemotherapy 
followed by surgical removal of the tumour and adjuvant chemotherapy (Morello, et al. 2011). 
Standard chemotherapy uses a combination of doxorubicin and cisplatin with a high-dose of 
methotrexate in the neoadjuvant and adjuvant regimens (Bielack, et al. 2002). This treatment 
procedure can improve the 5-year survival rate by 60-65% (Morello, et al. 2011; Serra and 
Hattinger 2017). However, studies have shown that early surgical removal of the tumour is the 
most successful treatment method (Coventry and Dahlin 1957; Bacci, et al. 2006).  
The prognostic indicators of human OS are the patient’s response to chemotherapy, the 
presence of metastases and satisfactory surgical margins (Hagleitner, et al. 2011). Other 
 17 
 
prognostic indicators such as histological subtype, age, high concentration of serum lactate 
dehydrogenase or alkaline phosphatase (ALP), tumour size, and site are still contentious 
(Hagleitner, et al. 2011). 
1.4.2.2 Canine OS 
Most canine OS patients have a history of acute or the start of chronic lameness with 
or without swelling of the affected area (Dernell, et al. 2007). The standard treatment method 
for canine OS in the USA is the surgical removal of the tumour, followed by three to six cycles 
of doxorubicin- or platinum- based chemotherapy (Dernell, et al. 2007). Even though the 
current standard therapy discussed above has considerably high survival rates, nearly 90% of 
dogs will ultimately have lung cancer metastases after three to six months (Selvarajah and 
Kirpensteijn 2010). 
With the current treatment, the average survival rates of dogs are from three months to 
one year and the one-year survival rate is less than 45% (Straw, et al. 1991; Frimberger, et al. 
2016). Fifty four percent of dogs that survive for more than one year will have metastasis (Culp, 
et al. 2014). The median survival time for those dogs is 243 days; while for dogs with metastasis 
at presentation median survival is 76 days (Culp, et al. 2014). Only less than 20% of dogs will 
live for more than two years after diagnosis (Selvarajah and Kirpensteijn 2010). 
In dogs, the most significant prognostic indicators are elevated serum ALP (Boerman, 
et al. 2012), the presence of metastasis, high body weight, and whether the OS is affecting the 
proximal humerus (Boerman, et al. 2012; Schmidt, et al. 2013; Amsellem, et al. 2014). The 
prognostic value for age, sex, breed size, tumour grade and histological subtype in canine OS 
is still controversial (Misdorp and Hart 1979; Spodnick, et al. 1992; Bergman, et al. 1996; 
Dernell, et al. 1998; Kirpensteijn, et al. 2002; Cavalcanti, et al. 2004; Loukopoulos and 
Robinson 2007; Schott, et al. 2018). 
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1.4.3 Differential diagnosis of OS 
In general, OS diagnosis is made with radiology imaging, which can sometimes be 
misleading (Mirra, et al. 1989). The results of imaging should be correlated with histology 
(Mirra, et al. 1989). Furthermore, it is very important to correlate the histological results with 
the clinical symptoms of the patient (Ewing 1922). Purely osteolytic OS may mimic the 
following tumours: giant cell, malignant fibrous histiocytoma or fibrosarcoma. OS with a 
diaphyseal site may have to be distinguished from lymphoma or Ewing's sarcoma (Mirra, et al. 
1989). In rare cases, the histological morphology of OS may mimic an aneurysmal bone cyst 
or osteoblastoma (Swaney 1973; Huvos 1991). 
Therefore, there is a need for improving diagnostic methods. The use of IHC for 
detecting protein markers known to be specific for OS could improve the accuracy of diagnosis 
and help in the differential diagnosis of OS. 
1.4.4 Histological classification of OS 
In both humans and dogs, the OS classification is based on the microscopic finding of 
malignant sarcomatous stroma along with the formation of osteoid (Rosenberg, et al. 2013; 
Thompson and Dittmer 2017). As mentioned previously, it is proposed that OS originates from 
mesenchymal stem cells, which have the ability to differentiate into bone, cartilage or fibrous 
tissue (Bielack, et al. 2009; Mohseny, et al. 2009; Xiao, et al. 2013). Hence, OS tumours have 
several similar features to fibrosarcoma and chondrosarcoma, which are also classified in the 
same bone tumour category (Wolf and Enneking 1996). Some OS tumours have limited 
formation of osteoid and different histological features. In such cases, IHC may be needed to 
confirm the diagnosis (Wolf and Enneking 1996). Histologically, OS tumours are classified 
based on their predominant extracellular matrix into the following: 
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1.4.4.1 Fibroblastic OS 
In this type of OS, there is minimal and focal production of osteoid. The histological 
morphology is similar to a high grade fibrosarcoma (Raymond, et al. 2002). Collecting 
adequate tumour tissue sample is important to correctly identify fibroblastic OS. Pleomorphic 
nuclei can be seen in some cases of fibroblastic OS, similar to those seen in malignant fibrous 
histiocytoma tumours (Raymond, et al. 2002). 
1.4.4.2 Osteoblastic OS 
 Osteoblastic OS is the most common histological subtype (Trost, et al. 2012; Nagamine, 
et al. 2015). In osteoblastic OS, malignant spindle cells of osteoblastic OS produce large 
amounts of osteoid and/or bone (Dorfman, et al. 2002; Trihia and Valavanis 2012), and often, 
mineralisation may spread to the surrounding soft tissue. Generally, the predominant malignant 
cells are spindle shaped but some can epithelioid and small (Schajowicz, et al. 1995). 
Commonly, a fine lace-like pattern of osteoid is formed between the malignant cells and this 
matrix is usually not trabecular and not mature (Schajowicz, et al. 1995). The bone can be 
basophilic or eosinophilic and may resemble the bone morphology of Paget’s disease, 
depending on the mineralization status of the bone (Trihia and Valavanis 2012). 
1.4.4.3 Chondroblastic OS 
Chondroblastic tumours produce cartilage and the major differentiating feature is the 
presence of chondroid material (Schajowicz, et al. 1995). The cartilage cells are organised in a 
lobular pattern and have distinct atypia and  rarely will the osteoid be seen in the centre of the 
lobule (Schajowicz, et al. 1995). 
1.4.5 Subtyping of OS and prognosis 
It has been argued that the three different histological subtypes of OS have similar 
responses to chemotherapy and survival time (Pochanugool, et al. 1997; Hauben, et al. 2002; 
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Gorlick 2009). The study conducted by Pochanugool, et al. (1997) suggested that OS subtypes 
could not predict survival. On the other hand, other studies found that OS subtypes could 
predict survival time (Uribe-Botero, et al. 1977; Bentzen, et al. 1988; Petrilli, et al. 1991; Bacci, 
et al. 1998; Hauben, et al. 2002). All patients are treated with the same chemotherapy, 
regardless of histological subtype, which suggests that these different histological features are 
reflective of one clinical disease (Bielack, et al. 2002; Morello, et al. 2011) and surgeons and 
oncologists see OS as one disease regardless of histological subtype (Bielack, et al. 2002; 
Morello, et al. 2011). Currently, there is a gap in knowledge regarding factors linked to an 
individual OS tumour having a specific histological pattern (Gorlick 2009). Furthermore, no 
large-scale study has investigated the correlation between histological subtypes of OS and the 
survival outcome of dogs. One aim of this thesis is to fill this gap in knowledge and answer the 
following controversial question: can OS subtyping predict prognosis? 
1.5 Use of animal models for studying OS 
Animal models have a long history in cancer research (Hewitt 1978; Herberman 1983a; 
Paoloni, et al. 2009) and have proven to be important for studying the biology of cancers and 
in finding new treatments. However, defining the most suitable animal models is often difficult, 
as only some animal cancers currently in use can provide significant data and help scientists to 
understand human tumours (Mak, et al. 2014). This could be due to the differences in the 
molecular biology, genetics, cellular characteristics, physiology and immunology between 
these animal models and humans (Chesler, et al. 2002; Fingleton 2007; Mak, et al. 2014). 
Herberman (1983b) suggested that animal models of human cancer should have similar 
pattern of cancers in humans. There are some difficulties with chemically induced cancers that 
produce artifacts which do not in naturally occur in human cancers (Hewitt 1978). Transgenic 
animals can be used as models for cancer due to the change, loss or gain of specific genes. 
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Transgenic animal models are useful to study the genetic basis of human OS (Ruther, et al. 
1989; Wang, et al. 1995).          
Examples of animal models that can be used to study OS are rodent, canine, and feline 
models. Although the discussion about which are the most appropriate animal models is still 
not concluded, rodents, dogs and cats can develop analogous tumours to those in humans (Lee, 
et al. 2004; Paoloni, et al. 2009; Varshney, et al. 2016). 
1.5.1 Rodent OS models 
Using mouse models to study human OS began before the availability of transgenic 
mice and xenografts. There are many ways to induce OS in wild-type mice (Tomita 1986; 
Heidenreich, et al. 2005). One of these ways is the embedding of radioisotopes of heavy metals 
emitting alpha and beta particles in the metaphyses of long bones (Tomita 1986; Heidenreich, 
et al. 2005). Another method is to expose mice to different forms of external beam radiation 
(Selbie 1938; Sutro, et al. 1939). The third way is the oral or intravenous administration of 
carcinogenic chemicals (Brunschwig and Bissell 1938). 
Genetically altered mouse models through gene targeting methods are used to 
understand the contributions of selected genes in OS disease pathogenesis (Donehower, et al. 
1992). An example of a genetically modified mouse model is Cre/LoxP mediated deletion 
of Trp53 and/or Rb1 (Guijarro, et al. 2014). Other models have been altered by transgenic 
overexpression of numerous oncogenes such as the mutation of Apc and co-deletion of one 
copy of Twist (Entz-Werlé, et al. 2010) or Fos and SV40 large T antigen (Ruther, et al. 
1989). OS transgenic mouse models can be created by deleting the Trp53 gene in cells of 
osteoblast lineage with the co-deletion of both copies of the Rb1 gene (Walkley, et al. 2008). 
Other pathway or genes that could be regulated or altered to produce genetically modified 
mouse models of OS are IGF1R, MET signalling and PVT1/MYC locus (Moriarity, et al. 
2015; Rao, et al. 2015). 
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Despite the advantage of being able to genetically manipulate the immune response of 
the host, the use of mouse models of OS has limitations. Mice develop OS more readily than 
human do (Sharpless and Depinho 2006). Moreover, there may be specific pathways of OS 
which are hard to translate between mice and humans (Sharpless and Depinho 2006). 
Importantly, there are differences in bone biology between the two species, as mice lack true 
lamellar bone (Walkley, et al. 2008). It has been found that the tumours in some mouse models 
of OS may be located in the head and jaw but not in the ends of long bones as in humans 
(Walkley, et al. 2008). In addition, metastasis in some mouse models of OS was primarily to 
the liver in contrast to the lung in human OS (Walkley, et al. 2008).   
Therefore, in order to expand our understanding of OS pathogenesis, new spontaneous 
OS models need to be established. In order to investigate new anti-metastatic agents, further 
studies should focus on creating models that produce metastases as this scenario is the most 
frequent reason for a poor prognosis in OS.  
1.5.2 Canine OS models 
Intriguingly, dogs and humans are similar on the basis of global gene expression 
signatures in OS, and this indicates that these two species may have analogous molecular 
pathways in the pathogenesis of OS (Paoloni, et al. 2009). A major reason behind using canine 
models for OS research is that it is a naturally occurring cancer in dogs, and they live under 
similar environmental conditions to humans (Vail and MacEwen 2000; Angstadt, et al. 2011). 
Besides, dogs have a physiologic gross anatomy similar to humans, as they are higher order 
mammals. Moreover, canine OS is 27 times more common than human OS (Simpson, et al. 
2017) and metastasis begins sooner in the disease process giving a better chance to study them 
(Dernell, et al. 2007; Mirabello, et al. 2009a) (Figure 1.4). 
Compared to mouse models, canine models could answer some non-clinical research 
queries more simply (Khanna, et al. 2006). In spontaneously arising canine OS, the tumour 
 23 
 
grows and progresses naturally due to the natural immune interactions between the tumour and 
the surrounding tissue (Riccardo, et al. 2015). Thus, the canine OS models may provide more 
reliable findings compared to rodent models. In addition, compared to mouse models, canine 
models are less expensive as dogs can be accessed as outpatients and there is no requirement 
for animal housing facilities. Furthermore, dogs provide a suitable model to assess different 
surgical procedures including amputation and limb sparing surgery (LaRue, et al. 1989; 
Lascelles, et al. 2005; Jeys, et al. 2007; Fenger, et al. 2014). Dogs could also provide a good 
model to study bone post-operative infections (Fenger, et al. 2014). Therefore, there are 
considerable advantages, and potentially greater relevance, in using canine models instead of 
rodent models to study human OS (Paoloni, et al. 2009; Morello, et al. 2011). 
Although canine and human OS have similarities, it is important to note their 
differences. These differences are the age at which dogs develop OS (younger age in canines), 
localisation, and the limitations in using neo-adjuvant chemotherapy in canine OS (Morello, et 
al. 2011). 
With regard to the similarities to humans that were discussed above, canine models 
could be used to understand human OS concerning genetics, pathogenesis, diagnosis and 
treatment (Paoloni, et al. 2009; Simpson, et al. 2017). Many discoveries have been gathered 
from previous studies, but further studies are needed to understand human OS, to find possible 
new therapies and overcome the side effects of chemotherapy (Paoloni, et al. 2009). 
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Figure 1.4 Reasons that make canine OS a promising model to human OS. Canine models 
for OS are valuable for the study of human disease because dogs and humans live under similar 
environmental conditions; OS is a naturally occurring cancer in dogs; it mostly affects long 
bone in both species; dogs have shorter life spans; canine OS is more common than human OS. 
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1.6 Pathogenesis of OS 
1.6.1 Bone growth and development of OS 
OS occurs with greatest frequency in bone that is growing rapidly such as the proximal 
tibia and distal femur of children and young adults (Gelberg, et al. 1997). Because of this, it 
has been proposed that there is a strong association between initiation of OS and rapid bone 
development (Kruzelock, et al. 1997). A study found that 56% of OS tumours arise around the 
knee (Vigorita 2008). It has been suggested that the pathogenesis of OS begins as a result of 
activation of the signal transduction pathways activated by growth factors such as transforming 
growth factor (TGF), connective tissue growth factor (CTGF) and insulin-like growth factor 
(IGF) (Dong, et al. 2010; Wang, et al. 2010). In addition, patients with Paget’s disease of the 
bone who generally suffer from excessive formation and breakdown of bone have an increased 
incidence of OS (Vigorita 2008). Paget's disease of bone is a condition affecting 2-5% of people 
older than 55 years (Galson and Roodman 2014). This disease involves an increase of bone 
resorption in one or more bones resulting in a weakness in the affected bone (Basle, et al. 1978). 
This may cause defective joints, pain, arthritis, or fractures (Paul Tuck, et al. 2017). 
1.6.2 Genetic mutations and OS 
The most prevalent genetic alterations seen in OS are in p53 and retinoblastoma tumour 
suppressor gene (Rb) pathways (Figure 1.5) (Gorlick 2009; Chen, Bahrami, et al. 2014; 
Bousquet, et al. 2016). Tumour suppressor genes are involved in preventing tumorigenesis 
through DNA repair or cell apoptosis (Marina, et al. 2004). Inactivation of the p53 tumour 
suppressor gene is found in 20 to 50% of OS cases (McIntyre, et al. 1994), whereas the 
incidence of Rb tumour suppressor gene mutations is detected in about 70% of primary OS 
patients (Wadayama, et al. 1994). The involvement of p53 and Rb in OS will be discussed in 
sections 1.6.2.1.1 and 1.6.2.1.2.  
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Increased expression of the c-myc oncogene in bone marrow stroma of mice results in 
the development of OS (Wu, et al. 1990; Ladanyi, Cha, et al. 1993) and c-jun and c-fos 
protooncogene expression in Fos-Jun double-transgenic mice play roles in the enhancement of 
OS development (Wang, et al. 1995). This could prove that mutation of c-myc, c-jun and c-fos 
is involved in OS tumorigenesis. Oncogenes are those mutated or overexpressed genes, which 
have the ability to cause cancer (section 1.6.2.2) (Gamberi, et al. 1998; Li and Ye 2014). 
BRCA1, MSH2, ITGA5 and CCND1 genes are also associated with the pathogenesis of OS 
(Yang and Wang 2016). These proteins encoded by these genes are involved in DNA repair or 
cell cycle progression and cell adhesion (Yang and Wang 2016). Table 1.2 summarizes the 
well-studied genes that may have a role in OS. 
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Figure 1.5 The most common genetic mutations seen in human, murine predisposition 
syndromes and in OS tissues. The only shared genetic mutations are the mutation of Rb and 
p53 tumour suppressor genes. (Modified from (Gorlick 2009)). 
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Table 1.2 The most well-defined genes involved in OS. 
 
Multiple attempts have been made to understand and evaluate the genetic mechanisms 
underlying OS in humans and dogs (Angstadt, et al. 2011; Mirabello, Yu, et al. 2011; Savage, 
et al. 2013). One study was carried out to test the hypothesis that proteins involved in ribosomal 
function and DNA repair may have roles in the pathogenesis of OS (Mirabello, Yu, et al. 2011). 
Genes coding for proteins involved in bone formation, DNA repair, ribosomal pathways and 
growth hormone (GH) were analysed (Mirabello, Yu, et al. 2011). In this study, 4836 tag-
single-nucleotide polymorphisms (SNPs) in 255 genes were evaluated using 1426 control cases 
and 96 OS cases. It was found that 12 SNPs in DNA repair and growth hormone (GH) genes 
were linked to OS (Mirabello, Yu, et al. 2011). One SNP in each of the following genes 
GNRH2, FGF2, MDM2, IGF1, MPG and FGFR3 were significantly associated with OS 
(Mirabello, Yu, et al. 2011). Larger sample sizes were required to confirm the present findings 
to better understand OS (Mirabello, Yu, et al. 2011; Savage, et al. 2013). Angstadt, et al. (2011) 
studied mutations in the following genes MYC, PTEN, RHOC, Runx2, TSC2 and TUSC3 in 
canine OS and compared the results with those previously obtained for human OS. They found 
Gene Tumour suppressor gene 
or oncogene 
Role in OS Reference 
p53 Tumour suppressor gene Metastasis 
 
(Li and Ye 2014) 
Rb Tumour suppressor gene Metastasis (Li and Ye 2014) 
c-myc Oncogene Metastasis and tumour 
growth 
(Gamberi, et al. 1998) 
c-fos Oncogene Metastasis and tumour 
growth 
(Gamberi, et al. 1998) (Wu, 
et al. 1990) 
erbB-2 Oncogene Metastasis and tumour 
growth 
(Onda, et al. 1996) 
MET Oncogene Metastasis (Ferracini, et al. 2000) 
c-sis Oncogene Metastasis and tumour 
growth 
(Levine 2002) 
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that human and canine OS share similar genetic abnormalities and protein expression patterns 
of the studied genes and proteins (Angstadt, et al. 2011).  
1.6.2.1 Role of tumour suppressor genes in OS tumorigenesis 
The etiological genetic abnormalities behind the development of OS are complex 
(Rickel, et al. 2017), but tumour suppressor genes may play a role in inherited familial 
syndromes with a susceptibility to OS (Tao, et al. 2013). Compared to other sarcomas, OS 
tumours do not show any specific molecular or genetic aberrations, which can act as novel 
diagnostic tumour markers (Martin, et al. 2012). For instance, most OS tumours reveal different 
non-specific genetic abnormalities, which include tumour suppressor gene inactivation or 
oncogene overexpression (Boehm, et al. 2000; Lau, et al. 2004). Tumour suppressor genes 
linked to OS will be discussed below and oncogenes will be discussed in section 1.6.2.2. 
The greatest rate of heterozygosity loss in OS is found in chromosome 13q, which 
includes the Rb gene and in chromosome 17q, which contains the p53 gene (Miller, et al. 1990). 
A high frequency of heterozygosity loss can be also seen in the chromosomes 3q and 18q 
(Yamaguchi, et al. 1992; Kruzelock, et al. 1997). The tumour suppressor genes Rb and p53 are 
the most well-defined genes that are involved in OS pathogenesis (Table 1.2) (Zheng and Lee 
2001; Ivanov, et al. 2003). 
1.6.2.1.1 P53 tumour suppressor gene 
Damage to somatic DNA will not necessarily result in a malignancy because of the 
functions of proteins encoded by tumour suppressor genes (Marina, et al. 2004). These proteins, 
such as p53, play critical roles in inducing apoptosis in abnormal cells or repairing damaged 
DNA (Diller, et al. 1990; Miller, et al. 1990; Marina, et al. 2004). P53 is mutated in some 
diseases such as cancer, which may result in loss of its function. Therefore, accumulation of 
these mutations may give rise to a new generation of cells with damaged DNA (Diller, et al. 
1990).  
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Mutations of  p53 can result in OS tumorigenesis in humans (Diller, et al. 1990; 
Mulligan, et al. 1990; Ueda, et al. 1993; Guo, et al. 1996; Marina, et al. 2004; Li and Ye 2014), 
dogs (Johnson, et al. 1998) and mice (Chandar, et al. 1992). In addition to the p53 mutation, 
the p53 onco-protein is highly expressed in human and canine OS (Guo, et al. 1996; Levine 
and Fleischli 2000). 
Masuda, et al. (1987) showed that p53 was mutated in 50% of human OS cases and that 
p53 onco-protein was overexpressed in 59% of the 46 human OS cases studied (Guo, et al. 
1996). In dogs, p53 was mutated in about 40% of OS cases (Kirpensteijn, et al. 2008), but was 
mutated in only 24% of 17 cases of dogs with OS (van Leeuwen, et al. 1997). Both these studies 
demonstrated that p53 is involved in OS tumorigenesis in dogs (van Leeuwen, et al. 1997; 
Kirpensteijn, et al. 2008). 
The p53 gene is an autosomal dominant mutation in human OS (Diller, et al. 1990; 
Hauben, et al. 2003). However, it is not clear whether mutation of p53 or loss of the whole 
gene is responsible for OS in humans (Ganjavi, et al. 2006). According to Park, et al. (2004), 
the mutation of p53 is more frequently seen in high grade OS such as osteoblastic, fibroblastic 
and chondroblastic OS compared to low grade cases. Expression of p53 was associated with 
increased survival rate (Park, et al. 2004) and reduced metastases in humans (Li and Ye 2014). 
A systematic review revealed that p53 mutation is linked to a decreased 3-year overall survival 
in humans, and is therefore a good survival biomarker for OS patients (Fu, et al. 2013). 
However, other work have found no correlation between p53 mutated protein and histological 
grades or survival rates (Lonardo, et al. 1997; Park, et al. 2001). These conflicting findings 
could be due to the different detection methods used and investigating different targets, either 
the p53 protein or gene.    
Collectively, p53 plays a critical role in the development of OS in both humans and 
dogs, but elucidation of the mechanism remains to be revealed.  
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1.6.2.1.2 Rb tumour suppressor gene 
The Rb gene product is involved in controlling the cell cycle (Wadayama, et al. 1994). 
This gene is a member of the retinoblastoma family, which also includes p130 and p107. These 
genes encode proteins that are involved in the regulation of cell differentiation and proliferation 
in dogs (Levine and Fleischli 2000). Dogs with inherited mutated Rb could develop 
retinoblastoma or other tumours (Levine and Fleischli 2000). These dogs have increased risk 
of developing multiple tumours including OS because of lack of cell cycle control (Friend, et 
al. 1986). Li and Ye (2014) found that a mutated Rb gene was associated with an increased risk 
of having OS and metastases in humans. 
The mutation of Rb results mostly in the loss of Rb protein expression (Levine and 
Fleischli 2000), and in fact, Rb gene mutations were found in 61% of human OS cases 
(Wadayama, et al. 1994), and IHC showed the Rb protein in 66% of canine OS (Russell, et al. 
2018). Rb expression was decreased or completely lost in 71% of human OS cases (Wadayama, 
et al. 1994). In contrast, Levine and Fleischli (2000) reported that Rb was weakly expressed in 
only 20% of OS cases of dogs. However, Heinsohn, et al. (2007) found that the Rb gene was 
mutated in 39% of OS cases, and that there was no link between this mutation and overall 
survival rate in humans.  
Several studies reported that OS patients with a wild-type Rb gene have better overall 
survival (Wadayama, et al. 1994; Benassi, et al. 1999). A human OS cell line (SaOS-2) with a 
mutated Rb gene was less sensitive to chemotherapy compared to the same OS cell line with 
wild-type Rb gene, supporting the hypothesis that Rb is involved in OS pathogenesis (Iida, et 
al. 2003). 
In summary, the mutation of Rb could play a critical role in pathogenesis of human and 
canine OS. 
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1.6.2.2 Role of oncogenes in OS tumorigenesis 
Some oncogenes may be involved in the pathogenesis of OS (Table 1.2) (Gamberi, et 
al. 1998; Li and Ye 2014). In addition, onco-proteins that are produced by these genes are also 
involved in OS tumorigenesis (Gamberi, et al. 1998; Li and Ye 2014). Examples of these 
oncogenes are c-myc, c-fos, erbB-2, MET, c-sis, GLI, SAS, cH-ras, N-myc and uPA (Wu, et al. 
1990; Ladanyi, Park, et al. 1993; Li and Ye 2014).  
It was reported that the hypermethylation of these oncogenes in tumour tissue can cause 
overexpression leading to OS (Li and Ye 2014). Another study mentioned that this deregulation 
or overexpression occurred due to DNA rearrangement such as translocation of chromosomes, 
amplification of DNA, and insertion of provirus (Gamberi, et al. 1998). This demonstrated that 
oncogenes could be overexpressed by more than one way. However, more studies are 
warranted to understand the critical role of oncogenes that may be involved in OS 
carcinogenesis. 
Despite several studies on OS characterisation and attempts to understand the 
involvement of tumour suppressor genes and oncogenes in OS, the molecular events leading 
to OS is not yet fully understood (Savage, et al. 2013). This is because of the complexity of OS 
genetics, and the inability to elucidate related pathways (Savage, et al. 2013). 
1.6.3 Apoptosis, cell proliferation and related pathways in OS 
OS tumour cells can avoid elimination and are able to proliferate without limitation by 
their resistance to apoptosis (Broadhead, et al. 2011). Initiation of apoptosis is regulated via 
the intrinsic and extrinsic pathways (Broadhead, et al. 2011). The intrinsic pathway depends 
on the ability of mitochondria to be more permeable to release pro-apoptotic proteins such as 
cytochrome c, Smac/DIABLO and the serine protease HtrA2/Omi, whereas the extrinsic 
pathway is stimulated following activation of death receptors such as tumour necrosis factor 
receptor-1 (TNFR-1) (Du, et al. 2000; Locksley, et al. 2001; Elmore 2007). 
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The type of apoptosis that is initiated when cells detach from the matrix or basement 
membrane is known as anoikis (Figure 1.6) (Broadhead, et al. 2011). It is believed that OS cells 
are resistant to anoikis and that gives tumour cells the ability to metastasise (Luu, Kang, et al. 
2005). This resistance is called anchorage-independent growth (AIG) (Broadhead, et al. 2011). 
The pathways that initiate AIG are complex (Jan, et al. 2004). These pathways involve 
interactions between many crucial factors of the extrinsic and intrinsic apoptosis pathways (Jan, 
et al. 2004). An example of interactions of factors in the intrinsic pathway occurs when normal 
cells attach to the surrounding matrix through integrin binding to fibronectin, the Bcl-2 
inhibitor Bit1 is activated resulting in apoptosis prevention (Jan, et al. 2004). Another example 
is the pathway that involves integrin subunits exchanging and that produces abnormal integrins 
resulting in phosphoinositide 3-OH kinase (PI3 kinase) up-regulation (Janes and Watt 2004). 
PI3 kinase can then suppress protein kinase B (PKB or Akt) leading to pro-apoptotic factor 
Bcl-2-associated death promoter (Bad) protein inhibition, resulting in surviving cancer cells 
(Figure 1.6) (Nicholson and Anderson 2002). 
In common with many other types of cancer, notch (Tsuru, et al. 2015; Anderson 2016), 
Wnt (Wang, et al. 2015), PI3K-AKT-mTOR (Zhang, et al. 2015), Ras-Raf-MEK-ERK 
(Jokinen and Koivunen 2015) and Ezrin (Ren and Khanna 2014) pathways also play a role in 
OS but this thesis focus on those pathways of particular interest in OS as PTHrP (section 
1.8.1.3) and PTHR1 (section 1.8.2.3). 
In summary, OS continues to be a challenging tumour to treat, and no significant 
improvement has been made with regards to survival time (Angulo, et al. 2017). Many 
pathways implicated in tumour growth, differentiation, survival and metastasis have been 
shown to be relevant to OS, but whether the therapeutic targets are useful in the treatment of 
OS has yet to be determined. The complexity of the signalling pathways involved in OS, and 
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the lack of clinical trials could explain the difficulty to determine or discover novel targets in 
OS (Angulo, et al. 2017). 
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Figure 1.6 Examples of pathways that disrupt anoikis of OS cells. (Modified from 
(Broadhead, et al. 2011)). The pathway involves attaching of normal cells to the 
surrounding matrix via integrin binding to fibronectin, the Bcl-2 inhibitor Bit1 is 
activated resulting in apoptosis inhibition. Another example is the pathway involving 
the exchange of integrin subunits and resulting in abnormal integrin phosphoinositide 
3-OH kinase (PI3 kinase) up-regulation. PI3 kinase subsequently suppresses protein 
kinase B (PKB or Akt) resulting in inhibition of pro-apoptotic factor Bcl-2-associated 
death promoter (Bad) protein, resulting in the prevention of apoptosis. 
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1.6.4 Angiogenesis in development of OS 
Angiogenesis refers to the growing of new blood vessels from pre-existing vessels. This 
process is essential for growing, metastasis, and maintenance of most solid cancers such as OS 
(Kreuter, et al. 2004). A lack of angiogenesis leads to neoplastic cells that cannot move to other 
organs, the rate of tumour cell apoptosis remains stable, and tumour size remains constant 
(Letson and Muro-Cacho 2001). Several attempts have been made to investigate the role of 
angiogenesis in OS (Folkman and Shing 1992; Wang, et al. 1997; Kreuter, et al. 2004; Ek, et 
al. 2007). It was assumed by Folkman and Shing (1992) that after angiogenesis induction in a 
tumour, there is an alteration in the balance between inhibitory and stimulatory factors involved 
in angiogenesis, and produced by tumour cells. Potentially, tumour growth, which depends on 
angiogenesis could be controlled via the inhibition of this process. Ek, et al. (2007) showed 
that the expression of pigment epithelium-derived factor (PEDF) might inhibit the process of 
angiogenesis in OS patients. This may be a promising therapeutic target in OS treatment. 
A previous study found that increasing angiogenesis might be a predictive marker for a 
greater response rate to chemotherapy and greater survival rate in OS patients (Kreuter, et al. 
2004). Conversely, another study revealed that a high rate of angiogenesis is correlated with 
low overall survival rate in patients with OS (Wang, et al. 1997). Another study examined the 
prognostic value of angiogenesis in 39 patients with non-metastatic OS (Mikulic, et al. 2004). 
In this study, it was found that the survival rate was low and the metastatic rate was high in OS 
patients with a greater rate of angiogenesis and therefore, an increase of angiogenesis was 
correlated with poor prognosis of OS patients (Mikulic, et al. 2004). Uehara, et al. (2014) found 
that OS cells may induce angiogenesis in the tumour which suggests that angiogenesis is a 
possible OS drug target. Future studies on the roles of angiogenesis in OS could provide 
promising therapies. 
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1.6.5 Metastasis of OS 
As with other cancers, death in OS patients is commonly associated with metastasis (Li, 
et al. 2018). In general, the primary tumours tend to be more aggressive when cells start to 
metastasise to other organs (Kansara and Thomas 2007). The steps of metastasis are cellular 
detachment, invasion into the extracellular matrix, angiogenesis, increasing of blood vessels 
and proliferation at the new organ (Kansara and Thomas 2007).               
OS metastases can affect many organs such as the brain, pleura, jejunum, stomach and 
other bones (Jeffree, et al. 1975; Bacci, et al. 2006; Kubo, et al. 2017). However, the tissue to 
which OS metastasizes to most frequently is the lungs (Jeffree, et al. 1975; Bacci, et al. 2006; 
Kubo, et al. 2017). The 5-year survival rate for patients with no metastasis is about 60 to 70%, 
whereas for patients with lung metastasis the prognosis is poorer and the 5-year survival rate 
is less than 30% (Diao, et al. 2014). Generally, metastases have been reported in nearly 10 to 
20% of OS patients at presentation (Diao, et al. 2014). According to van der Deen, et al. (2013), 
30 to 40% of OS patients will die from metastases regardless of treatment. Around 80 to 90% 
of diagnosed OS patients with metastases will die with lung cancer (Raymond, et al. 2002). In 
dogs, approximately 90% will have lung metastases three to six months after diagnosis 
(Selvarajah and Kirpensteijn 2010). 
Many genetic abnormalities have been found to be linked to OS metastasis (Diao, et al. 
2014). Examples of these abnormalities are the p53 tumour suppressor gene deactivation and 
the overexpression of Ezrin, microRNA-9 and microRNA-202 (Diao, et al. 2014). Ezrin protein 
was found in both human (92%) and canine (83%) OS and was linked to short disease-free 
intervals and survival time (Khanna, et al. 2004; Wan, et al. 2005).  
Numerous studies have been conducted to identify anti-metastasis factors effective 
against OS (Wan, et al. 2005; Walter, et al. 2014; Li, et al. 2018). Wan, et al. (2005) found that 
rapamycin could be used to inhibit the pro-metastatic function of ezrin in mice, which suggests 
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that this could be a suitable target to control OS metastasis. Rapamycin is an anti-tumour and 
immunosuppressant targeted drug that inhibits the mTOR protein kinase-signalling pathway 
(Heitman, et al. 1991). Another study showed that sorafenib can inhibit OS metastasis and can 
be used as an effective chemotherapeutic agent targeting the Fos, CXCR4 and S100A4 genes 
(Walter, et al. 2014). Sorafenib is another therapeutic agent that can inhibit the growth of 
tumours by stopping the formation of new blood vessels (Roberts and Der 2007). Recently, Li, 
et al. (2018) also revealed that Metformin (Met) could be used in combination with other 
chemotherapeutic agents to target metastasis of OS cells. Met inhibits tumour growth via 
inhibiting phosphorylation of Akt signalling pathway (Li, et al. 2018). 
In summary, several agents could be used for treatment of OS via inhibition of the 
metastasis. However, further investigation might be required to assess their applicability in the 
treatment of OS. 
1.7 The expression of cell tumour markers in OS 
The detection of tumour markers in OS is significant for accurate diagnosis, prediction 
of prognosis, response to chemotherapy and metastases (Trieb, et al. 2003; Won, et al. 2009). 
Even though the aetiology of OS is complex, many tumour markers were found to be 
underexpressed or overexpressed in OS (Trieb, et al. 2003; Won, et al. 2009). The following 
tumour markers are important for diagnosis and prediction of prognosis of human OS and they 
are the subject of the thesis. 
1.7.1 Vimentin 
Vimentin is the most common intermediate filament protein (Eckert, et al. 1994). It is 
expressed by mesenchymal cells and by various sarcomatoid carcinoma tumours (Eckert, et al. 
1994). Vimentin plays an important role in maintaining cellular integrity and supporting and 
anchoring the position of organelles in the cytoplasm (Katsumoto, et al. 1990; Goldman, et al. 
1996). 
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Usually, vimentin is known as a biomarker for mesenchymal tumours (Leader, et al. 
1987). It has been shown that vimentin is expressed by human OS tissues (Loning, et al. 1985; 
Poradowski, et al. 2016) and cell lines such as U2OS and MG-63 (Wang, et al. 2016; Dong, et 
al. 2018).  
Similar to human OS, numerous studies revealed that canine OS expresses vimentin 
(Barger, et al. 2005; Nagamine, et al. 2015) and that it was localised in the cytoplasm of 
neoplastic cells in canine OS tissues (Poradowski, et al. 2016), and cell line (D-17) (Gebhard, 
et al. 2016). 
1.7.2 Alkaline phosphatase (ALP) 
ALP is a membrane-bound enzyme that is produced by many tissues such as bone, 
kidney, and liver (Reid and Wilson 1971; Mornet, et al. 2001). Bone is found to be the only 
connective tissue that synthesises ALP in dogs (Sanecki, et al. 1993). ALP has a role in the 
mineralisation of bone and the dephosphorylation of various molecules, such as proteins, 
nucleotides, and alkaloids (Reid and Wilson 1971; Mornet, et al. 2001). 
ALP is a useful tumour marker to differentiate canine OS from other mesenchymal 
tumours such as chondrosarcoma, fibrosarcoma and synovial cell sarcoma with 100% 
sensitivity (Barger, et al. 2005). Recently, Agustina, et al. (2018) revealed that ALP is a useful 
marker to discriminate human OS from other primary bone tumours with a sensitivity of 96% 
and specificity of 80%. It has also been shown that ALP is expressed by all canine OS tumours 
and that only 18% tumours other than OS revealed positive immunolabelling for ALP (Barger, 
et al. 2005). The sensitivity of ALP immunolabelling was 100% for OS and specificity was 
89% (Barger, et al. 2005). Recently, Sternberg, et al. (2013)  and Gebhard, et al. (2016) also 
detected ALP in canine OS tissues and cell line (D-17). Moreover, it has been revealed that 
human OS tissues and cell lines such as HOS, U-393 OS and U-2 OS express ALP gene and 
protein (Rosenberg 1995; Ali, et al. 1996). 
 40 
 
1.7.3 Desmin 
Desmin is an intermediate filament protein expressed by smooth and striated muscle 
cells (Carlsson and Thornell 2001) and is expressed in lower amounts by normal and neoplastic 
myofibroblasts (Fanburg-Smith and Miettinen 1999). Desmin plays a role in the maintenance 
of the structure and mechanical integrity of muscle cells (Paulin and Li 2004). Desmin has high 
sensitivity as a marker for skeletal and smooth muscle differentiation, but it has low specificity 
because other cancers such as embryonal sarcomas, rhabdomyosarcomas and angiomatoid 
malignant fibrous histiocytoma also express desmin (Dias, et al. 1987; Fanburg-Smith and 
Miettinen 1999). 
Ueda, et al. (2002) revealed that desmin was expressed in 9% of human OS, whereas 
Hasegawa, et al. (1997) showed that 57% of human OS express desmin. These differences 
could be due to use of different clones of anti-desmin antibody or investigate different subtypes 
of human OS. Recently, Nagamine, et al. (2015) found that desmin was localised in 33% of 
canine skeletal OS. Together, desmin might be expressed by specific types of OS or at specific 
stages but not by all. 
1.7.4 S100 
S100 is a member of the calcium-binding protein subfamily, and so far, there have been 
25 members that have been identified as belonging to the subfamily (Chen, Xu, et al. 2014). 
S100 is involved in cell cycle regulation, migration, growth, regulation of transcriptional 
factors, calcium homeostasis and phosphorylation (Chen, Xu, et al. 2014). In general, S100 is 
a biomarker for the differentiation of neural and nerve sheaths (Gao and Kahn 2005). Usually, 
S100 is used to differentiate melanoma and cancers of neural origin from other cancers (Gao 
and Kahn 2005). Additionally, S100 is an essential marker to differentiate cartilaginous bone 
cancers such as chondromyxoid fibroma and chondroblastoma (Gao and Kahn 2005). 
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Several studies have confirmed the localisation of S100 in human OS tissues 
(Hasegawa, et al. 1991; Luu, Zhou, et al. 2005; Mandal, et al. 2014) and in canine OS cell line 
(D-17) (Gebhard, et al. 2016). Different types of S100 proteins were shown to be linked with 
human OS including S100A4 (Mathisen, et al. 2003), S100A6 (Luu, Zhou, et al. 2005; Li, et 
al. 2015) S100A7 (Kataoka, et al. 2012) and S100B (Muramatsu, et al. 1997). 
1.7.5 Neuron-specific enolase (NSE) 
NSE is an enzyme of the glycolytic pathway (Gao and Kahn 2005). In general, NES 
can be found in neuronal and neuroendocrine tissues and is involved in stimulating 
neuroprotection and neuroinflammation in spinal cord injury (Haque, et al. 2018). It has been 
shown that increased expression of NSE might stimulate the remodelling of actin and the 
proliferation of inflammatory glial cells, resulting in an increase in the migration of activated 
macrophages and microglia to the injury location and promoting death of neuronal cells 
(Haque, et al. 2018). Currently, NSE is considered as a marker for traumatic brain injury, 
ischemic brain damage, anoxic and stroke encephalopathy after cardiac arrest (Haque, et al. 
2016). NSE is also expressed by tumours of neural origin and by numerous non-neural tumours 
such as renal cell carcinoma and small cell lung cancer (Mjones, et al. 2017; Zhou, Wang, et 
al. 2017) and is frequently used as a diagnostic marker for Ewing's sarcoma (Gao and Kahn 
2005) and neuroendocrine tumours in humans (Said, et al. 1985). NSE is commonly localised 
in human OS (Trihia and Valavanis 2012) but this localisation might vary from one OS tumour 
to another (Rosenberg 1995). 
1.7.6 Runt-related protein 2 (Runx2) 
Runx2 plays a vital role in the stimulation of proliferation and differentiation of 
osteoblasts and it is de-regulated in human OS (van der Deen, et al. 2013). Runx2 also has roles 
in activation of bone matrix, adhesion proteins and matrix metallo-proteinases (Pratap, et al. 
2005). Numerous studies confirmed the detection of Runx2 in human OS (Andela, et al. 2005; 
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Won, et al. 2009; van der Deen, et al. 2013). Sharili, et al. (2011) also showed that canine OS 
tissue and cell lines express Runx2. 
It has been demonstrated that Runx2 is overexpressed in human OS (van der Deen, et 
al. 2013) and that this overexpression is correlated with metastasis (Pratap, et al. 2005; Won, 
et al. 2009) and resistance to chemotherapy (Sadikovic, et al. 2010). Zeng and Xu (2015) 
revealed that the knockdown of Runx2 inhibited cell invasion in OS using a human OS SaOS-
2 cell line. Moreover, Roos, et al. (2015) revealed that reduced expression of Runx2 stimulated 
chemosensitivity and apoptosis in vitro and in vivo. Sugawara, et al. (2011) stated that the 
expression of Runx2 gene is fundamental for neoplasia and development of human OS and that 
it may be regulated by BMP2. Further research found that cell adhesion, and motility of human 
OS cells are regulated by Runx2 (van der Deen, et al. 2012). 
It has been found that overexpression of the Runx2 gene is associated with cell 
transformation and cancer progression (Selvamurugan, et al. 2004; Javed, et al. 2005; Xiong, 
et al. 2016). This gene is overexpressed in many other cancers such as prostate and breast 
cancers (Inman and Shore 2003; Selvamurugan, et al. 2004; Akech, et al. 2010). In breast 
cancer, Runx2 activates angiogenic factors that are linked to metastasis (Barnes, et al. 2004). 
Runx2 could form co-repressor or co-regulatory complexes with other co-activators and 
proteins. These complexes could lead to growth of secondary bone tumours (Barnes, et al. 
2004). 
More studies are required to identify a master regulatory transcription factor of Runx2 
that could regulate gene expression directly related to stages of cancer and metastasis 
(Sadikovic, et al. 2010). 
1.7.7 Bone morphogenetic protein 4 (BMP4) 
BMP4 is an extracellular signalling molecule and is a member of the bone 
morphogenetic protein family (Miyazono, et al. 2010). BMP4 is involved in the formation of 
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ectopic bone (Urist 1965). BMP4 gene and protein play a role in activating the formation of 
bone, including periosteal reactions through normal bone cells, but not the production of 
osteoid by neoplastic cells (Yoshikawa, Shimizu, et al. 1994). Furthermore, the BMP4 gene 
has a role in the repair of bone fracture (Shore, et al. 1998). It has been shown that BMP4 is 
also involved in cell proliferation, differentiation, motility and apoptosis (Kallioniemi 2012).  
Localisation of BMP4 was confirmed in human OS tissues (Yoshikawa, et al. 1985; 
Yoshikawa, et al. 1988; Rosier and Bukata 2007; Gill, et al. 2017; Xie, et al. 2018) and cell 
lines such as SaOS-2 and U-2 OS (Raval, et al. 1996). Detection of a BMP receptor and BMP 
genes in OS cartilage cap suggests that BMP signalling through its receptor may play a role in 
OS pathogenesis (Yoshikawa, et al. 1985). BMP genes could be helpful as prognostic or 
diagnostic markers in the staging of mesenchymal cancers and the differentiation of 
mesenchymal cells (Yoshikawa, et al. 1988). Clinically, these genes might be important in the 
prediction of OS prognosis (Yoshikawa, et al. 1988). 
Other studies have examined BMP2 and BMP4 genes and proteins in different bone 
tumours and it was reported that these genes are involved in OS and other bone cancers 
(Yoshikawa, Rettig, et al. 1994; Guo, et al. 1999). A further study, found that around 60% of 
human OS expressed BMP2 and BMP4 proteins using IHC (Yoshikawa, Rettig, et al. 1994). 
Yoshikawa, Rettig, et al. (1994) revealed that OS of the fibrohistiocytic subtype has the 
strongest expression of BMP2 and BMP4. In addition, Shore, et al. (1998) suggested that 
BMP4 is highly expressed in cases of progressive fibrodysplasia ossificans. The BMP4 gene 
could be expressed in tumours other than OS, such as dedifferentiated chondrosarcomas, 
malignant fibrous histiocytomas of bone (Yoshikawa, Rettig, et al. 1994) and osteoid osteomas 
(Urist, et al. 1979). 
Recently, overexpression of BMP4 was associated with resistance to chemotherapy in 
patients with OS (Zhou, Shi, et al. 2017) and that it could be a therapeutic target in cancers 
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such as malignant glioma (Xi, et al. 2017) and lung carcinoma (Wu, et al. 2017). Furthermore, 
BMP4 expression was correlated with poor prognosis (Yoshikawa, et al. 1988; Yoshikawa, et 
al. 1993) and may play a role in the tumorigenesis of human OS (Yoshikawa, et al. 1985; 
Yoshikawa, et al. 1993).  
Data collected from bone cancer studies of BMPs help to elucidate not only the 
pathogenesis of bone cancers, but also the genetic basis of normal bone formation and repair. 
Further studies are required to elucidate the signalling pathway of BMP in OS. 
1.8 Parathyroid hormone-related protein (PTHrP) and its receptor (PTHR1) in OS 
1.8.1 PTHrP in normal and tumour tissue 
PTHrP was first discovered as the causative factor of humoral hypercalcemia of 
malignancy syndrome (Strewler, et al. 1987; Suva, et al. 1987). This syndrome occurs because 
of increased secretion of PTHrP from tumour cells resulting in elevated levels of calcium in 
serum and increasing cyclic adenosine 3′,5′-monophosphate (cAMP) excretion in urine 
(Stewart, et al. 1980; Moseley, et al. 1987). In humans, PTHrP is synthesised as a protein with 
either 139, 141 or 173 amino acids due to differences in mRNA splicing (Brandt, et al. 1994). 
PTHrP shares homology of its N-terminal amino acid sequence (1-34) with parathyroid 
hormone (PTH) (Suva, et al. 1987). This allows both hormones to act through a common 
receptor (PTH/PTHrP receptor or PTHR1) (Juppner, et al. 1991) as discussed below (section 
1.8.2). 
1.8.1.1 Normal roles for PTHrP 
PTHrP acts as an autocrine or paracrine factor, and has a role in numerous significant 
physiological processes in bone, such as the regulation of chondrocyte and osteoblast 
differentiation and the proliferation in the growth plates of developing long bones (Kano, et al. 
1992; Kronenberg 2003). In bone tissue, PTHrP maintains the columnar organisation of the 
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chondrocytes and slows down their differentiation (Kronenberg 2003). Recently, Garcia-
Martin, et al. (2014) suggested that PTHrP promotes proliferation of osteoblasts and matrix 
mineralisation via three partially redundant mechanisms. These mechanisms are an intracrine 
nuclear localisation signal-dependent mechanism, an autocrine/paracrine signal-
peptide/PTHR1-dependent mechanism, and mixed mechanism (Garcia-Martin, et al. 2014). 
Thus, secretion of PTHrP and subsequent activation of PTHR1 would induce proliferation and 
mineralisation of osteoblastic cells (Garcia-Martin, et al. 2014). 
In addition, PTHrP is involved in significant processes in other tissues including breast 
(Neville, et al. 2002; VanHouten, et al. 2004) and placenta (Rodda, et al. 1988; Kovacs, et al. 
1996).  In the breast, PTHrP is abundant in milk, it is produced via the lactating breast and has 
an important role in branching morphogenesis of the mammary glands (Neville, et al. 2002; 
VanHouten, et al. 2004). The concentration of PTHrP in plasma is increased during lactation 
resulting in the regulation of calcium transport from blood into the milk (VanHouten, et al. 
2004) and stimulation of calcium mobilisation from bone (Neville, et al. 2002). In the placenta, 
PTHrP has a role in regulating the direct transport of maternal calcium to the fetus across the 
placental membrane (Rodda, et al. 1988; Kovacs, et al. 1996). 
1.8.1.2 Roles of PTHrP in cancer 
In addition to its normal roles, several studies have reported the involvement of PTHrP 
in tumorigenesis (Luparello, et al. 1995; Cataisson, et al. 2000; Hiraki, et al. 2002; Rabbani, et 
al. 2005). It has been found that PTHrP has a role in the activation of protein kinase A (PKA) 
and C (PKC) pathways (Maioli, et al. 2007), regulation of primary tumour growth and in 
metastasis (Rabbani, et al. 2005). Luparello, et al. (1995) found that PTHrP stimulates cell 
invasion using the 8701-BC human primary breast ductal infiltrating carcinoma cell line. 
Further data obtained from immortalised human mammary epithelial cell lines (S1T3, S2T2 
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and NS2T2A1) indicated that PTHrP stimulates proliferation of tumour cells (Cataisson, et al. 
2000).  
Another study found that PTHrP concentration was a prognostic factor for short 
survival and bone metastases in patients with lung carcinoma (Hiraki, et al. 2002). Recently, 
Hastings, et al. (2017) also revealed that increased expression of PTHrP is correlated with poor 
prognosis in lung carcinoma. Iguchi, et al. (1996) established the role of PTHrP in bone 
metastasis in mice models using human lung squamous cell carcinoma-derived cells. Breast 
and lung cancers usually cause osteolytic metastases in bone (Hofbauer and Schoppet 2004). 
This osteolytic process depends on osteoclast-mediated bone resorption via up-regulated 
osteoclastogenesis (Hofbauer and Schoppet 2004). Osteoclast differentiation factors, which 
play a significant role in this process are receptor activator of nuclear factor-jB (RANK), its 
ligand (RANKL) and the decoy receptor, osteoprotegerin (OPG) (Hofbauer and Schoppet 
2004). In humans, positive PTHrP staining was seen in 60% of primary breast tumours 
(Southby, et al. 1990) and 92% of bone metastases (Powell, et al. 1991). Recently, Kim, et al. 
(2016) showed that activation of the calcium-sensing receptor (CaSR), a G protein-coupled 
receptor (GPCR), up-regulated the production of PTHrP in breast cancer in vitro. As a result, 
this enhanced proliferation of breast cancer cells and reduced apoptosis (Kim, et al. 2016). It 
was observed that reducing the expression of CaSR in vivo and in vitro inhibited the production 
of PTHrP and reduced the growth of the breast cancer (Kim, et al. 2016).  
In addition to breast and lung cancers, PTHrP has been found to stimulate tumour cell 
survival and proliferation in other cancers including chondrosarcoma (Miyaji, et al. 2003), 
anaplastic thyroid cancer (Dackiw, et al. 2005), medulloblastoma (Embryonal neuroepithelial 
tumour of the cerebellum) (Gessi, et al. 2007), adrenocortical cancer (Rizk-Rabin, et al. 2008), 
oral squamous cancer (Yamada, et al. 2008), colon cancer (Parri and Chiarugi 2010), prostate 
cancer (Bhatia, et al. 2009) and renal cancer (Talon, et al. 2006). It has also been found that 
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PTHrP is an essential growth factor for human clear cell renal carcinoma (CCRC) and acts as 
a novel target for the von Hippel-Lindau tumour suppressor protein in vitro (Massfelder, et al. 
2004). Talon, et al. (2006) revealed that apoptosis could be induced in the human CCRC cell 
line via the induction of PTHrP-neutralising antibodies followed by the inhibition of PTHR1. 
Furthermore, Danilin, et al. (2009) showed that the mRNA-binding protein HuR is involved in 
increased expression of PTHrP and in mRNA stabilisation in CCRC. Recently, PTHrP was 
observed to be highly expressed in pancreatic adenocarcinoma (Yamada, et al. 2017), 
intrahepatic cholangiocarcinoma (Takeda, et al. 2017), pancreatic neuroendocrine cancer and 
that PTHrP levels were elevated in the patient serum (Symington, et al. 2017). In addition to 
its role in tumorigenesis, Kir, et al. (2014) showed that PTHrP is involved in cancer cachexia, 
a wasting disorder of adipose and skeletal muscle tissues that leads to intensive weight loss 
resulting in reduced survival time in patients with cancer. PTHrP drives the expression of genes 
that are involved in thermogenesis in adipose tissue (Kir, et al. 2014). It was demonstrated that 
the genes responsible for fat and muscle tissue loss were neutralised by anti-PTHrP antiserum 
(Kir, et al. 2014). In summary, PTHrP is a crucial factor in the pathogenesis of many tumours. 
1.8.1.3 Roles of PTHrP in OS 
The first attempt to understand the role of PTH in OS was by Martin, et al. (1976) via 
inducing OS in rats using radioactive phosphorous isotopes. Several later studies found that 
PTHrP also plays a role in pathogenesis of OS (Rodan, et al. 1989; Suda, et al. 1996; Walsh, 
et al. 1997; Jemtland, et al. 1999; Pasquini, et al. 2002). Suda, et al. (1996) demonstrated the 
expression of PTHrP mRNA in all investigated rat UMR 106-01 and UMR 106-06 OS cell 
lines. Recently, Ho, et al. (2015) revealed that PTHrP is also expressed by murine OS cells. In 
contrast, PTHrP mRNA was not detected in aggressive human OS xenografts (Yang, et al. 
2007). It has also been found that increased expression of the PTHrP gene is associated with 
reduced tumour growth and cell proliferation using a murine OS cell line (Pasquini, et al. 2002) 
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and a rat OS cell line (Motomura, et al. 1996). Previous findings discussed above showed that 
over-expression of PTHrP could be correlated with better prognosis for OS.    
However, Gagiannis, et al. (2009) noted that PTHrP caused tumour cells of the SaOS-
2 human OS cell line to be chemoresistant. This was observed after inhibiting major apoptosis 
signalling pathways via blocking the death receptor and mitochondria-mediated apoptosis 
signalling (Gagiannis, et al. 2009). It has also been found that PTHrP stimulates migration of 
SaOS-2 and MG-63 OS cell lines (Berdiaki, et al. 2010). These two studies suggest that 
overexpression of PTHrP could be correlated with a poorer prognosis of OS (Gagiannis, et al. 
2009; Berdiaki, et al. 2010). These conflicting data may be related to the use of different PTHrP 
sequences in these different studies (Garcia-Martin, et al. 2014; Martin 2016).  
Ho, et al. (2015) found that the three major OS subtypes (osteoblastic, chondroblastic 
and fibroblastic OS) produce PTHrP, which act through the PTHR1 to activate adenylyl 
cyclase, PKA, and the transcription factor cAMP responsive element binding protein 1 
(CREB1) (Ho, et al. 2015). The osteoblastic subtype produces a greater amount of PTHrP 
protein compared with the fibroblastic subtype (Ho, et al. 2015). This may explain the increased 
differentiation of the osteoblastic subtype and may explain all the steps of OS pathogenesis 
from initiation and establishment of the disease, to invasion, and the spreading to other sites 
(Martin 2016). The knockdown of PTHrP in OS, reduced cell growth and invasion in vitro and 
increased apoptosis and growth inhibition in vivo while, the knockdown of CREB1 had a much 
greater growth inhibition and apoptosis (Ho, et al. 2015). 
Moreover, Walia, et al. (2016) revealed that PTHrP is a key factor for initiation of OS 
in p53-deficient osteoblasts. The production of cAMP is stimulated by PTHrP (Walia, et al. 
2016). This stimulation is followed by PTHR1 activation, then, CREB1 phosphorylation and 
transcription is activated in p53-deficient OS (Walia, et al. 2016). It was suggested that PTHrP-
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cAMP-CREB1-axis is essential for the initiation and progression of OS in p53-deficient 
osteoblasts (Walia, et al. 2016).  
In summary, the above data showed that PTHrP is crucial for tumorigenesis of OS and 
increased expression could be linked with poor prognosis. However, further in vivo studies are 
necessary to clarify the exact roles of PTHrP in the tumorigenesis of OS.  
1.8.2 PTHR1 in normal and tumour tissue  
PTHR1 is a seven-transmembrane class B GPCR (Gensure, et al. 2005). Examples of 
receptors included in this family are the receptors for secretin, glucagon, pituitary adenylate 
cyclase-activating peptide, growth hormone-releasing hormone, vasoactive intestinal peptide, 
corticotrophin-releasing factor, glucagon-like peptide, calcitonin, and gastric inhibitory peptide 
(Kolakowski 1994). Structurally, PTHR1 contains N-terminal extracellular domain (ECD) of 
∼100-160 amino acid residues, a transmembrane domain (TMD) containing the seven 
membrane-spanning α-helices and a C-terminal tail (Hoare 2005). 
PTHR1 is activated by the binding of the N-terminal (1-34) amino acids of PTH or 
PTHrP (Kolakowski 1994). The NH2-terminal part of PTH/PTHrP binds to the extracellular 
connecting loops and the TMD α-helices of PTHR1 (Gardella, et al. 1994; Luck, et al. 1999). 
This interaction induces conformational changes in PTHR1, which initiates intracellular 
signalling (Shimizu, et al. 2000; Castro, et al. 2005). However, the COOH-terminal part of 
PTH/PTHrP binds to the N-terminal ECD of PTHR1 (Caulfield, et al. 1990; Juppner, et al. 
1994). 
Activation of PTHR1 initiates events of intracellular processes by signalling through 
the stimulatory G-protein α-subunit (Gsα) (Schwindinger, et al. 1998). Subsequently, the 
synthesis of cAMP is stimulated and PKA is triggered (Abou-Samra, et al. 1992). However, 
PTHR1 can be activated by another signalling pathway through the Gq class of G-protein α-
subunits (Gqα) (Offermanns, et al. 1996). This activation results in triggering phospholipase C 
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(Offermanns, et al. 1996) which in turn activates PKC and raises inositol triphosphate and 
intracellular calcium in tissues (Abou-Samra, et al. 1992; Mannstadt, et al. 1999). 
1.8.2.1 Normal roles for PTHR1 
PTHR1 is found mainly in bone and kidney (Liao and McCauley 2006), and is involved 
in mineral ion homeostasis, bone turnover and skeletal development (Cheloha, et al. 2015). In 
bone, PTHR1 regulates function, differentiation and proliferation of chondrocytes and 
osteoblasts (Bos, et al. 1996; Amizuka, et al. 1999; Langub, et al. 2001). It also controls calcium 
release from the matrix (Quinn, et al. 1998; Yasuda, et al. 1998). 
In the kidney, PTHR1 has a role in the reabsorption of calcium in the distal convoluted 
tubule (Gensure, et al. 2005; Bacic, et al. 2006) and in the maintenance of blood phosphate 
levels via inhibiting phosphate reabsorption in the distal and proximal tubules (Cheng and 
Sacktor 1981; Bringhurst 1989). It also increases the activity of 1α-hydoxylase, resulting in 
increased calcium absorption from the intestine through increasing levels of 1,25-
dihydroxycholecalciferol (Gensure, et al. 2005; Bacic, et al. 2006).   
1.8.2.2 Roles of PTHR1 in cancer 
Expression of PTHR1 protein was demonstrated in human primary tumours, including 
melanoma (100%), prostate adenocarcinoma (100%), colorectal carcinoma (100%), OS (50%), 
renal cell carcinoma (23%) and breast carcinoma (17%) (Lupp, et al. 2010). Studies showed 
that expression of PTHR1 was also detected in several human breast cancer cell lines (Birch, 
et al. 1995; Cataisson, et al. 2000). Previously, Linforth, et al. (2002) found that expression of 
PTHR1 is correlated with poor prognosis in patients with primary breast cancer whilst Hoey, 
et al. (2003) reported that PTHR1 was highly expressed in breast cancer metastases compared 
to the primary cancer using MCF-7 cells. The overexpression of PTHR1 stimulates tumour cell 
proliferation through autocrine signals, which are mediated by cAMP and extracellular signal-
regulated kinase (ERK) pathways (Hoey, et al. 2003). 
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In addition to PTHR1, recent studies have shown that overexpression of other GPCRs 
were associated with poor prognosis in pancreatic, breast and prostate cancers (Li, et al. 2013; 
Yang, et al. 2016; Wang, et al. 2017). Li, et al. (2013) found that increased expression of 
purinergic receptor P2Y2, a class A GPCR, is correlated with a poor prognosis in prostate 
cancer. Moreover, protease-activated receptor 1 (PAR1), a second class A GPCR, was reported 
to be highly expressed in aggressive breast tumours (Yang, et al. 2016). (Wang, et al. 2017) 
found that overexpression of GPR87, another class A GPCR, is linked with reduced survival 
for patients with pancreatic cancer. Furthermore, GPR87 was reported to stimulate metastasis 
in vitro (Wang, et al. 2017). These data might support the carcinogenesis of PTHR1 and other 
GPCRs. 
PTHR1 was not well studied in cancers other than breast and OS. The coming section 
highlights the critical roles of PTHR1 in OS. 
1.8.2.3 Roles of PTHR1 in OS 
Numerous studies using human cell lines (Yang, et al. 2007), murine tissues (Ho, et al. 
2015) and human tissues (Lupp, et al. 2010) have reported the correlation between 
overexpression of PTHrP and PTHR1 in OS. Mutsaers, et al. (2013) detected PTHR1 in 
primary and metastatic OS of osteoblastic and fibroblastic subtypes in vivo. It has been 
suggested that increased expression of PTHR1 in OS could stimulate progression by formation 
of a more aggressive subtype (Yang, et al. 2007). PTHR1 mRNA is highly expressed in 
metastatic human OS compared with primary tumours (Yang, et al. 2007). Overexpression of 
PTHR1 was linked with increased invasion and proliferation in OS cell lines (Yang, et al. 
2007). In addition, Ho, et al. (2015) reported that knockdown of PTHR1 in murine OS cells 
stimulated tumour differentiation and decreased invasion and growth. It has been found that 
reduced expression of PTHR1 in vivo enhanced mineralisation and differentiation in OS (Ho, 
et al. 2015). 
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The pathway of PTHR1 in tumorigenesis of OS was suggested by Walkley, et al. 
(2014). Under normal conditions, PTHrP binds and activates PTHR1 located on the surface of 
osteoblasts. Activation of PTHR1 leads to the synthesis of cAMP from ATP via adenylyl 
cyclase. Consequently, cAMP induces the detachment of cAMP-dependent PKA from its α 
regulatory subunit of PKA type 1 (PRKAR1A) (Walkley, et al. 2014). Activated PKA 
translocates into the nucleus to phosphorylate and activate CREB. As a result, target genes 
downstream of PTHR1 signalling are activated (Walkley, et al. 2014). In OS, several 
abnormalities in the PTHrP-PTHR1-PKA pathway increased the activity of PKA pathway. 
This includes an elevated number of PTHR1 on the cell surface and increased expression of 
the Prkaca gene that encodes the catalytic component of PKA (Walkley, et al. 2014). Other 
abnormalities are increased production of PTHrP, which can bind to PTHR1 and promote the 
formation of cAMP and mutations in PRKAR1A gene, which result in an increase in the PKA 
activity (Walkley, et al. 2014). 
Past studies have reported that integrin adhesion molecules are involved in the 
migration of OS cells (Scotlandi, et al. 1993; Miura, et al. 2005; Tome, et al. 2013). Up-
regulation of integrins including α5β1, α2β1, α6β1 (Scotlandi, et al. 1993), β1 (Miura, et al. 
2005) and αvβ3 (Tome, et al. 2013) was associated with metastasis in OS. PTHR1 could have 
a role in down-regulation or up-regulation of cell-cell or cell-extracellular matrix adhesion 
molecules. Integrins might be up-regulated by PTHR1 in aggressive OS. 
In summary, these studies show that detection of PTHR1 in OS could be correlated with 
poor prognosis and may be able to be used as a therapeutic target. 
In conclusion, OS is a rare, deadly and complex disease. Although several studies have 
been carried out to elucidate the molecular pathogenesis and etiology of OS using human tissue, 
murine and canine models, the disease remains an unsolved puzzle. 
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Canine models are rarely used to study human OS, even though they are more similar 
to human OS than other models. Further studies should focus on future possibilities of using 
canine models to understand human OS and on investigating new novel tumour markers that 
may help to design new chemotherapeutic agents. More studies are also required to clarify the 
correlation between OS histological subtypes and the prognosis. Moreover, further studies are 
warranted to investigate the expression of PTHrP and PTHR1 and its association with survival 
time for patients with OS. This could help categorise patients based on their risk-based 
assessment. 
1.9 Hypothesis and aims of the project  
1.9.1 Hypothesis 
The broad aims of the thesis were to investigate the utility of canine OS as a model for 
human OS and to examine whether PTHR1, PTHrP and the histological subtypes are 
significant prognostic indicators in canine OS. Based on previous findings, we hypothesized 
that: 
1- Canine OS is a suitable natural model for human disease. 
2- Canine patients with OS tumours showing strong PTHrP and PTHR1 immunoreactivity have 
shorter survival times when compared with those with a moderate or weak staining. 
3- Canine patients with different OS histological subtypes have different prognoses. 
1.9.2 Aims 
This project aims to: 
1- Validate canine OS as a model for human OS by demonstration and analysis of the 
expression of the following tumour cell markers previously identified in human OS: 
vimentin, alkaline phosphatase (ALP), desmin, S100, neuron-specific enolase (NSE), 
runt-related transcription factor 2 (Runx2) and bone morphogenetic protein 4 (BMP4). 
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2- Investigate whether the detection of PTHrP and PTHR1 are significant prognostic 
indicators of canine OS by demonstrate whether their detection in tissues correlates 
with survival. 
3- Examine whether the histological subtypes of canine OS have different prognoses and 
whether the differences in the localisation of desmin, S100 and NSE are associated with 
histological subtypes. 
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Chapter 2 
2.0 Materials and methods 
All materials used in this thesis are mentioned in Table 2.1 and all antibodies are 
described in Table 2.2. 
2.1 Materials 
Table 2.1 Details of reagents and materials used for different methods. 
Reagents  Company City, Country Catalogue number  
Instant skim milk 
powder 
Commercial sources NA - 
3,3'-diaminobenzidine 
(DAB) buffered 
substrate 
CINtec Newcastle, Australia 9511 
3,3'-diaminobenzidine 
(DAB) chromogen 
CINtec Newcastle, Australia 9511 
Dibutylphthalate 
polystyrene xylene 
(DPX) 
Grale Scientific Ringwood, Australia TC72440QQ 
En vision FLEX 
(Antibody diluent) 
Dako Sydney, Australia K8006 
Eosin (1 % aqueous 
solution) 
Amber Scientific Perth, Australia  EOS1-1L 
Epitope retrieval 
solution with high pH 
(pH 8.0)  
CINtec  Newcastle, Australia 9511 
Epitope retrieval 
solution with low pH 
(pH 6.0)  
Dako  Sydney, Australia K8005 
Ethanol absolute Grale Scientific Ringwood, Australia AL048/20P 
Hydrogen peroxide 
(3%) 
Biotech 
pharmaceuticals 
Laverton North, 
Australia 
- 
Mayer’s haematoxylin Amber Scientific  Midvale, Australia  MH-5L 
Negative reagent 
control 
CINtec Newcastle, Australia 9511 
Neutral buffered 
formalin (10%) 
Grale Scientific Ringwood, Australia NBF-5L 
Tissue embedding 
medium (Paraplast) 
Leica Mount Waverley, 
Australia  
39601006 
Triton x-100 (1%) Amersham 
Biosciences 
Uppsala, Sweden 17-1315-01 
Xylene  Grale Scientific Ringwood, Australia XL005/20 
 
  
 57 
 
Table 2.2 Details of primary and secondary antibodies used for IHC staining. 
 Antibody Source Species reactivity Clone Cat. No. Company 
P
ri
m
ar
y
 a
n
ti
b
o
d
ie
s 
Anti-vimentin Mouse Human  V9 CM048A Biocare 
Anti-ALP Rabbit Human, mouse and 
rat 
Polyclonal ab95462 Abcam 
Anti-Runx2 Rabbit Human, dog, mouse 
and rat 
Polyclonal ab23981 Abcam 
Anti-BMP4 Rabbit Human,  cow, 
mouse, pig and rat 
Polyclonal ab39973 Abcam 
Anti-desmin Mouse Human, mouse and 
rat 
D33 CM036A Biocare 
Anti-S100 Rabbit Human  Polyclonal IS504 Dako 
Anti-NSE Mouse Human BBS/NC/VI-
H14 
IS612 Dako 
Anti-PTHR1 
(H-125) 
Rabbit Dog, cow, horse and 
pig 
Polyclonal Sc-20749 Santa Cruz 
Anti-PTHrP 
(N-19) 
Goat Dog, chicken, cow, 
hours, human, 
mouse, pig and rat 
Polyclonal Sc-9680 Santa Cruz 
       
S
ec
o
n
d
ar
y
 a
n
ti
b
o
d
ie
s 
Dual Link 
System-HRP 
IgG (En vision 
FLEX) 
Goat Mouse/Rabbit Polyclonal K4061 Dako 
Mouse anti-
rabbit 
Mouse Rabbit MR12/53 M0737 Dako 
Rabbit anti-
goat 
Rabbit Goat Polyclonal P0449 Dako 
Goat anti-
mouse 
Goat Mouse Polyclonal 9511 CINtec 
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2.2 Methods 
2.2.1 Ethics statement 
Because the tissue used in this project was not collected specifically for the purposes 
of research, but was discard tissue removed as part of normal treatment, it did not meet the 
definition of scientific procedure within the legislation of Australian Code for the Care and Use 
of Animals for Scientific Purposes, 8th edition (2013). As a result, Animal Ethics Committee 
approval for this project was not required (see Appendix 1). 
2.2.2 Canine OS tumour samples and data collection 
For this project, a total of 106 formalin-fixed, paraffin-embedded (FFPE) tissue blocks 
which had been diagnosed as being primary canine OS (sex: 57 males, 49 females; age: 1-15 
years; 71 appendicular OS, 35 axial OS) were collected between 1991 and 2016 either from 
Bristol University Veterinary Pathology Department, Bristol, UK (Bristol-56 group) (n= 56) 
(see Table 2.3) or from Australian Specialised Animal Pathology (ASAP) laboratory, Clayton, 
Australia (ASAP-50 group) (n= 50) (see Table 2.4). 
The tissue blocks that originated from Bristol University Veterinary Pathology 
Department were collected from the archival collection of the Pathology Unit. The diagnostic 
report for each case was available and contained patient data including breed, sex, age and the 
affected area. Data for metastasis, survival time, body weight and serum alkaline phosphatase 
(ALP) measurements were not available for this group.  
The samples that were obtained from the ASAP laboratory were collected 
prospectively. For each case, the following data were gathered from the patient report: breed, 
sex, age and the affected part of the body. Data for metastasis was gathered from veterinary 
clinics and from the dogs’ histopathology diagnostic reports. Survival data and treatment 
regimens were obtained by contacting the veterinary clinics that treated the dogs. Data for body 
weight was not available for this group of dogs, while serum ALP concentrations were 
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available for some of the patients. Dogs were followed up through intermittent visits to the 
treating veterinarians but not by radiographs or blood tests. The classification of dog breed 
sizes as small or large breeds was modified from (Australian.National.Kennel.Council 2019) 
and based on the general body weight of each breed. According to Australian National Kennel 
Council (ANKC), group 1 (Toys) and group 2 (Terriers) are classified as small breeds, while 
other groups such as group 3 (Gundogs); group 4 (Hounds); group 5 (Working Dogs) are 
classified as large breeds.   
All canine OS specimens included were decalcified using hard decalcification fluid 
(formic acid 9.8%, hydrochloric acid 8.46%) (Australian Biostain, Traralgon, Australia) or 
decalcification fluid (formic formal saline - (formaldehyde BP 4%, formic acid 33%, sodium 
chloride 0.85%)) (Australian Biostain, Traralgon, Australia). The decalcification time 
depended on the hardness and size of the bone biopsy and ranged from one hour to three weeks. 
The fixation time and processing method for these tumour tissues were unknown and assumed 
to be standard (fixation: in 10% neutral buffered formalin fixative solution for 24 hours, 
processing as is seen in Table 2.6).  
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Table 2.3 Clinicopathological data for canine OS tumours collected from the Bristol 
University Veterinary Pathology Department (Bristol-56).   
Case 
number 
Breed Sex Age Body part 
1 Retriever F 6 Jaw 
2 Rottweiler M 9 Tibia 
3 Old English sheepdog F 5 Femur  
4 Rottweiler F 10 Tibia 
5 Rottweiler F 7 Radius 
6 Doberman F 9 Femur 
7 Great Dane M 7 Radius 
8 St Bernard F 7 Radius 
9 Golden Retriever F 6 Jaw  
10 German Shepherd Dog F 8 Jaw 
11 Border Collie M 11 Tibia 
12 Border Collie M 7 Rib 
13 Border Collie M 6 Femur 
14 Flat Coated Retriever M 1 Tibia 
15 Rottweiler F 6 Radius 
16 Rottweiler F 2 Rib 
17 Labrador M 10 Humerus  
18 Rottweiler M 8 Rib 
19 Spaniel M 11 Humerus  
20 Mastiff M 8 Scapula  
21 German Shepherd Dog 
Cross 
F 10 Humerus 
22 Great Dane M 5 Radius 
23 Boxer F 11 Femur  
24 Rottweiler F 5 Jaw 
25 Golden Retriever M 12 Ulna  
26 Rottweiler M 3 Radius 
27 Lurcher M 8 Radius 
28 Rottweiler F 7 Tibia 
29 Rottweiler F 6 Tibia 
30 German SH Pointer F 4 Radius 
31 Bull Mastiff M 4 Rib 
32 German Shepherd Dog 
Cross 
F 3 Humerus 
33 Greyhound M 11 Radius 
34 Labrador F 11 Rib 
35 Staffordshire Bull Terrier M 8 Skull 
36 Doberman F 7 Jaw  
37 Labrador M 10 Rib 
38 Golden Retriever F 6 Vertebrae 
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39 Golden Retriever F 9 Vertebrae 
40 Golden Retriever F 9 Ilium  
41 Irish Red Setter M 1 Tibia 
42 German Shepherd Dog 
Cross 
F 9 Humerus 
43 Border Collie M 11 Humerus 
44 Lurcher M 10 Radius 
45 Lurcher M 10 Scapula  
46 Labrador M 7 Tibia 
47 Labrador F 10 Tibia 
48 Boxer Cross F 11 Jaw 
49 Greyhound F 8 Tibia  
50 Collie Cross M 13 Toe 
51 Retriever F 9 Skull 
52 Border Collie cross M 8 Skull 
53 Labrador M 13 Humerus 
54 Doberman M 8 Skull 
55 Doberman F 9 Femur  
56 German Shepherd Dog F 5 Skull 
F, female; M, male. 
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Table 2.4 Clinicopathological data for canine OS tumours collected from ASAP 
laboratory (ASAP-50). 
Case 
number 
Breed Sex Age Body part 
1 Staffordshire Bull Terrier F 12 Humerus 
2 Greyhound M 10 Tibia 
3 Rottweiler M 1 Humerus 
4 Boxer Cross M 11 Femur 
5 Mastiff F 7 Rib 
6 Bulldog M 10 Tibia 
7 Labrador Retriever M 8 Radius 
8 Giant Schnauzer M 7 Radius 
9 Boxer   F 10 Rib 
10 German Shepherd Dog F 11 Radius 
11 Rottweiler Cross F 8 Jaw 
12 Spoodle M 10 Rib 
13 Schnauzer Cross M 11 Rib 
14 Doberman F 10 Tibia 
15 Rottweiler M 8 Humerus 
16 Rottweiler F 9 Jaw 
17 Golden Retriever M 8 Humerus 
18 Golden Retriever M 14 Femur 
19 Rottweiler Cross M 9 Ilium  
20 Doberman M 9 Radius 
21 Labrador F 7 Radius 
22 Jack Russell Terrier M 8 Jaw 
23 Rottweiler F 4 Humerus 
24 Blue Heeler M 12 Tibia 
25 Golden Retriever M 13 Jaw 
26 Mastiff Cross M 6 Femur 
27 Cairn Terrier F 12 Humerus 
28 Boxer Cross F 15 Jaw 
29 Jack Russell Terrier F 9 Scapula 
30 Labrador M 11 Humerus 
31 Cavalier Cross M 10 Humerus 
32 Labrador M 13 Jaw 
33 Border Collie M 6 Femur 
34 Labradoodle M 3 Rib 
35 Pointer Cross F 9 Radius 
36 Rottweiler Cross F 9 Humerus 
37 Border Collie Cross F 13 Scapula 
38 American Staffordshire Bull 
Terrier 
M 12 Vertebrae  
39 White Swiss Shepherd Dog F 9 Ilium  
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40 Maltese Cross M 13 Jaw 
41 SBT Cross F 9 Humerus 
42 Alaskan Malamute M 6 Radius 
43 Rottweiler F 11 Tibia 
44 Curly Coated Retriever F 11 Humerus 
45 Boxer F 7 Skull 
46 Labrador M 8 Humerus 
47 Jack Russell Terrier M 14 Jaw 
48 Labrador M 7 Femur 
49 Greyhound M 11 Femur 
50 Labradoodle M 7 Humerus 
SBT, Staffordshire Bull Terrier; F, female; M, male. 
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2.2.3 Control canine tissue samples 
 Normal control tissue for each tumour marker was obtained from The University of 
Melbourne Veterinary Hospital, Werribee, Australia (see Table 2.5). These canine tissues were 
FFPE, sectioned at 3 μm-thickness and fixed on positively charged glass slides (see Section 
2.2.4). Positive ‘with primary antibody’ and negative ‘no primary antibody’ controls (negative 
reagent control) were run with each IHC experiment. A negative control section (without 
primary antibody) for each case was run to eliminate false positive results and to check the 
cross-reactivity as well as the specificity of the secondary antibody. 
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Table 2.5 Normal canine positive control tissue used for each tumour marker.  
Protein tumour 
marker  
Positive control tissue 
Vimentin Skin (abdomen) 
ALP Kidney (glomeruli and tubules) 
Runx2 Skeletal muscle (limb) 
BMP4 Kidney (glomeruli and tubules) 
Desmin Uterus (smooth muscle) 
S100 Brain (cerebrum region) 
NSE Brain (cerebrum region) 
PTHR1 Kidney (glomeruli and tubules) 
PTHrP Kidney (glomeruli and tubules) 
ALP, alkaline phosphatase; Runx2, Runt-related protein 2; BMP4, bone morphogenetic protein 4; NSE, neuron-
specific enolase; PTHR1, parathyroid hormone receptor 1; PTHrP, parathyroid hormone-related protein. 
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2.2.4 Tissue fixation, processing and sectioning 
Tissue samples were received in 10% neutral buffered formalin fixative solution and 
were kept in the fixative for 24 hours before processing. Tissue samples were processed using 
a Leica ASP200S sample processor sourced from Leica, Mount Waverley, Australia. The 
tissues were initially dehydrated through graded alcohol. Then, they were cleared using xylene 
and were run through three changes of paraffin wax. Next, the tissues were embedded in 
paraffin wax using a Leica EG1160 Embedding Centre sourced from Leica, Mount Waverley, 
Australia (see Table 2.6). 
Paraffin-embedded blocks of canine control and OS tissues were sectioned (RM2235, 
Leica, Mount Waverley, Australia) at 3 μm-thickness using a microtome, and were fixed on 
positively charged microscopic glass slides (Superfrost plus sourced from Trajan Scientific, 
Ringwood, Australia). Four mega paraffin-embedded blocks of canine OS tissues were 
received from Bristol University Veterinary Pathology Department, Bristol, UK and sectioned 
using a special microtome mega block holder. In order for the tissue sections to fit onto standard 
glass slides, each tissue section from a mega block was cut in half and fixed on two slides. 
2.2.5 Progressive Mayer’s haematoxylin and eosin (H&E) staining 
Progressive Mayer’s H&E staining was performed on sections for each case to localise 
malignant spindle-cells and to identify the type of extracellular matrix. This was carried out 
according to the staining protocol shown in Table 2.7. The slides were de-waxed in two changes 
of xylene for five minutes each. Sections on the slides were hydrated with graded alcohol and 
then running tap water. After that, they were stained with Mayer’s haematoxylin for five 
minutes. The sections were washed briefly in running tap water then immersed in Scott’s 
tapwater for one minute. Then, they were examined microscopically and washed again in 
running tap water for two minutes, before being stained in 1% aqueous eosin for two minutes 
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and then rinsed with tap water. Finally, the sections were dehydrated through graded alcohol 
and running tap water, cleared in xylene, mounted in DPX, cover-slipped and labelled. 
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Table 2.6 The method of tissue processing used for canine tissue samples. 
Reagent  Temperature (ºC) Duration (min) 
Neutral buffered formalin 
(10%) 
25 20 
Ethanol 70% 25 45 
Ethanol 90% 25 45 
Ethanol 100% x 3 25 60 each 
Ethanol/xylene (50/50) 25 60 
Xylene x 2 37 60 each 
Xylene 37 80 
Paraffin wax x 2 62 90 each 
Paraffin wax 62 140 
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Table 2.7 Protocol for progressive Mayer’s H&E staining, modified from (Gamble 2008). 
Steps Duration 
Xylene x 2 ………………………………. 
Absolute alcohol 100 % ………………... 
Absolute alcohol 100 % ……………… 
70 % alcohol ……………………………. 
Running tap water ……………………... 
Mayer haematoxylin …………………… 
Running tap water ……………………... 
Scott’s tapwater ………………………... 
Running tap water ……………………... 
1 % aqueous eosin ……………………… 
Tap water ………………………………. 
70 % alcohol ……………………………. 
Absolute alcohol 100 % x 2 …...………... 
Clear in xylene x 2 ……………………… 
Mount in DPX 
Each 5 min 
2 min 
2 min 
2 min 
5 min 
3-5 min 
Brief rinse  
1 min 
2 min 
1-2 min 
Rinse 
2 min 
Each 2 min 
Each 5 min  
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2.2.6 Confirmation, sub-classification and tumour grading of canine OS 
Canine OS was confirmed and sub-classified histopathologically by the detection of 
osteoid (osteoblastic OS), cartilage (chondroblastic OS) or non/minimal amounts of both 
(fibroblastic OS) (Fletcher, et al. 1994; Kirpensteijn, et al. 2002; Thompson and Dittmer 2017), 
according to the World Health Organisation (WHO) classification of bone tumours for human 
OS (Dorfman, et al. 2002) and the classification of bone tumours for domestic animals 
(Thompson and Dittmer 2017). Mixed subtypes of OS were observed in 34/106 cases. The final 
diagnosis was based on the most common histological features of the tumour and the 
extracellular matrix (see Table 5.1).  
Tumours were categorised as low (G1) or high grade (G2) (see Table 5.1) based on the 
grading system described by Enneking, et al. (1980). According to this system, the grade (G) 
of the tumour is an indication of how likely a tumour is to grow and spread based on the 
histological assessment (i.e. how aggressive the tumour appears). Histologically, in low grade 
tumours (G1), cells appear morphologically close to normal cells but display other features of 
neoplasia such as high mitotic figures and a presence of giant cells. These tumours grow and 
spread slowly. In high grade tumours (G2), cells widely display the aggressive features of a 
neoplasm (multi-shaped; multinucleated; high mitotic figures) and are likely to grow and 
spread quickly (Enneking, et al. 1980). 
Confirmation of diagnosis of canine OS, subtyping and tumour grading were carried 
out by a veterinary pathologist Dr. Mourad Tayebi, Western Sydney University, Sydney, 
Australia.  
2.2.7 Survival time 
One hundred canine OS histopathological reports were collected from the ASAP 
laboratory. More than 30 veterinary hospitals and clinics were contacted for survival times and 
other clinical data such as treatment procedures, metastasis status, serum ALP measurements, 
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radiograph reports and body weight at presentation for these dogs with OS. Response were 
received for 50 canine OS patients (ASAP-50) (see Appendix 2). FFPE tissue blocks for these 
50 cases were obtained from the ASAP laboratory. The survival times were analysed for the 
ASAP-50 group (n= 50 dogs) using a multivariate Cox regression analysis. Censored data were 
considered for those dogs who were still alive at the date of data collection (n= 3 dogs) or died 
because of post-surgical complications (n= 4 dogs). Survival time was defined as the number 
of days between surgery and euthanasia (n= 22 dogs) or death (n= 21 dogs) due to OS (see 
Appendix 2). 
In order to minimise variation in the samples and to study survival times for the smaller 
group that contained 20 dogs (ASAP-20) using univariate Cox regression analysis, dogs that 
had no surgical (n= 24) or no chemotherapy (n= 26) treatments were excluded from survival 
analyses. Additionally, four dogs that had pulmonary metastasis at presentation and 15 dogs 
that presented with OS localised in axial parts were excluded from survival analyses. The three 
dogs that were still alive at the date of data collection and the four dogs that died because of 
post-surgical complications were also excluded from survival analyses (see Appendix 2). The 
remaining 20 dogs (40%) (ASAP-20) that were affected with appendicular OS, had limb 
amputation and adjuvant chemotherapy using cisplatin or carboplatin as a single or multiple 
dose, did not have pulmonary metastasis at presentation and died due to their OS (see Table 
2.8).  
Samples were obtained from the following veterinary clinics and hospitals: Southpaws 
Specialty Surgery for Animals (16 cases), Advanced Veterinary Care (three cases), Gasing 
Veterinary Clinic (three cases), Preston Veterinary Clinic (three cases), Glenhuntly Road 
Veterinary Clinic (two cases), Hampton Veterinary Hospital (two cases), Knox Veterinary 
Clinic (two cases), Northcote Plaza Veterinary Clinic (two cases), Prahran Veterinary Hospital 
(two cases), Boronia Veterinary Clinic (one case), Burvale Heights Veterinary Hospital (one 
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case), Canterbury Veterinary Clinic (one case), Care Collingwood (one case), Carnegie 
Veterinary Clinic (one case), Endeavour Hills Veterinary (one case),  Ferntree Gully Veterinary 
(one case), Maroondah Veterinary Clinic (one case), Mitcham Pet Hospital (one case), Old 
Sale Road Veterinary (one case), Tarwin Veterinary Group (one case), Warby Street Veterinary 
Hospital (one case), West Gippsland Veterinary Care (one case), Westernport Veterinary 
Group (one case) and Yarrambat Veterinary Hospital (one case).  
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Table 2.8 Clinicopathological data for the 20 dogs (ASAP-20) with appendicular OS 
included in the survival analysis. 
Case 
number 
Breed Sex Age at 
diagnosis 
(year) 
Body 
part 
1 Cavalier Cross M 10 Humerus 
2 SBT Cross F 9 Humerus 
3 Alaskan 
Malamute 
M 6 Radius 
4 Greyhound M 10 Tibia 
5 Curly Coated 
Retriever 
F 11 Humerus 
6 Rottweiler F 4 Humerus 
7 Rottweiler M 1 Humerus 
8 Cairn Terrier F 12 Humerus 
9 Bulldog M 10 Tibia 
10 Dobermann F 10 Tibia 
11 Rottweiler Cross F 9 Humerus 
12 Labrador 
Retriever 
F 7 Radius 
13 Rottweiler F 11 Tibia 
14 Giant Schnauzer M 7 Radius 
15 Boxer Cross M 11 Femur 
16 Mastiff Cross M 6 Femur 
17 German 
Shepherd Dog 
F 11 Radius 
18 Labrador 
Retriever 
M 11 Humerus 
19 Greyhound M 11 Femur 
20 Labrador 
Retriever 
M 8 Radius 
SBT, Staffordshire Bull Terrier; F, female; M, male. 
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2.2.8 Optimisation of antibodies for immunostaining 
All antibodies were optimised for the different conditions listed in Tables 2.9a 
(monoclonal antibodies) and 2.9b (polyclonal antibodies). Slides with known positive control 
tissues were stained for the purpose of antibody optimisation, they were also screened and 
compared for background staining, intensity and specificity. Next, optimal conditions for each 
antibody were noted and recorded in Tables 3.2 and 4.2. Then, each targeted protein was 
localised in canine OS samples using the appropriately optimised conditions as described in 
Section 2.2.9. 
  
 75 
 
Table 2.9a The plan of monoclonal antibody optimisation used for IHC. 
Conditions Vimentin Desmin NSE 
Type of antigen retrieval Solution 1  
Solution 2 
Solution 1 
Solution 2 
Solution 1 
Solution 2 
Incubation time for antigen 
retrieval 
10 min / 97 °C 
20 min / 97 °C 
10 min / 97 °C 
20 min / 97 °C 
10 min / 97 °C 
20 min / 97 °C 
Dilution of primary Ab 1:50 & 1:100  RTU RTU 
Time and temperature of 
incubation with primary Ab 
20 min / RT 
30 min / RT 
30 min / RT 
45 min / RT 
20 min / RT 
30 min / RT 
Dilution of secondary Ab Goat anti-mouse 
RTU 
Goat anti-mouse 
RTU 
Goat anti-mouse 
RTU 
Time and temperature of 
incubation with secondary Ab 
20 min / RT 
30 min / RT 
20 min / RT 
30 min / RT 
20 min / RT 
30 min / RT 
Incubation time for DAB 5 min 
10 min 
5 min 
10 min 
5 min 
10 min 
RT, room temperature; RTU, ready to use; solution 1, (epitope retrieval solution with low pH (pH 6.0)); solution 
2, (epitope retrieval solution with high pH (pH 8.0)); NSE, neuron-specific enolase.  
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Table 2.9b. The plan of polyclonal antibody optimisation used for IHC. 
Conditions ALP S100 Runx2 BMP4 PTHR1 PTHrP 
Type of antigen 
retrieval 
Solution 1  
Solution 2 
Solution 1  
Solution 2 
Solution 1  
Solution 2 
Solution 1  
Solution 2 
Solution 1  
Solution 2 
Solution 1  
Solution 2 
Incubation time 
for antigen 
retrieval 
10 min / 97 °C 
20 min / 97 °C 
10 min / 97 °C 
20 min / 97 °C 
10 min / 97 °C 
20 min / 97 °C 
10 min / 97 °C 
20 min / 97 °C 
10 min / 97 °C 
20 min / 97 °C 
10 min / 97 °C 
20 min / 97 °C 
Dilution of 
primary Ab 
1:400 & 1:500    RTU 1:600  & 1:700    1:100 & 1:200     1:100 & 1:50 1:100 & 1:50 
Time and 
temperature of 
incubation with 
primary Ab 
30 min / RT 
60 min / RT 
20 min / RT 
30 min / RT 
20 min / RT 
30 min / RT 
20 min / RT 
30 min / RT 
30 min / RT 
60 min / RT 
30 min / RT 
60 min / RT 
Dilution of 
secondary Ab 
Mouse anti-
rabbit 
1:100 & 1:50 
Mouse anti-
rabbit 
1:100 & 1:50 
Mouse anti-
rabbit 
1:100 & 1:50 
Mouse anti-
rabbit 
1:100 & 1:50 
Mouse anti-
rabbit 
RTU 
Rabbit anti-goat 
 
1:100 & 1:200 
Time and 
temperature of 
incubation with 
secondary Ab 
20 min / RT 
30 min / RT 
20 min / RT 
30 min / RT 
20 min / RT 
30 min / RT 
20 min / RT 
30 min / RT 
20 min / RT 
30 min / RT 
20 min / RT 
30 min / RT 
Incubation time 
for DAB 
5 min 
10 min 
5 min 
10 min 
5 min 
10 min 
5 min 
10 min 
5 min 
10 min 
5 min 
10 min 
RT, room temperature; RTU, ready to use; solution 1, (epitope retrieval solution with low pH (pH 6.0)); solution 
2, (epitope retrieval solution with high pH (pH 8.0)); Runx2, Runt-related protein 2; BMP4, bone morphogenetic 
protein 4; ALP, alkaline phosphatase; PTHR1, parathyroid hormone receptor 1; PTHrP, parathyroid hormone-
related protein. 
  
 77 
 
2.2.9 IHC staining and localisation of proteins 
IHC staining was carried out to localise specific protein markers in canine OS tissue 
sections. IHC was performed in duplicate for each targeted protein according to optimal 
conditions specified in Tables 3.2 and 4.2 and to the IHC manual protocol shown in Table 2.10. 
Sections were de-waxed by immersion in xylene twice for three minutes each then rehydrated 
through graded alcohol and running tap water before being immersed in antigen retrieval 
solution (K8005, Dako or 9511, CINtec) and processing in a PT Link® (Dako, Sydney, 
Australia) at high pressure with heat retrieval cycles at 97 °C for 20 minutes (Taylor and Shi 
2013). After processing at a specific incubation time for each protein marker, sections were 
cooled at room temperature and washed twice in Tris-buffered saline (TBS), treated with 1% 
Triton x-100 for 30 minutes to prevent unspecific binding, then hydrogen peroxide for 10 
minutes to block endogenous peroxidase activity and 0.4% casein protein block for 30 minutes 
to block nonspecific binding sites (Taylor and Shi 2013). The sections were washed twice in 
TBS between each treatment step. The sections were incubated in primary and secondary 
antibodies (see Table 2.2) according to the conditions shown in Tables 3.2 and 4.2, then washed 
twice in TBS and stained with 3,3'-diaminobenzidine (DAB) (1 drop of DAB chromogen added 
to 2 ml of DAB buffered substrate) for 10 minutes to visualise and localise the targeted proteins. 
Finally, the sections were counterstained with progressive Mayer’s haematoxylin, dehydrated, 
cleared, mounted in DPX, cover-slipped and labelled. 
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Table 2.10 Manual IHC protocol for localisation of targeted proteins, modified from 
(Taylor and Shi 2013). 
Steps Duration 
Xylene ………………………………………………….......... 
Xylene ………………………………………………….......... 
100 % Alcohol ……………………………………………..... 
100 % alcohol ……………………………………………….. 
70 % Alcohol ………………………………………………… 
Running water ……………………………………………….. 
Antigen retrieval method (at 97 °C high or low pH) ……....... 
Wash sections with Tris-buffered saline (TBS) two times ….. 
Treat with 200 μl 1% Triton X-100 …………………………. 
Wash with buffer (TBS, pH 7.2) …………………………….. 
Wash with buffer (TBS, pH 7.2) …………………………….. 
Incubate with 200 μl hydrogen peroxide H2O2 (3 %) .………. 
Wash with buffer (TBS, pH 7.2) …………………………….. 
Wash with buffer (TBS, pH 7.2) …………………………….. 
Treat with 200 μl 0.4 % casein protein block ……………….. 
Wash with buffer (TBS, pH 7.2) …………………………….. 
Wash with buffer (TBS, pH 7.2) …………………………….. 
Incubate with 200 μl primary Ab (diluted) / RT……………. 
Wash with buffer (TBS, pH 7.2) …………………………….. 
Wash with buffer (TBS, pH 7.2) …………………………….. 
Incubate with 200 μl secondary Ab (as required) …………… 
Wash with buffer (TBS, pH 7.2) …………………………….. 
Wash with buffer (TBS, pH 7.2) …………………………….. 
200 μl of DAB (until the color change to brown) …………… 
Wash with buffer (TBS, pH 7.2) …………………………….. 
Wash with distilled water ……………………………………. 
Counter stain with haematoxylin ……………………………. 
Running water ……………………………………………….. 
Blue with Scott’s tapwater …………………………………... 
Wash with running water ……………………………………. 
70 % Alcohol ………………………………………………… 
100 % alcohol ………………………………………………... 
100 % Alcohol ……………………………………………...... 
Xylene ……………………………………………………...... 
Xylene ……………………………………………………...... 
Mounting, cover-slipping and labelling   
3 min 
2 min 
1 min 
1 min 
20 dips 
4 min 
20 min 
5 min each  
30 min  
5 min  
5 min  
10 min  
5 min  
5 min  
30 min  
5 min  
5 min  
30 min  
5 min  
5 min  
30 min  
5 min  
5 min  
10 min  
5 min  
5 min  
3 min  
1 min 
1 min  
1 min 
10 dips 
10 dips 
20 dips   
1 min 
2 min 
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2.2.10 Microscopy and image analysis 
2.2.10.1 Slide scanning and image analysis using CellSens Dimension Microscope 
Imaging Software 
Slides that had been immunostained for vimentin, ALP, desmin, S100, NSE, Runx2 
and BMP4 were scanned and microscopic digital images were taken with a digital camera 
(Olympus slide scanner microscope U-TV0.5XC-3, Olympus, Tokyo, Japan) at an absolute 
magnification of 20x using Olympus VS-ASW software (Olympus, Tokyo, Japan). Expression 
and localisation of vimentin, ALP, desmin, S100, NSE, Runx2 and BMP4 were evaluated and 
analysed using CellSens Dimension Microscope Imaging Software (version: 1.14, Olympus, 
Tokyo, Japan). Six selected fields of the representative tumour area were analysed. Expression 
was assessed quantitatively by estimating the percentage of positive cells and negative cells in 
the selected areas. Tumours with >1% positively stained cells were considered positive and 
tumours with <1% positively stained cells were considered negative. CellSens Dimension 
Microscope Imaging Software has been used in previous research to evaluate IHC staining in 
several tumours (Featherston, et al. 2017; Mehrotra, et al. 2018). 
2.2.10.2 Slide scanning and image analysis using Aperio ImageScope 
Tissue sections were scanned and microscopic digital images were produced using the 
Aperio Scanscope XT digital pathology slide scanners at Austin Health, Heidelberg, Australia 
(Leica, Mount Waverley, Australia) at an absolute magnification of 40x. A pre-scan procedure 
was carried out to calibrate background illumination levels. 
Sections that were immunostained with PTHR1 and PTHrP-specific antibodies were 
assessed by a semiquantitative approach. Histology score (H-score) is a common method used 
to score immunostained slides whilst taking into consideration the percentage of neoplastic 
positively stained cells as well as staining intensity: 0 (negative), 1+ (weak), 2+ (moderate) and 
3+ (strong). The H-score was obtained by using Aperio ImageScope (v10.0.35.1800, Leica, 
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Mount Waverley, Australia). Aperio ImageScope analysis software was used to view and 
analyse the digital image-slides. The IHC staining was quantified by applying a colocalisation 
algorithm (v11, Leica, Mount Waverley, Australia).  
The quality of the digital images that were produced for whole tissue sections was 
evaluated. Images were labelled and stored in an external hard drive. The threshold for each 
stain was specified by the ImageScope software and the percentage area of positive staining 
was calculated by an algorithm based on a de-convolution method to separate the stains 
(Ruifrok and Johnston 2001). Each pixel was classified according to the number of stained 
cells present and according to location of the positive stain (nuclear, membrane or cytoplasmic) 
(Krajewska, et al. 2009). Finally, the report was produced by the algorithm showing the H-
score. 
The H-score is a scoring system for measuring the positivity or the intensity of nuclear, 
membrane and cytoplasmic immunoreactivity of tumour cells (Bobinac, et al. 2005; 
Branstetter, et al. 2015). The score is calculated using the following equation: 3 x percentage 
of strongly staining nuclei/cytoplasm + 2 x percentage of moderately staining nuclei/ cytoplasm 
+ percentage of weakly staining nuclei/cytoplasm. The range of the final score is from 0 to 300, 
where 300 is equivalent to 100 % of tumour cells with strong intensity (3+) (Ishibashi, et al. 
2003). Six representative tumour fields were selected for each slide. Tumour immunostaining 
with scores from 2 to 100 were considered weakly positive; scores from 101 to 200 were 
considered moderately positive and scores from 201 to 300 were considered strongly positive, 
whilst tumour immunostaining with scores from 0 to 2 were considered negative. 
The average H-score for each section was calculated by dividing the total H-score by 
six (number of selected fields). Then, the overall H-score was calculated by taking the average 
of run 1 and run 2. 
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2.2.11 Statistical analyses 
Data were analysed using SPSS Statistics 25 software. P-values < 0.05 were considered 
to be statistically significant. The data were described using mean ± standard error (SE) with a 
95% confidence interval (CI). 
Differences in localisation of vimentin, ALP, desmin, S100, NSE, Runx2 and BMP4 
between canine and human OS were analysed using the Mann-Whitney U test (Mann and 
Whitney 1947). 
Immunostaining of PTHR1 and PTHrP was analysed and the relationship with different 
parameters of dogs with OS including breed size, sex, age, affected part, histological subtypes 
of OS, metastasis and tumour grade were evaluated using Pearson’s Chi-Square test (Pearson 
1900). The Kaplan-Meier method (Kaplan and Meier 1958) was utilised to generate survival 
curves and to measure the differences in survival that occurred over time for dogs with OS 
showing different staining intensity of PTHR1 and PTHrP by using the log-rank test (Mantel 
1966). The prognostic significance of the breed size, sex, age, affected skeleton, metastasis, 
tumour grade, histological subtype of OS, chemotherapy, surgery (tumour removal), PTHR1 
and PTHrP staining intensity in the ASAP-50 group of dogs with OS was analysed using 
multivariate Cox regression proportional hazard model (Cox 1972). In addition, univariate and 
multivariate analyses were performed using Cox regression (Cox 1972) to analyse potential 
prognostic indicators in the ASAP-20 group of dogs whilst considering the following 
parameters: breed size, sex, age, tumour grade, histological subtype of OS, PTHR1 and PTHrP 
staining intensity. 
The survival rate of dogs was analysed using the Kaplan-Meier survival analysis to 
estimate the cumulative survival distributions between groups of dogs with different 
histological subtypes of OS. Furthermore, the differences in survival were compared using the 
log-rank test. Pearson’s Chi-Square test (Pearson 1900) was used to evaluate the correlation 
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between subtypes of canine OS and the different clinical and pathological parameters including 
breed size, sex, age, affected skeleton and tumour grade. Immunoreactivity of desmin, S100 
and NSE among canine OS histological subtypes was compared using the Mann-Whitney U 
test.  
Analyses were performed after consultation with statistical support services provided 
by Drs. Stella Stylianou and Alice Johnstone from Department of Mathematical Sciences, 
School of Science at RMIT University, Melbourne, Australia. 
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Chapter 3 
3.0 Immunohistochemical validation of spontaneously arising canine osteosarcoma as a 
model for human osteosarcoma 
3.1 Introduction 
A pilot study was conducted to investigate whether tumour markers currently used to 
classify human OS, are applicable to canine OS by using five samples of canine OS tissue. It 
was found that similar to human OS, a panel of antibodies (vimentin, CK7, desmin, 
neurofilament protein, CD45, NSE, CD57 and S100) could be used to differentiate canine OS 
from other tumours including chondosarcoma, neuroblastoma, neuroendocrine carcinoma, 
rhabdomyosarcoma and lymphoma. This was the first demonstration of the presence of CK7, 
desmin and S100 in canine OS (Gunn HJ. unpublished data (2011), RMIT University, 
Melbourne, Australia, personal communication). This panel of antibodies was modified for the 
purpose of cost benefit and the size of some of the canine OS tissue samples available for the 
current study. Neurofilament protein and CD45 were excluded because they are not expressed 
in human OS. CK7 and CD57 were also excluded because they are not mesenchymal cell 
markers. Antibodies specific for ALP, Runx2 and BMP4 were added. 
Showing differences or similarities in expression profiles of specific protein markers in 
canine and human OS could help in therapeutic and comparative histopathological studies to 
improve our understanding of this tumour. Thus, the aim of this chapter was to validate canine 
OS as a model for human OS by investigating and analysing the expression of the selected 
marker proteins in spontaneously arising canine OS. The expression profiles were then 
compared with those previously obtained for human OS (Rosenberg 1995; Andela, et al. 2005; 
Coffin and Belchis 2006; Rosier and Bukata 2007).  
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3.2 Results 
3.2.1 Analysis of clinical and epidemiological data of dogs with OS 
Data were gathered from the 56 primary canine OS samples (Bristol-56) that were 
obtained from Bristol University Veterinary Pathology Department, Bristol, UK (see Section 
2.2.2; Table 3.1). Their ages ranged from one to 13 years with a mean and median of eight 
years (see Figure 3.1). Slightly more dogs were female (52%, 29 dogs). Fifty dogs (89%) were 
of pure breed and six (11%) were of mixed breed. All dogs included in the study were from 
large breeds. The descending order of frequency of the most common breeds was Rottweiler 
(21%), Labrador (11%), Golden Retriever (9%) and Doberman (7%) (see Figure 3.2). OS was 
mostly localised in the tibia (18%, 10 dogs), radius (18%, 10 dogs), humerus (13%, 7 dogs), 
jaws (11%, 6 dogs), ribs (11%, 6 dogs), femur (9%, 5 dogs) or the skull (9%, 5 dogs) (see 
Figure 3.3; Table 2.3). 
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Table 3.1 Clinicopathological data for canine OS tumours collected from the Bristol 
University Veterinary Pathology Department (Bristol-56).   
Case 
number 
Breed Sex Age Body part Tumour 
grade 
Diagnosis (OS) 
1 Retriever F 6 Jaw 2 Osteoblastic 
2 Rottweiler M 9 Tibia 2 Osteoblastic 
3 Old English sheepdog F 5 Femur  1 Osteoblastic 
4 Rottweiler F 10 Tibia 2 Osteoblastic 
5 Rottweiler F 7 Radius 2 Fibroblastic 
6 Doberman F 9 Femur 1 Osteoblastic 
7 Great Dane M 7 Radius 1 Chondroblastic 
8 St Bernard F 7 Radius 1 Fibroblastic 
9 Golden Retriever F 6 Jaw  1 Fibroblastic 
10 German Shepherd Dog F 8 Jaw 1 Chondroblastic 
11 Border Collie M 11 Tibia 2 Chondroblastic 
12 Border Collie M 7 Rib 2 Chondroblastic 
13 Border Collie M 6 Femur 2 Chondroblastic 
14 Flat Coated Retriever M 1 Tibia 1 Chondroblastic 
15 Rottweiler F 6 Radius 2 Osteoblastic 
16 Rottweiler F 2 Rib 2 Osteoblastic 
17 Labrador M 10 Humerus  2 Osteoblastic 
18 Rottweiler M 8 Rib 1 Fibroblastic 
19 Spaniel M 11 Humerus  1 Osteoblastic 
20 Mastiff M 8 Scapula  1 Osteoblastic 
21 German Shepherd Dog 
Cross 
F 10 Humerus 
1 
Osteoblastic 
22 Great Dane M 5 Radius 2 Chondroblastic 
23 Boxer F 11 Femur  2 Osteoblastic 
24 Rottweiler F 5 Jaw 1 Fibroblastic 
25 Golden Retriever M 12 Ulna  2 Osteoblastic 
26 Rottweiler M 3 Radius 2 Osteoblastic 
27 Lurcher M 8 Radius 2 Osteoblastic 
28 Rottweiler F 7 Tibia 2 Osteoblastic 
29 Rottweiler F 6 Tibia 2 Osteoblastic 
30 German SH Pointer F 4 Radius 2 Chondroblastic 
31 Bull Mastiff M 4 Rib 2 Chondroblastic 
32 German Shepherd Dog 
Cross 
F 3 Humerus 
2 
Osteoblastic 
33 Greyhound M 11 Radius 1 Fibroblastic 
34 Labrador F 11 Rib 2 Chondroblastic 
35 Staffordshire Bull Terrier M 8 Skull 1 Osteoblastic 
36 Doberman F 7 Jaw  2 Osteoblastic 
37 Labrador M 10 Rib 1 Fibroblastic 
38 Golden Retriever F 6 Vertebrae 2 Osteoblastic 
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39 Golden Retriever F 9 Vertebrae 2 Osteoblastic 
40 Golden Retriever F 9 Ilium  2 Osteoblastic 
41 Irish Red Setter M 1 Tibia 2 Chondroblastic 
42 German Shepherd Dog 
Cross 
F 9 Humerus 
2 
Fibroblastic 
43 Border Collie M 11 Humerus 2 Fibroblastic 
44 Lurcher M 10 Radius 2 Fibroblastic 
45 Lurcher M 10 Scapula  2 Osteoblastic 
46 Labrador M 7 Tibia 2 Fibroblastic 
47 Labrador F 10 Tibia 2 Osteoblastic 
48 Boxer Cross F 11 Jaw 2 Fibroblastic 
49 Greyhound F 8 Tibia  1 Fibroblastic 
50 Collie Cross M 13 Toe 1 Osteoblastic 
51 Retriever F 9 Skull 1 Fibroblastic 
52 Border Collie cross M 8 Skull 1 Osteoblastic 
53 Labrador M 13 Humerus 2 Osteoblastic 
54 Doberman M 8 Skull 2 Chondroblastic 
55 Doberman F 9 Femur  2 Fibroblastic 
56 German Shepherd Dog F 5 Skull 2 Chondroblastic  
F, female; M, male. 
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Figure 3.1 Distribution of age at diagnosis for dogs with OS, Bristol-56 group (n= 56). The 
age distribution shows a single peak at the age range between 7-9 years.  
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Figure 3.2 Number of dogs with OS and their breeds, Bristol-56 group (n= 56). This graph 
shows that canine OS is more common in large breeds such as Rottweiler, Labrador, Golden 
Retriever and Doberman. 
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Figure 3.3 Number of dogs with OS and the affected part of the body, Bristol-56 group (n= 
56). This graph shows that canine OS predominantly affects long bones such as radius, tibia 
and humerus.  
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3.2.2 Optimisation of conditions for IHC 
Staining conditions for detection of vimentin, ALP, desmin, S100, NSE, Runx2 and 
BMP4 using IHC were optimised by testing different reagents, dilutions and incubation times 
(see Tables 2.9a and 2.9b). 
3.2.2.1 Optimisation of conditions for vimentin immunostaining 
For the detection of vimentin, the following conditions showed negative vimentin 
immunostaining in the canine skin control tissue (see Figure 3.4B) which could be due to the 
insufficient unmasking of the vimentin antigen under these conditions. 
1- Antigen was retrieved using solution 1 (pH 6.0) for 10 or 20 minutes at 97 °C, mouse 
monoclonal primary antibody was diluted 1:50 or 1:100, the section was incubated for 20 or 
30 minutes at room temperature, then the section was incubated in ready to use (RTU)-
secondary antibody (goat anti-mouse polyclonal antibody) for 20 or 30 minutes at room 
temperature and in DAB for 5 or 10 minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 10 minutes at 97 °C, primary antibody 
was diluted 1:50 or 1:100, the section was incubated for 20 or 30 minutes at room temperature, 
then the section was incubated in RTU-secondary antibody for 20 or 30 minutes at room 
temperature and in DAB for 5 or 10 minutes. 
The following conditions showed weak vimentin immunostaining in the canine skin 
control tissue which could be due to the inability of the anti-vimentin antibody to bind to all 
the vimentin proteins or the inability of the secondary antibody to detect primary antibody or 
the inability of DAB to visualise secondary antibody. 
1- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody 
was diluted 1:100 and the section was incubated for 20 or 30 minutes at room temperature, 
then the section was incubated in RTU-secondary antibody for 20 or 30 minutes at room 
temperature and in DAB for 5 or 10 minutes. 
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2- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody 
was diluted 1:50 and the section was incubated for 20 minutes at room temperature, then the 
section was incubated in RTU-secondary antibody for 20 or 30 minutes at room temperature 
and in DAB for 5 or 10 minutes. 
3- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody 
was diluted 1:50 and the section was incubated for 30 minutes at room temperature, then the 
section was incubated in RTU-secondary antibody for 20 minutes at room temperature and in 
DAB for 5 or 10 minutes. 
4- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody 
was diluted 1:50 and the section was incubated for 30 minutes at room temperature, then the 
section was incubated in RTU-secondary antibody for 30 minutes at room temperature and in 
DAB for 5 minutes. 
The optimal conditions for vimentin immunostaining occurred when the vimentin 
antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody was 
diluted 1:50 and the section was incubated for 30 minutes at room temperature, then the section 
was incubated in secondary antibody for 30 minutes at room temperature and in DAB for 10 
minutes (see Table 3.2; Figure 3.4A). 
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Figure 3.4 Optimisation of vimentin immunohistochemical staining in canine skin control 
tissue showed different immunostaining. (A) Canine skin was positive for vimentin with 
antigen retrieval using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody (1:50) 
incubated for 30 minutes at room temperature, then incubated in secondary antibody for 30 
minutes at room temperature and in DAB for 10 minutes; (B) using the other protocols 
described in section 3.2.2.1 the skin was negative for vimentin, IHC. Scale bar, 100 µm. 
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Table 3.2 Details of optimal conditions used in IHC for vimentin, ALP, desmin, S100, 
NSE, Runx2 and BMP4. 
Antibody Retrieval Dilution 
of 
Primary 
Ab 
Incubation (min) 
at RT 
Dilution of 
secondary Ab and 
incubation 
at RT 
Incubation 
time for 
DAB 
(min) 
Staining 
Vimentin 20 min / 97 °C  
high pH 
1:50 
 
30  Goat anti-mouse 
RTU  for 30 min 
10 Cytoplasmic 
ALP  20 min / 97 °C  
high pH 
1:400 60 Mouse anti Rb 1:50 
for 30 min 
10 Cytoplasmic 
Desmin 20 min / 97 °C  
high pH 
RTU 45  Goat anti-mouse 
RTU  for 30 min 
10 Cytoplasmic 
S100 20 min / 97 °C  
high pH 
RTU 30  Mouse anti Rb 1:50 
for 30 min 
10 Cytoplasmic 
& Nuclear  
NSE 20 min / 97 °C  
high pH 
RTU 30  Goat anti-mouse 
RTU  for 30 min 
10 Cytoplasmic 
& Nuclear  
Runx2 20 min / 97 °C  
high pH 
1:600 30  Mouse anti Rb 1:50 
for 30 min 
10 Cytoplasmic 
& Nuclear 
BMP4 20 min / 97 °C  
high pH 
1:100 30  Mouse anti Rb 1:50 
for 30 min 
10 Cytoplasmic 
RT, room temperature; min, minutes; RTU, ready to use; Rb, rabbit; ALP, alkaline phosphatase; Runx2, Runt-
related protein 2; BMP4, bone morphogenetic protein 4; NSE, neuron-specific enolase. 
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3.2.2.2 Optimisation of conditions for alkaline phosphatase (ALP) immunostaining 
Using the following conditions showed negative immunostaining for ALP in canine 
kidney control tissue (see Figure 3.5B). 
1- Antigen was retrieved using solution 1 (pH 6.0) for 10 or 20 minutes at 97 °C, rabbit 
polyclonal primary antibody was diluted 1:400 or 1:500 and the section was incubated for 30 
or 60 minutes at room temperature, mouse anti-rabbit monoclonal secondary antibody was 
diluted 1:50 or 1:100 and the section was incubated for 20 or 30 minutes at room temperature 
and in DAB for 5 or 10 minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 10 minutes at 97 °C, primary antibody 
was diluted 1:400 or 1:500, the section was incubated for 30 or 60 minutes at room temperature, 
secondary antibody was diluted 1:50 or 1:100 and the section was incubated for 20 or 30 
minutes at room temperature and in DAB for 5 or 10 minutes. 
The following conditions showed weak ALP immunostaining in the canine kidney 
control tissue which could be due to the inability of anti-ALP antibody to bind strongly or the 
inability of secondary antibody to detect primary antibody or the inability of DAB to visualise 
secondary antibody. 
1- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody 
was diluted 1:500 and the section was incubated for 30 or 60 minutes at room temperature, 
secondary antibody was diluted 1:50 or 1:100 and the section was incubated for 20 or 30 
minutes at room temperature and in DAB for 5 or 10 minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody 
was diluted 1:400 and the section was incubated for 30 minutes at room temperature, secondary 
antibody was diluted 1:50 or 1:100 and the section was incubated for 20 or 30 minutes at room 
temperature and in DAB for 5 or 10 minutes. 
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3- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody 
was diluted 1:400 and the section was incubated for 60 minutes at room temperature, secondary 
antibody was diluted 1:100 and the section was incubated for 20 or 30 minutes at room 
temperature and in DAB for 5 or 10 minutes. 
4- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody 
was diluted 1:400 and the section was incubated for 60 minutes at room temperature, secondary 
antibody was diluted 1:50 and the section was incubated for 20 minutes at room temperature 
and in DAB for 5 or 10 minutes. 
5- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody 
was diluted 1:400 and the section was incubated for 60 minutes at room temperature, secondary 
antibody was diluted 1:50 and the section was incubated for 30 minutes at room temperature 
and in DAB for 5 minutes. 
The optimal conditions for ALP immunostaining occurred when the ALP antigen was 
retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody was diluted 1:400 
and the section was incubated for 60 minutes at room temperature, secondary antibody was 
diluted 1:50 and the section was incubated for 30 minutes at room temperature and in DAB for 
10 minutes (Table 3.2; Figure 3.5A). 
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Figure 3.5 Optimisation of ALP immunohistochemical staining in canine kidney control 
tissue showed different immunostaining. (A) The canine kidney was positive for ALP with 
antigen retrieval using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody (1:400) 
incubated for 60 minutes at room temperature, then incubated in secondary antibody (1:50) for 
30 minutes at room temperature and in DAB for 10 minutes; (B) using the other protocols 
described in section 3.2.2.2 the kidney was negative for ALP, IHC. Scale bar, 100 µm.  
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3.2.2.3 Optimisation of conditions for desmin immunostaining 
For the localisation of desmin, the following conditions showed negative desmin 
immunostaining in the canine smooth muscle control tissue (see Figure 3.6B) due to 
insufficient antigen retrieval. 
1- Antigen was retrieved using solution 1 (pH 6.0) for 10 or 20 minutes at 97 °C, the section 
was incubated in RTU-primary antibody (mouse monoclonal antibody) for 30 or 45 minutes at 
room temperature, the section was then incubated in RTU-secondary antibody (goat anti-mouse 
polyclonal antibody) for 20 or 30 minutes at room temperature and in DAB for 5 or 10 minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 10 minutes at 97 °C, the section was 
incubated in RTU-primary antibody for 30 or 45 minutes at room temperature, the section was 
then incubated in RTU-secondary antibody for 20 or 30 minutes at room temperature and in 
DAB for 5 or 10 minutes. 
The following conditions showed weak desmin immunostaining in the canine smooth 
muscle control tissue which could be due to the inability of the anti-desmin antibody to bind to 
all the desmin proteins or the inability of secondary antibody to detect primary antibody or the 
inability of DAB to visualise secondary antibody. 
1- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was 
incubated in RTU-primary antibody for 30 minutes at room temperature, the section was then 
incubated in RTU-secondary antibody for 20 or 30 minutes at room temperature and in DAB 
for 5 or 10 minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was 
incubated in RTU-primary antibody for 45 minutes at room temperature, the section was then 
incubated in RTU-secondary antibody for 20 minutes at room temperature and in DAB for 5 
or 10 minutes. 
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3- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was 
incubated in RTU-primary antibody for 45 minutes at room temperature, the section was then 
incubated in RTU-secondary antibody for 30 minutes at room temperature and in DAB for 5 
minutes. 
The optimal conditions for desmin immunostaining occurred when the desmin antigen 
was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was incubated in 
primary antibody for 45 minutes at room temperature, the section was then incubated in 
secondary antibody for 30 minutes at room temperature and in DAB for 10 minutes (Table 3.2; 
Figure 3.6A). 
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Figure 3.6 Optimisation of desmin immunohistochemical staining in canine smooth 
muscle control tissue showed different immunostaining. (A) Canine smooth muscle was 
positive for desmin with antigen retrieval using solution 2 (pH 8.0) for 20 minutes at 97 °C, 
primary antibody (RTU) incubated for 45 minutes at room temperature, then incubated in 
secondary antibody for 30 minutes at room temperature and in DAB for 10 minutes; (B) using 
the other protocols described in section 3.2.2.3 the smooth muscle was negative for desmin, 
IHC. Scale bar, 100 µm.  
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3.2.2.4 Optimisation of conditions for S100 immunostaining 
Negative S100 immunostaining was detected in the canine brain control tissue using 
the following conditions (Figure 3.7B). 
1- Antigen was retrieved using solution 1 (pH 6.0) for 10 or 20 minutes at 97 °C, the section 
was incubated in RTU-primary antibody (rabbit polyclonal antibody) for 20 or 30 minutes at 
room temperature, then in the mouse anti-rabbit monoclonal secondary antibody that was 
diluted 1:50 or 1:100 for 20 or 30 minutes at room temperature in DAB for 5 or 10 minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 10 minutes at 97 °C, the section was 
incubated in RTU-primary antibody for 20 or 30 minutes at room temperature, then in the 
secondary antibody that was diluted 1:50 or 1:100 for 20 or 30 minutes at room temperature in 
DAB for 5 or 10 minutes. 
The following conditions showed weak S100 immunostaining in the canine brain 
control tissue which could be due to the inability of the anti-S100 antibody to bind to all the 
S100 proteins or the inability of secondary antibody to detect primary antibody or the inability 
of DAB to visualise secondary antibody. 
1- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was 
incubated in RTU-primary antibody for 20 minutes at room temperature, then in the secondary 
antibody that was diluted 1:50 or 1:100 for 20 or 30 minutes at room temperature in DAB for 
5 or 10 minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was 
incubated in RTU-primary antibody for 30 minutes at room temperature, then in the secondary 
antibody that was diluted 1:100 for 20 or 30 minutes at room temperature in DAB for 5 or 10 
minutes. 
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3- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was 
incubated in RTU-primary antibody for 30 minutes at room temperature, then in the secondary 
antibody that was diluted 1:50 for 20 minutes at room temperature in DAB for 5 or 10 minutes. 
4- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was 
incubated in RTU-primary antibody for 30 minutes at room temperature, then in the secondary 
antibody that was diluted 1:50 for 30 minutes at room temperature in DAB for 5 minutes. 
The optimal conditions for S100 immunostaining occurred when the S100 antigen was 
retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was incubated in primary 
antibody for 30 minutes at room temperature, then in the secondary antibody that was diluted 
1:50 for 30 minutes at room temperature in DAB for 10 minutes (see Table 3.2; Figure 3.7A). 
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Figure 3.7 Optimisation of S100 immunohistochemical staining in canine brain control 
tissue showed different immunostaining. (A) Canine brain was positive for S100 with 
antigen retrieval using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody (RTU) 
incubated for 30 minutes at room temperature, then incubated in secondary antibody (1:50) for 
30 minutes at room temperature and in DAB for 10 minutes; (B) using the other protocols 
described in section 3.2.2.4 the brain was negative for S100, IHC. Scale bar, 100 µm. 
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3.2.2.5 Optimisation of conditions for NSE immunostaining 
For the localisation of NSE, the following conditions showed negative NSE 
immunostaining in the canine brain control tissue (Figure 3.8B). 
1- Antigen was retrieved using solution 1 (pH 6.0) for 10 or 20 minutes at 97 °C, the section 
was incubated in the RTU-primary antibody (mouse monoclonal antibody) for 20 or 30 minutes 
at room temperature, then the section was incubated in the RTU-secondary antibody (goat anti-
mouse polyclonal antibody) for 20 or 30 minutes at room temperature and in DAB for 5 or 10 
minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 10 minutes at 97 °C, the section was 
incubated in the RTU-primary antibody for 20 or 30 minutes at room temperature, then 
incubated in the RTU-secondary antibody for 20 or 30 minutes at room temperature and in 
DAB for 5 or 10 minutes. 
The following conditions showed weak NSE immunostaining in the canine brain 
control tissue which could be due to the inability of the anti-NSE antibody to bind to all the 
NSE proteins or the inability of secondary antibody to detect primary antibody or the inability 
of DAB to visualise secondary antibody. 
1- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was 
incubated in the RTU-primary antibody for 20 minutes at room temperature, then incubated in 
the RTU-secondary antibody for 20 or 30 minutes at room temperature and in DAB for 5 or 10 
minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was 
incubated in the RTU-primary antibody for 30 minutes at room temperature, then incubated in 
the RTU-secondary antibody for 20 minutes at room temperature and in DAB for 5 or 10 
minutes. 
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3- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was 
incubated in RTU-primary antibody for 30 minutes at room temperature, then incubated in the 
RTU-secondary antibody for 30 minutes at room temperature and in DAB for 5 minutes. 
The optimal conditions for NSE immunostaining occurred when the NSE antigen was 
retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was incubated in the 
primary antibody for 30 minutes at room temperature, then incubated in the secondary antibody 
for 30 minutes at room temperature and in DAB for 10 minutes (see Table 3.2; Figure 3.8A). 
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Figure 3.8 Optimisation of NSE immunohistochemical staining in canine brain control 
tissue showed different immunostaining. (A) Canine brain was positive for NSE with antigen 
retrieval using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody (RTU) incubated 
for 30 minutes at room temperature, then incubated in secondary antibody for 30 minutes at 
room temperature and in DAB for 10 minutes; (B) using the other protocols described in section 
3.2.2.5 the brain was negative for NSE, IHC. Scale bar, 100 µm. 
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3.2.2.6 Optimisation of conditions for Runx2 immunostaining 
Negative immunostaining for Runx2 was detected in the canine skeletal muscle control 
tissue when using the following conditions (Figure 3.9B). 
1- Antigen was retrieved using solution 1 (pH 6.0) for 10 or 20 minutes at 97 °C, the rabbit 
polyclonal primary antibody was diluted 1:600 or 1:700 and the section was incubated for 20 
or 30 minutes at room temperature, then in the mouse anti-rabbit monoclonal secondary 
antibody that was diluted 1:50 or 1:100, then the section was incubated for 20 or 30 minutes at 
room temperature and in DAB for 5 or 10 minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 10 minutes at 97 °C, the primary 
antibody was diluted 1:600 or 1:700 and the section was incubated for 20 or 30 minutes at room 
temperature, then in the secondary antibody that was diluted 1:50 or 1:100, the section was 
incubated for 20 or 30 minutes at room temperature and in DAB for 5 or 10 minutes. 
The following conditions showed weak Runx2 immunostaining in the canine skeletal 
muscle control tissue which could be due to the inability of the anti-Runx2 antibody to bind 
strongly to the Runx2 proteins or the inability of the secondary antibody to detect all the 
primary antibody or the inability of DAB to visualise the secondary antibody. 
1- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:700 and the section was incubated for 20 or 30 minutes at room 
temperature, the secondary antibody was diluted 1:50 or 1:100 and the section was incubated 
for 20 or 30 minutes at room temperature and in DAB for 5 or 10 minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:600 and the section was incubated for 20 minutes at room temperature, 
the secondary antibody was diluted 1:50 or 1:100 and the section was incubated for 20 or 30 
minutes at room temperature and in DAB for 5 or 10 minutes. 
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3- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:600 and the section was incubated for 30 minutes at room temperature, 
the secondary antibody was diluted 1:100 and the section was incubated for 20 or 30 minutes 
at room temperature and in DAB for 5 or 10 minutes. 
4- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:600 and the section was incubated for 30 minutes at room temperature, 
the secondary antibody was diluted 1:50 and the section was incubated for 20 minutes at room 
temperature and in DAB for 5 or 10 minutes. 
5- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:600 and the section was incubated for 30 minutes at room temperature, 
the secondary antibody was diluted 1:50 and the section was incubated for 30 minutes at room 
temperature and in DAB for 5 minutes. 
The optimal conditions for Runx2 immunostaining occurred when the Runx2 antigen 
was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary antibody was 
diluted 1:600 and the section was incubated for 30 minutes at room temperature, the secondary 
antibody was diluted 1:50 and the section was incubated for 30 minutes at room temperature 
and in DAB for 10 minutes (see Table 3.2; Figure 3.9A). 
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Figure 3.9 Optimisation of Runx2 immunohistochemical staining in canine skeletal 
muscle control tissue showed different immunostaining. (A) Canine skeletal muscle was 
positive for Runx2 with antigen retrieval using solution 2 (pH 8.0) for 20 minutes at 97 °C, 
primary antibody (1:600) incubated for 30 minutes at room temperature, then incubated in 
secondary antibody (1:50) for 30 minutes at room temperature and in DAB for 10 minutes; (B) 
using the other protocols described in section 3.2.2.6 the skeletal muscle was negative for 
Runx2, IHC. Scale bar, 100 µm. 
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3.2.2.7 Optimisation of conditions for BMP4 immunostaining 
For the anti-BMP4 antibody, the following conditions showed negative 
immunostaining in the canine kidney control tissue (see Figure 3.10B). 
1- Antigen was retrieved using solution 1 (pH 6.0) for 10 or 20 minutes at 97 °C, the rabbit 
polyclonal primary antibody was diluted 1:100 or 1:200 and the section was incubated for 20 
or 30 minutes at room temperature, the mouse anti-rabbit monoclonal secondary antibody was 
diluted 1:50 or 1:100 and the section was incubated for 20 or 30 minutes at room temperature 
and in DAB for 5 or 10 minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 10 minutes at 97 °C, the primary 
antibody was diluted 1:100 or 1:200 and the section was incubated for 20 or 30 minutes at room 
temperature, the secondary antibody was diluted 1:50 or 1:100 and the section was incubated 
for 20 or 30 minutes at room temperature and in DAB for 5 or 10 minutes. 
The following conditions showed weak BMP4 immunostaining in the canine kidney 
control tissue which could be due to the inability of the anti-BMP4 antibody to strongly bind 
to the BMP4 proteins or the inability of secondary antibody to detect primary antibody or the 
inability of DAB to visualise secondary antibody. 
1- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:200 and the section was incubated for 20 or 30 minutes at room 
temperature, the secondary antibody was diluted 1:50 or 1:100 and the section was incubated 
for 20 or 30 minutes at room temperature and in DAB for 5 or 10 minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:100 and the section was incubated for 20 minutes at room temperature, 
the secondary antibody was diluted 1:50 or 1:100 and the section was incubated for 20 or 30 
minutes at room temperature and in DAB for 5 or 10 minutes. 
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3- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:100 and the section was incubated for 30 minutes at room temperature, 
the secondary antibody was diluted 1:100 and the section was incubated for 20 or 30 minutes 
at room temperature and in DAB for 5 or 10 minutes. 
4- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:100 and the section was incubated for 30 minutes at room temperature, 
the secondary antibody was diluted 1:50 and the section was incubated for 20 minutes at room 
temperature and in DAB for 5 or 10 minutes. 
5- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:100 and the section was incubated for 30 minutes at room temperature, 
the secondary antibody was diluted 1:50 and the section was incubated for 30 minutes at room 
temperature and in DAB for 5 minutes. 
The optimal conditions for BMP4 immunostaining occurred when the BMP4 antigen 
was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary antibody was 
diluted 1:100 and the section was incubated for 30 minutes at room temperature, the secondary 
antibody was diluted 1:50 and the section was incubated for 30 minutes at room temperature 
and in DAB for 10 minutes (see Table 3.2; Figure 3.10A). 
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Figure 3.10 Optimisation of BMP4 immunohistochemical staining in canine kidney 
control tissue showed different immunostaining. (A) Canine kidney was positive for BMP4 
with antigen retrieval using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody 
(1:100) incubated for 30 minutes at room temperature, then incubated in secondary antibody 
(1:50) for 30 minutes at room temperature and in DAB for 10 minutes; (B) using the other 
protocols described in section 3.2.2.7 the kidney was negative for BMP4, IHC. Scale bar, 100 
µm.  
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3.2.3 Localisation of vimentin, ALP, desmin, S100, NSE, Runx2 and BMP4 tumour cell 
markers in spontaneous canine OS tumours was similar to results previously found in 
human OS     
In order to validate canine OS as a model for human OS, IHC was carried out to localise 
vimentin, ALP, desmin, S100, NSE, Runx2 and BMP4 in canine OS tumours and then the 
results were compared with those previously obtained for human OS. The results of IHC (see 
Section 2.2.9) for vimentin, ALP, desmin, S100, NSE, Runx2 and BMP4 with the negative (no 
primary antibody) and positive controls (see Section 2.2.3) are shown in Figure 3.11 (n= 56). 
Vimentin, ALP, Runx2 and BMP4 were detected in all canine OS (see Section 2.2.10.1; Figure 
3.12) (see Appendix 3), which is a similar result to human OS (see Table 3.3). Vimentin was 
expressed in the cytoplasm of cells in normal canine skin and in canine OS samples (see Figure 
3.11 A1). ALP demonstrated cytoplasmic labelling of canine kidney, and there was 
cytoplasmic and nuclear labelling in the canine OS samples (see Figure 3.11 B1). ALP was 
localised in the cytoplasm in 80% of OS samples. Runx2 demonstrated cytoplasmic expression 
in the normal canine skeletal muscle and cytoplasmic plus nuclear labelling was found in the 
canine OS samples (see Figure 3.11 C1). Nuclear localisation of Runx2 was observed in the 
tumour cells of most (90%) positive cases. BMP4 expression was demonstrated in the 
cytoplasm of normal canine kidney and in the all canine OS samples (see Figure 3.11 D1). 
Desmin was localised in 23% (13/56) and S100 in 16% (9/56) of cases of canine OS, 
while NSE was detected in 55% (31/56) of the cases (see Section 2.2.10.1; Table 3.4; Figure 
3.12) (see Appendix 3). These findings are similar to those found in human OS (see Table 3.3) 
(Rosenberg 1995; Andela, et al. 2005; Coffin and Belchis 2006; Rosier and Bukata 2007).  
Desmin was demonstrated in the cytoplasm of normal canine smooth muscle and in the OS 
samples (14/56) (see Figure 3.11 E1). S100 demonstrated nuclear labelling in the normal canine 
brain and nuclear plus cytoplasmic labelling in minority of the canine OS samples (9/56) (see 
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Figure 3.11 F1). Nuclear localisation of S100 was observed in most (67%) of the positive cases. 
NSE demonstrated cytoplasmic expression in the normal canine brain and in the canine OS 
samples (33/56) (see Figure 3.11 G1). 
Tests with no primary antibody (negative control) showed no immunostaining (see 
Figures 3.11 A2, B2, C2, D2, E2, F2, G2) and specific labelling was demonstrated in positive 
control tissues (see Figures 3.11 A3, B3, C3, D3, E3, F3, G3). 
Statistical analyses (see Section 2.2.11) revealed no significant differences in the 
expression levels of the tested tumour markers between canine and human OS tissue samples 
(see Table 3.3) (P= 1.00, Mann-Whitney U test). The statistical analysis was carried out using 
the data presented in Table 3.3 (+) or (+/−), where (+) refers to the presence of protein in all 
cases and (+/−) refers to the presence of protein in some cases and not present in others. 
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Figure 3.11 Immunohistochemical expression of the investigated tumour markers in 
representative examples of canine OS. (A1) Localisation of vimentin in test section (case 
number: 08-0491); (A2) test with no primary antibody; (A3) Localisation of vimentin in canine 
skin positive control tissue.  (B1) Localisation of ALP in test section (case number: 03-1585); 
(B2) test with no primary antibody; (B3) localisation of ALP in canine kidney positive control 
tissue. (C1) Localisation of Runx2 in test section (case number: 08-1319); (C2) test with no 
primary antibody; (C3) Localisation of Runx2 in canine skeletal muscle positive control tissue. 
(D1) Localisation of BMP4 in test section (case number: 07-0201B); (D2) test with no primary 
antibody; (D3) Localisation of BMP4 in canine kidney positive control tissue. (E1) 
Localisation of desmin in test section (case number: 13-0869A); (E2) test with no primary 
antibody; (E3) Localisation of desmin in canine smooth muscle positive control tissue. (F1) 
Localisation of S100 in test section (case number: 01-349); (F2) test with no primary antibody; 
(F3) Localisation of S100 in canine brain positive control tissue. (G1) Localisation of NSE in 
test section (case number: 06-0638); (G2) test with no primary antibody; (G3) Localisation of 
NSE in canine brain positive control tissue, IHC. The experiment was carried out in duplicate 
and repeated twice, n= 56 (Bristol-56 group). Scale bar, 100 µm (small box, magnification 
200X). 
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Figure 3.12 Percentage of cases of canine OS showing positive immunostaining for each 
protein marker, Bristol-56 group (n= 56). All canine OS cases were positive for vimentin, 
ALP, Runx2 and BMP4. Twenty three percent of canine OS cases were positive for desmin, 
16% for S100 and 55% for NSE. 
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Table 3.3 Comparison of presence of vimentin, ALP, desmin, S100, NSE, Runx2 and 
BMP4 in canine and human OS. 
 Vimentin ALP Desmin S100 NSE Runx2 BMP4 
Canine 
OS 
n= 56  
+ + +/− +/− +/− + + 
Human 
OS 
+1 +1 +/−2 +/−2 +/−1 +3 +4 
+, present; +/−, present in some cases and not present in others; ALP, alkaline phosphatase; NSE, neuron-specific 
enolase; Runx2, Runt-related protein 2; BMP4, Bone morphogenetic protein 4. 1(Rosenberg 1995).  2(Coffin and 
Belchis 2006).  3(Andela, et al. 2005).  4(Rosier and Bukata 2007). 
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Table 3.4 Immunostaining of desmin, S100 and NSE in canine OS. 
Case 
number 
Breed Desmin 
staining 
S100 
staining 
NSE 
staining 
1 Retriever Negative Positive Negative 
2 Rottweiler Positive Negative Positive 
3 Old English sheepdog Positive Positive Positive 
4 Rottweiler Negative Negative Positive 
5 Rottweiler Negative Negative Positive 
6 Doberman Negative Negative Positive 
7 Great Dane Negative Negative Positive 
8 St Bernard Negative Positive Positive 
9 Golden Retriever Negative Negative Negative 
10 German Shepherd Dog Negative Negative Negative 
11 Border Collie Positive Positive Positive 
12 Border Collie Negative Negative Positive 
13 Border Collie Negative Negative Negative 
14 Flat Coated Retriever Negative Negative Positive 
15 Rottweiler Negative Negative Negative 
16 Rottweiler Positive Negative Negative 
17 Labrador Negative Negative Positive 
18 Rottweiler Negative Negative Negative 
19 Spaniel Negative Negative Positive 
20 Mastiff Positive Negative Positive 
21 German Shepherd Dog 
Cross 
Positive Negative Positive 
22 Great Dane Negative Negative Positive 
23 Boxer Negative Negative Positive 
24 Rottweiler Negative Negative Negative 
25 Golden Retriever Negative Negative Positive 
26 Rottweiler Positive Negative Negative 
27 Lurcher Negative Negative Positive 
28 Rottweiler Negative Negative Negative 
29 Rottweiler Negative Negative Negative 
30 German SH Pointer Negative Negative Positive 
31 Bull Mastiff Negative Negative Positive 
32 German Shepherd Dog 
Cross 
Negative Positive Negative 
33 Greyhound Negative Negative Positive 
34 Labrador Positive Negative Negative 
35 Staffordshire Bull 
Terrier 
Negative Negative Negative 
36 Doberman Negative Positive Negative 
37 Labrador Positive Positive Negative 
38 Golden Retriever Negative Negative Positive 
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39 Golden Retriever Negative Negative Positive 
40 Golden Retriever Positive Positive Positive 
41 Irish Red Setter Negative Negative Negative 
42 German Shepherd Dog 
Cross 
Negative Negative Positive 
43 Border Collie Negative Negative Positive 
44 Lurcher Negative Negative Positive 
45 Lurcher Negative Negative Negative 
46 Labrador Negative Positive Positive 
47 Labrador Negative Negative Negative 
48 Boxer Cross Negative Negative Negative 
49 Greyhound Negative Negative Negative 
50 Collie Cross Negative Negative Negative 
51 Retriever Positive Negative Positive 
52 Border Collie cross Negative Negative Positive 
53 Labrador Positive Negative Positive 
54 Doberman Negative Negative Negative 
55 Doberman Positive Negative Negative 
56 German Shepherd Dog Negative Negative Positive 
NSE, neuron-specific enolase. 
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3.3 Discussion 
This study aimed to validate canine OS as a model for human OS using 
immunohistochemical labelling. The data revealed that vimentin, ALP, Runx2 and BMP4 were 
highly expressed in all canine OS tissue samples, while desmin, S100 and NSE were expressed 
variably. These observations are similar to those for human OS (Rosenberg 1995; Andela, et 
al. 2005; Coffin and Belchis 2006; Rosier and Bukata 2007). Statistical analysis demonstrated 
no significant differences in the expression levels of tested tumour markers between OS tissue 
samples from dogs and humans. 
3.3.1 Localisation of vimentin in canine and human OS 
Vimentin is usually used as a marker of tumours of mesenchymal origin (Leader, et al. 
1987). Vimentin was expressed in the cytoplasm of neoplastic cells in all canine OS samples 
analysed in the present study. Recent studies have shown cytoplasmic expression of vimentin 
in spontaneously arising canine OS (Poradowski, et al. 2016) and in a canine OS cell line (D-
17) (Gebhard, et al. 2016). In addition, Barger, et al. (2005) (31/31 tissue samples) and 
Nagamine, et al. (2015) (60/60 tissue samples) found that vimentin was expressed in the 
cytoplasm of canine OS cells. Several studies have shown that similar to canine OS, human OS 
cell lines such as U2OS (Wang, et al. 2016) and MG-63 (Dong, et al. 2018) and tissues (Loning, 
et al. 1985; Poradowski, et al. 2016) also expressed vimentin. 
3.3.2 Localisation of ALP in canine and human OS 
ALP is a useful marker for differentiating canine OS from other mesenchymal tumours 
such as fibrosarcoma, synovial cell sarcoma and chondrosarcoma (Barger, et al. 2005). The 
data presented above revealed that ALP was located in the cytoplasm and nuclei of neoplastic 
cells in all canine OS tissues. Barger, et al. (2005) carried out a study to investigate the ability 
of ALP labelling to differentiate canine OS from other vimentin-positive tumours using 33 
canine OS and 28 canine tumours other than OS. All OS and only five of the 28 non-OS 
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tumours were labelled positively for ALP. It was concluded that the sensitivity of ALP IHC 
for such differentiation was 100% and the specificity was 89% (Barger, et al. 2005). In addition, 
Sternberg, et al. (2013) detected the expression of ALP in canine OS and Gebhard, et al. (2016) 
found similar expression in the canine OS cell line D-17. Similar results have been shown in 
human OS (Rosenberg 1995). Ali, et al. (1996) also confirmed the expression of the ALP gene 
and protein in several human OS cell lines (i.e. U-2 OS, U-393 OS and HOS) which is similar 
to the present results. 
3.3.3 Localisation of desmin in canine and human OS 
Desmin has been detected with variable expression levels in many tumours such as 
rhabdomyosarcoma and embryonal sarcoma (Dias, et al. 1987). The present work demonstrated 
cytoplasmic desmin expression in 23% of canine OS. Nagamine, et al. (2015) showed that 
desmin was less frequently detected (33%, 20/60 tissue samples) in canine appendicular OS. 
In human OS, Ueda, et al. (2002) showed that desmin was localised in only 9% (1/11 tissue 
samples) of tested tumours. Another study mentioned that 17 out of 30 (57%) human OS 
expressed desmin (Hasegawa, et al. 1997). However, Hasegawa, et al. (1991) found that desmin 
was localised in 22% (4/18 tissue samples) of human OS samples, which is similar to the 
findings of the current study. 
3.3.4 Localisation of S100 in canine and human OS 
S100 is used as a marker for diagnostic differentiation of cartilaginous bone tumours 
such as chondroblastoma and chondromyxoid fibroma (Gao and Kahn 2005). Examples of 
S100 proteins, which were found to be associated with human OS are S100A6 (Luu, Zhou, et 
al. 2005; Li, et al. 2015), S100A4 (Mathisen, et al. 2003), S100A7 (Kataoka, et al. 2012) and 
S100B (Muramatsu, et al. 1997). The antibody used in the present study detected S100B, 
S100A1 and S100A6. The findings showed that S100 expression was nuclear plus cytoplasmic 
and was found in 16% of canine OS. Similarly, S100 nuclear expression was detected in the 
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canine D-17 OS cell line (Gebhard, et al. 2016). Mandal, et al. (2014) detected expression of 
S100 in 78% (31/40 tissue samples) of human OS. Furthermore, Hasegawa, et al. (1991) 
detected S100 in 50% (9/18 tissue samples) of human OS. Other findings showed that S100A6 
was expressed in 84% (42/50 tissue samples) of human OS (Luu, Zhou, et al. 2005). These 
differences could be due to different sample sizes, different subtypes of OS or to the use of 
different types of anti-S100 antibodies. In contrast, Chano, et al. (1996) reported that S100 was 
rarely localised (33%, 9/27 tissue samples) in human OS, which is similar to the findings of 
the current study. This may indicate that human and canine OS share a similar profile of tumour 
markers. 
3.3.5 Localisation of NSE in canine and human OS 
In man, NSE tumour marker can be used to diagnose Ewing’s sarcoma (Pinto, et al. 
1989; Devaney, et al. 1993; Gao and Kahn 2005) and is one of the panel of tumour markers 
used to diagnosed neuroendocrine tumours (Said, et al. 1985). In the current study, cytoplasmic 
localisation of NSE was detected in 55% of canine OS. Trihia and Valavanis (2012) stated that 
NSE is commonly expressed in human OS, but the expression levels may be variable 
(Rosenberg 1995). 
3.3.6 Localisation of Runx2 in canine and human OS 
The over-expression of Runx2 in human OS is linked with poor responses to 
chemotherapy (Sadikovic, et al. 2010) and with metastasis (Won, et al. 2009). Using several 
human OS cell lines (U2OS, SaOS, HOS, MG63, 143B and G292), Lucero, et al. (2013) found 
that the growth of all six cell lines was suppressed by expression of Runx2. This indicates that 
increasing Runx2 concentration in these OS cell lines activates one or more pathways of that 
inhibit proliferation (Lucero, et al. 2013). Further research found that Runx2 regulated cell 
adhesion and motility of human OS cells (van der Deen, et al. 2012). In addition, Runx2 has 
been shown to be involved in the metastasis of human bone tumours (Pratap, et al. 2005). 
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Increased expression of the Runx2 gene is related to cancer progression and cell transformation 
(Javed, et al. 2005; Xiong, et al. 2016). Another group found that decreased expression of 
Runx2 enhanced apoptosis and chemosensitivity in vitro and in vivo (Roos, et al. 2015). The 
present work documented nuclear and cytoplasmic expression of Runx2 in all canine OS. 
Sharili, et al. (2011) detected expression of Runx2 in canine osteoblastic OS tumours. 
Similarly, previous studies have confirmed the localisation of Runx2 in human OS tumours 
(Andela, et al. 2005; Won, et al. 2009). 
3.3.7 Localisation of BMP4 in canine and human OS 
In human OS, overexpression of the BMP4 gene was correlated with chemoresistance 
(Zhou, Shi, et al. 2017) and this molecule was suggested to be a therapeutic target in many 
cancers such as lung carcinoma (Wu, et al. 2017) and malignant glioma (Xi, et al. 2017). BMP4 
expression was linked with poor prognosis of human OS (Yoshikawa, et al. 1988; Yoshikawa, 
et al. 1993) and could be involved in OS pathogenesis (Yoshikawa, et al. 1985; Yoshikawa, et 
al. 1993). The current data showed that BMP4 was localised to the cytoplasm of canine OS 
cells. Yoshikawa, et al. (2004) detected a similar expression of BMP4 in human OS. Rosier 
and Bukata (2007) also noted the expression of BMP4 in human OS. In addition, Raval, et al. 
(1996) confirmed the expression of BMP4 in human OS cell lines (SaOS-2 and U2OS). 
Previous findings of BMP4 expression in human OS are similar to the findings of the current 
study. 
3.3.8 Analysis of clinical and epidemiological data of dogs with OS (Bristol-56) 
The samples analysed here did show a bimodal age distribution for dogs with OS, which 
is consistent  with previous findings that showed only a small peak of incidence in younger 
dogs (Cohen, et al. 1974). This is not the case with humans (Mirabello, et al. 2009b). Canine 
OS was slightly more common in females, which differs from the findings of another study in 
dogs (Spodnick, et al. 1992) and in humans (Price 1958; Stark, et al. 1990). These differences 
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in the findings could be due to the small sample size of the current study. Similar to previous 
studies (Spodnick, et al. 1992; Boston, et al. 2006) the data presented in the current study 
showed that the median age of onset of canine OS patients was eight years. The present work 
also showed that dogs of large breeds, such as the Rottweiler, Labrador, Golden Retriever and 
Doberman are more predisposed to OS than small breeds and this has also been reported by 
previous studies (Cohen, et al. 1974; Norrdin, et al. 1989; Spodnick, et al. 1992; Cooley and 
Waters 1997). Similar to what has been previously found (Liptak, et al. 2004; Sapierzynski and 
Czopowicz 2017), the current results showed that canine OS occurred predominantly in the 
appendicular skeleton compared to the axial skeleton. 
  
 126 
 
3.4 Conclusion  
This study has shown that the expression of vimentin, ALP, desmin, S100, NSE, Runx2 
and BMP4 in canine OS recapitulates observations made in human OS. Therefore, canine OS 
is potentially a good model for the study of prognostic and diagnostic biomarkers for human 
OS. 
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Chapter 4 
4.0 Parathyroid hormone receptor 1 (PTHR1) is a prognostic indicator in canine 
osteosarcoma  
4.1 Introduction 
PTHrP was discovered as a factor responsible for causing hypercalcemia of malignancy 
in some tumours (Suva, et al. 1987). PTH and PTHrP share a similar amino acid sequence 
(residues: 1–34) in the N-terminal region  (see Figure 4.1) (Suva, et al. 1987). This allows the 
two to activate a common G-protein coupled receptor known as the PTH/PTHrP receptor 
(PTHR1) (see Figure 4.2) (Juppner, et al. 1991). PTHrP and its receptor are highly conserved 
amongst all vertebrates (Danks and Richardson 2011). 
 
 
Figure 4.1 The N-terminal amino acid sequence of human PTH aligns with that of PTHrP 
residues 1–34. The α-helices of PTHR1 illustrated above and below the sequences (Pioszak, 
et al. 2009). 
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Figure 4.2 The structure of PTH-PTH1R complex. PTHR1 is indicated in green, PTH in 
yellow, with the disulfide bonds illustrated by green bars. The dashed red line indicates the 
disordered loop between residues 57 and 105 (Pioszak and Xu 2008). 
 
PTHrP is produced in many normal tissues where it acts as an autocrine/paracrine 
regulator of cell growth, development and differentiation (Wysolmerski and Stewart 1998). In 
addition, PTHrP has been localised in numerous human cancers including breast cancers 
(Southby, et al. 1990), neuroendocrine cancers (Martin and Moseley 2000), prostate cancers 
(Iwamura, et al. 1994), squamous cell carcinoma of skin (Danks, et al. 1989), pancreatic 
adenocarcinoma (Yamada, et al. 2017), intrahepatic cholangiocarcinoma (Takeda, et al. 2017) 
and OS (Partridge, et al. 1981). Hastings, et al. (2017) recently revealed that increased 
expression of PTHrP was associated with poor prognosis in lung carcinoma. In addition, 
secretion of PTHrP by tumour cells may be involved in metastasis and in the regulation of 
primary breast tumour growth (Rabbani, et al. 2005).   
PTHR1 is a member of the class B G-protein coupled receptor (GPCR) family 
(Gensure, et al. 2005). Several studies carried out using human tissues (Lupp, et al. 2010), 
murine tissues (Ho, et al. 2015) and human cell lines (Yang, et al. 2007) have noted the 
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association between PTHrP/PTHR1 expression and OS. Yang and his group (2007) suggested 
that over-expression of PTHR1 may stimulate human OS progression through the formation of 
a more aggressive phenotype. Furthermore, Ho and colleagues (2015) demonstrated that a 
knockdown of PTHR1 in murine OS cells reduced growth and invasion and increased tumour 
differentiation. Recently, a study showed that PTHrP is an essential factor for initiation, 
hyperproliferation and maintenance of murine p53-deficient OS (Walia, et al. 2016). The 
authors found that PTHrP activated PTHR1 and increased cAMP leading to CREB1 
phosphorylation and transcriptional activation (Walia, et al. 2016). It has been suggested that 
the PTHrP-cAMP-CREB1 axis was crucial for initiation of murine OS in p53-deficient 
osteoblasts (Walia, et al. 2016). 
Recently, it was shown that if PTHR1 expression was decreased in vivo, this resulted 
in enhanced mineralisation and differentiation of OS (Ho, et al. 2015). In addition, Ho et al. 
(2015) found that levels of PTHrP were higher in the osteoblastic histological subtype of 
murine OS compared to the less aggressive subtype (Ho, et al. 2015). However, PTHR1 and 
PTHrP have not been investigated in canine OS and there are no data about their association 
with survival time. 
To further evaluate the prognostic value of PTHR1 and PTHrP in OS, their expression 
was investigated by immunostaining in naturally occurring canine OS and the association of 
expression with survival determined. 
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4.2 Results  
4.2.1 Analysis of clinical, epidemiological data for dogs with OS 
Fifty canine primary OS samples (ASAP-50) were collected prospectively from the 
ASAP laboratory and the data were obtained independently (see Table 4.1). The age of the 
dogs ranged from one to 15 years with a mean and median age of nine years (see Figure 4.3) 
with male dogs (30 dogs, 60%) predominant. Thirty dogs (60%) were of a pure breed and 20 
(40%) were of a mixed breed. There were 42 dogs (84%) of large breeds and eight dogs (6%) 
of small breeds. The frequency of the top five represented breeds was Labrador (five dogs, 
10%), Rottweiler (five dogs, 10%), Golden Retriever (three dogs, 6%), Jack Russell Terrier 
(three dogs, 6%) and Rottweiler Cross (three dogs, 6%) (see Figure 4.4). Tumours were located 
mostly in the humerus (13 dogs, 26%), jaw (eight dogs, 16%), radius (seven dogs, 14%), femur 
(six dogs, 12%), tibia (five dogs, 10%) and rib (five dogs, 10%) (see Figure 4.5). 
Serum ALP measurement at presentation was available for only 13 dogs and it was not 
possible to collect data related to body weight at presentation and radiograph reports. 
Therefore, these three variables were excluded from the analysis.  
It was not possible to collect the survival times for the other 50 cases of canine OS due 
to lack of response from the veterinary clinics, unknown date of death, or inability of the 
veterinary clinic to contact the owner due to no response or changing of the contact details. 
According to the veterinarians, 26 dogs did not receive surgery or chemotherapy but they often 
continued with painkillers and anti-inflammatory medication.  
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Table 4.1 Clinicopathological data for those cases collected from ASAP laboratory with 
survival time (ASAP-50). 
Case 
number 
Breed Sex Age Body part Tumour 
grade 
Diagnosis of OS Survival 
time 
(days) 
1 Staffordshire Bull Terrier F 12 Humerus 1 Osteoblastic 28* 
2 Greyhound M 10 Tibia 1 Osteoblastic 90 
3 Rottweiler M 1 Humerus 1 Osteoblastic 114 
4 Boxer Cross M 11 Femur 1 Osteoblastic 458 
5 Mastiff F 7 Rib 1 Chondroblastic 14* 
6 Bulldog M 10 Tibia 1 Osteoblastic 193 
7 Labrador Retriever M 8 Radius 1 Osteoblastic 702 
8 Giant Schnauzer M 7 Radius 2 Osteoblastic 380 
9 Boxer   F 10 Rib 2 Chondroblastic 240* 
10 German Shepherd Dog F 11 Radius 2 Osteoblastic 485 
11 Rottweiler Cross F 8 Jaw 1 Osteoblastic 83* 
12 Spoodle M 10 Rib 2 Osteoblastic 71* 
13 Schnauzer Cross M 11 Rib 2 Fibroblastic 4* 
14 Doberman F 10 Tibia 1 Osteoblastic 240 
15 Rottweiler M 8 Humerus 1 Chondroblastic 150* 
16 Rottweiler F 9 Jaw 1 Osteoblastic 157* 
17 Golden Retriever M 8 Humerus 1 Chondroblastic 65* 
18 Golden Retriever M 14 Femur 2 Osteoblastic 115* 
19 Rottweiler Cross M 9 Ilium  1 Chondroblastic 1* 
20 Doberman M 9 Radius 1 Chondroblastic 104* 
21 Labrador F 7 Radius 2 Osteoblastic 277 
22 Jack Russell Terrier M 8 Jaw 2 Osteoblastic 21* 
23 Rottweiler F 4 Humerus 2 Chondroblastic 96 
24 Blue Heeler M 12 Tibia 1 Chondroblastic 150* 
25 Golden Retriever M 13 Jaw 1 Fibroblastic 180* 
26 Mastiff Cross M 6 Femur 2 Fibroblastic 470 
27 Cairn Terrier F 12 Humerus 1 Osteoblastic 155 
28 Boxer Cross F 15 Jaw 1 Fibroblastic 43* 
29 Jack Russell Terrier F 9 Scapula 2 Osteoblastic 27* 
30 Labrador M 11 Humerus 1 Fibroblastic 578 
31 Cavalier Cross M 10 Humerus 2 Osteoblastic 26 
32 Labrador M 13 Jaw 2 Osteoblastic 21* 
33 Border Collie M 6 Femur 2 Osteoblastic 17* 
34 Labradoodle M 3 Rib 2 Chondroblastic 11* 
35 Pointer Cross F 9 Radius 1 Osteoblastic 17* 
36 Rottweiler Cross F 9 Humerus 2 Osteoblastic 270 
37 Border Collie Cross F 13 Scapula 2 Chondroblastic 135* 
38 American Staffordshire Bull 
Terrier 
M 12 Vertebrae  1 Osteoblastic 54* 
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39 White Swiss Shepherd Dog F 9 Ilium  2 Osteoblastic 3* 
40 Maltese Cross M 13 Jaw 2 Osteoblastic 47* 
41 SBT Cross F 9 Humerus 2 Chondroblastic 76 
42 Alaskan Malamute M 6 Radius 1 Osteoblastic 82 
43 Rottweiler F 11 Tibia 2 Osteoblastic 288 
44 Curly Coated Retriever F 11 Humerus 1 Osteoblastic 90 
45 Boxer F 7 Skull 1 Osteoblastic 24* 
46 Labrador M 8 Humerus 2 Osteoblastic 14* 
47 Jack Russell Terrier M 14 Jaw 2 Osteoblastic 154* 
48 Labrador M 7 Femur 1 Osteoblastic 7* 
49 Greyhound M 11 Femur 1 Fibroblastic 655 
50 Labradoodle M 7 Humerus 1 Osteoblastic 142* 
*Cases excluded from the larger ASAP-50 group of dogs with OS to make a homogenous group (ASAP-20). 
Excluded dogs had no surgical or no chemotherapy, or had pulmonary metastasis at presentation, or presented 
with OS localised in axial parts, or still alive at the date of data collection, or died because of post-surgical 
complications; SBT, Staffordshire Bull Terrier; F, female; M, male.
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Figure 4.3 Pattern of age at presentation distribution for dogs with OS, ASAP-50 group 
(n= 50). The age distribution shows a small single peak at age range of 8-10 years. 
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Figure 4.4 Comparison between the number of dogs with OS and the top 10 represented 
breeds, ASAP-50 group (n= 29). The graph shows that canine OS frequently affects large 
breeds such as Rottweiler, Labrador, Golden Retriever and Rottweiler Cross. 
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Figure 4.5 The sites most commonly affected by canine OS, ASAP-50 group (n= 50). The 
most prevalent site of OS is in the humerus. P < 0.05, one-way ANOVA. 
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4.2.2 Histopathological findings of the dogs with OS  
Histopathological data were analysed to find the proportion of each subtype and each 
grade of the canine OS tumours. These proportions were correlated with the staining intensity 
of PTHR1 and PTHrP to investigate whether there was any significant correlation. The 
histopathological review classified osteoblastic OS (33 dogs, 66%) as the most common 
subtype of canine OS while, chondroblastic (11 dogs, 22%) and fibroblastic (six dogs, 12%) 
OS were less frequent (see Figure 4.6). Twenty-seven canine OS tumours (54%) were graded 
as G1 and 23 tumours (46%) as G2 (see Table 4.1). 
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Figure 4.6 Comparison between the number of dogs diagnosed with osteoblastic, 
chondroblastic or fibroblastic OS, ASAP-50 group (n= 50). The frequency of osteoblastic 
subtype is significantly higher than chondroblastic and fibroblastic subtypes. P < 0.05, one-
way ANOVA. 
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4.2.3 Optimisation of conditions for PTHR1 and PTHrP IHC 
Staining conditions for the detection of PTHR1 and PTHrP using IHC were optimised 
by testing different reagents, dilutions and incubation times (see Table 2.9b). 
4.2.3.1 Optimisation of conditions for PTHR1 immunostaining 
Negative PTHR1 immunostaining was detected in the canine kidney control tissue using 
the following conditions (see Figure 4.7B). 
1- Antigen was retrieved using solution 1 (pH 6.0) for 10 or 20 minutes at 97 °C, the rabbit 
polyclonal primary antibody was diluted 1:50 or 1:100 and the section was incubated for 30 or 
60 minutes at room temperature, the section was incubated in the RTU-goat anti-rabbit 
polyclonal secondary antibody (En vision FLEX) for 20 or 30 minutes at room temperature 
and in DAB for 5 or 10 minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 10 minutes at 97 °C, the primary 
antibody was diluted 1:50 or 1:100 and the section was incubated for 30 or 60 minutes at room 
temperature, the section was incubated in the RTU-secondary antibody for 20 or 30 minutes at 
room temperature and in DAB for 5 or 10 minutes. 
The following conditions showed weak PTHR1 immunostaining in the canine kidney 
control tissue which could be due to the inability of the anti-PTHR1 antibody to bind to all the 
PTHR1 proteins or the inability of the secondary antibody to detect primary antibody or the 
inability of DAB to visualise secondary antibody. 
1- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:100 and the section was incubated for 30 or 60 minutes at room 
temperature, then the section was incubated in the RTU-secondary antibody for 20 or 30 
minutes at room temperature and in DAB for 5 or 10 minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:50 and the section was incubated for 30 minutes at room temperature, 
 140 
 
then the section was incubated in the RTU-secondary antibody for 20 or 30 minutes at room 
temperature and in DAB for 5 or 10 minutes. 
3- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:50 and the section was incubated for 60 minutes at room temperature, 
then the section was incubated in the RTU-secondary antibody for 20 minutes at room 
temperature and in DAB for 5 or 10 minutes. 
4- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:50 and the section was incubated for 60 minutes at room temperature, 
then the section was incubated in the RTU-secondary antibody for 30 minutes at room 
temperature and in DAB for 5 minutes. 
The optimal conditions for PTHR1 immunostaining occurred when the PTHR1 antigen 
was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary antibody was 
diluted 1:50 and the section was incubated for 60 minutes at room temperature, then the section 
was incubated in the secondary antibody for 30 minutes at room temperature and in DAB for 
10 minutes (see Table 4.2; Figure 4.7A). 
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Figure 4.7 Optimisation of immunohistochemical staining of PTHR1 in canine kidney 
control tissue showed different immunostaining. (A) canine kidney was positive for PTHR1 
with antigen retrieval using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody 
(1:50) incubated for 60 minutes at room temperature, then incubated in secondary antibody for 
30 minutes at room temperature and in DAB for 10 minutes; (B) Using the other protocols 
described in section 4.2.3.1 the kidney was negative for PTHR1, IHC. Scale bar, 100 µm. 
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Table 4.2 Details of optimal conditions used for anti-PTHR1 and anti-PTHrP in IHC. 
Antibody Retrieval Dilution of 
Primary Ab 
Incubation 
(min) at RT 
Dilution of 
secondary 
Ab and 
incubation 
at RT 
Incubation 
time for 
DAB 
(min) 
Staining 
PTHR1 20 min at 97 
°C  high pH 
1:50 60 Dual Link 
System-HRP 
(En vision 
FLEX), RTU 
for 30 min 
10 Cytoplasmic 
& Nuclear 
PTHrP 20 min at 97 
°C  high pH 
1:50 60 RP anti-goat 
1:100 for 30 
min  
10 Cytoplasmic 
& Nuclear 
RT, room temperature; min, minutes; HRP, horseradish peroxidase; RTU, ready to use; Rb, polyclonal rabbit 
antibody; PTHR1, parathyroid hormone receptor 1; PTHrP, parathyroid hormone-related protein. 
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4.2.3.2 Optimisation of conditions for PTHrP immunostaining 
For the anti-PTHrP antibody, the following conditions showed negative 
immunostaining in the canine kidney control tissue (see Figure 4.8B). 
1- Antigen was retrieved using solution 1 (pH 6.0) for 10 or 20 minutes at 97 °C, the goat 
polyclonal primary antibody was diluted 1:50 or 1:100 and the section was incubated for 30 or 
60 minutes at room temperature, the rabbit anti-goat polyclonal secondary antibody was diluted 
1:100 or 1:200 and the section was incubated for 20 or 30 minutes at room temperature and in 
DAB for 5 or 10 minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 10 minutes at 97 °C, the primary 
antibody was diluted 1:50 or 1:100 and the section was incubated for 30 or 60 minutes at room 
temperature, the secondary antibody was diluted 1:100 or 1:200 and the section was incubated 
for 20 or 30 minutes at room temperature and in DAB for 5 or 10 minutes. 
The following conditions showed weak PTHrP immunostaining in the canine kidney 
control tissue which could be due to the inability of the anti-PTHrP antibody to bind to all the 
PTHrP proteins or the inability of the secondary antibody to detect primary antibody or the 
inability of DAB to visualise secondary antibody. 
1- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:100 and the section was incubated for 30 or 60 minutes at room 
temperature, then the secondary antibody was diluted 1:100 or 1:200 and the section was 
incubated for 20 or 30 minutes at room temperature and in DAB for 5 or 10 minutes. 
2- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:50 and the section was incubated for 30 minutes at room temperature, 
then the secondary antibody was diluted 1:100 or 1:200 and the section was incubated for 20 
or 30 minutes at room temperature and in DAB for 5 or 10 minutes. 
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3- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:50 and the section was incubated for 60 minutes at room temperature, 
then the secondary antibody was diluted 1:200 and the section was incubated for 20 or 30 
minutes at room temperature and in DAB for 5 or 10 minutes. 
4- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:50 and the section was incubated for 60 minutes at room temperature, 
then the secondary antibody was diluted 1:100 and the section was incubated for 20 minutes at 
room temperature and in DAB for 5 or 10 minutes. 
5- Antigen was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary 
antibody was diluted 1:50 and the section was incubated for 60 minutes at room temperature, 
then the secondary antibody was diluted 1:100 and the section was incubated for 30 minutes at 
room temperature and in DAB for 5 minutes. 
The optimal conditions for PTHrP immunostaining occurred when the PTHrP antigen 
was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the primary antibody was 
diluted 1:50 and the section was incubated for 60 minutes at room temperature, then the 
secondary antibody was diluted 1:100 and the section was incubated for 30 minutes at room 
temperature and in DAB for 10 minutes (see Table 4.2; Figure 4.8A). 
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Figure 4.8 Optimisation of immunohistochemical staining of PTHrP in canine kidney 
control tissue showed different immunostaining. (A) Canine kidney was positive for PTHrP 
with antigen retrieval using solution 2 (pH 8.0) for 20 minutes at 97 °C, primary antibody 
(1:50) incubated for 60 minutes at room temperature, then secondary antibody (1:100) 
incubated for 30 minutes at room temperature and in DAB for 10 minutes; (B) Using the other 
protocols described in section 4.2.3.2 the kidney was negative for PTHrP, IHC. Scale bar, 100 
µm. 
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4.2.4 Localisation of PTHR1 in canine OS by IHC 
The localisation of PTHR1 in 50 canine OS tissues was investigated using IHC. PTHR1 
was detected in all cases (n= 50). PTHR1 showed weak staining in two (4%) cases (see Figure 
4.9A, Figure 4.9D: non-immune control), moderate staining in 27 cases (54%) (see Figure 
4.9B, Figure 4.9E: non-immune control) and strong staining in 21 cases (42%) (see Figure 
4.9C, Figure 4.9F: non-immune control). Cytoplasmic plus nuclear localisation of PTHR1 was 
observed in the neoplastic cells in all cases. 
4.2.5 The association between PTHR1 staining intensity and clinicopathological 
parameters of dogs with OS 
The correlation between PTHR1 staining intensity and clinicopathological features in 
50 dogs with OS was assessed using Pearson’s Chi-Square test. There was a significant 
correlation between the staining intensity of PTHR1 and PTHrP (P= 0.004) (see Figure 4.10; 
Table 4.3), however, no statistically significant correlations were found between PTHR1 
staining intensity and clinicopathological characteristics including breed size, sex, age, affected 
skeleton, subtype of OS, metastasis and tumour grade (P > 0.05) (see Table 4.3).
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Figure 4.9 Representative immunohistochemical staining for PTHR1 in canine OS. (A) Case number: V15-629, osteoblastic OS, neoplastic 
cells are characterised by weak cytoplasmic plus nuclear positive immunostaining for PTHR1; (B) case number: V15-1034, chondroblastic OS, 
neoplastic cells are characterised by moderate cytoplasmic plus nuclear positive staining for PTHR1; (C) case number: V15-4414, chondroblastic 
OS, neoplastic cells are characterised by strong cytoplasmic plus nuclear immunolabelling for PTHR1; (D, E and F) non-immune control for the 
above cases. IHC. Mayer’s haematoxylin counterstaining. ASAP-50 group, n= 50. Scale bar, 100 μm (small box, magnification 200X).
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4.2.6 Localisation of PTHrP in canine OS by IHC 
The localisation of PTHrP in 50 canine OS tissues was examined by IHC. PTHrP was 
localised in all canine OS cases (n= 50). Weak staining of PTHrP was detected in 10 cases 
(20%) (see Figure 4.11A, Figure 4.11D: non-immune control), moderate in 31 cases (62%) 
(see Figure 4.11B, Figure 4.11E: non-immune control) and strong staining in nine cases (18%) 
(see Figure 4.11C, Figure 4.11F: non-immune control). PTHrP was localised to the cytoplasm 
of neoplastic cells in 33 cases (66%) and to the nucleus plus the cytoplasm in 17 cases (34%).  
4.2.7 The association between PTHrP staining intensity and clinicopathological 
parameters in dogs with OS 
The association between PTHrP staining intensity and clinicopathological 
characteristics in 50 dogs with OS was determined using Pearson’s Chi-Square test. As 
mentioned previously (see Section 4.2.5.), the current analyses showed significant correlation 
between the staining intensity of PTHrP and PTHR1 (P= 0.004) (see Figure 4.10). However, 
no statistically significant correlations were found between PTHrP staining intensity and the 
other clinicopathological characteristics such as breed size, sex, age, affected skeleton, subtype 
of OS, metastasis and tumour grade (P > 0.05) (see Table 4.4). 
PTHR1 and PTHrP staining of normal canine kidney tissue revealed strong cytoplasmic 
positivity in proximal and distal tubules, in contrast to weak staining in glomeruli (Lupp, et al. 
2010; Nishikawa, et al. 2015). 
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Table 4.3 The correlation between PTHR1 immunostaining and clinical and pathological 
features in dogs with OS (ASAP-50). 
Variable All cases, n= 50 (%) Strong PTHR1 
immunostaining, 
n= 21 (%) 
Moderate PTHR1 
immunostaining, 
n= 27 (%) 
Weak PTHR1 
immunostaining, 
n= 2 (%) 
P-value*  
Breed size     0.115 
Large 42 (84.0) 15 (35.7) 25 (59.5) 2 (4.8)  
Small 8 (16.0) 6 (75.0) 2 (25.0) 0 (0.0)  
Sex     0.452 
Male 30 (60.0) 13 (43.3) 15 (50.0) 2 (6.7)  
Female 20 (40.0) 8 (40.0) 12 (60.0) 0 (0.0)  
**Age (years)     0.959 
<9 25 (50.0) 11 (44.0) 13 (52.0) 1 (4.0)  
>9 25 (50.0) 10 (40.0) 14 (56.0) 1 (4.0)  
Affected 
skeleton 
    0.193 
Appendicular 35 (70.0) 12 (34.3) 21 (60.0) 2 (5.7)  
Axial 15 (30.0) 9 (60.0) 6 (40.0) 0 (0.0)  
Subtype of OS     0.221 
Osteoblastic 33 (66.0) 17 (51.1) 14 (42.4) 2 (6.1)  
Chondroblastic 11 (22.0) 3 (27.3) 8 (72.7) 0 (0.0)  
Fibroblastic 6 (12.0) 1 (16.7) 5 (83.3) 0 (0.0)  
Metastasis     0.372 
Yes 4 (8.0) 3 (75.0) 1 (25.0) 0 (0.0)  
No 46 (92.0) 18 (39.1) 26 (56.5) 2 (4.4)  
Tumour grade     0.411 
Low grade (G1) 27 (54.0) 11 (40.7) 14 (51.9) 2 (7.4)  
High grade (G2) 23 (46.0) 10 (43.5) 13 (56.5) 0 (0.0)  
PTHrP 
staining 
intensity 
    0.004*** 
Strong 9 (18.0) 7 (77.8) 2 (22.2) 0 (0.0)  
Moderate 31 (62.0) 13 (41.9) 18 (58.1) 0 (0.0)  
Weak 10 (20.0) 1 (10.0) 7 (70.0) 2 (20.0)  
*Pearson’s Chi-Square test; **Dogs were divided according to the median age; ***p < 0.05; PTHR1, parathyroid 
hormone receptor 1; PTHrP, parathyroid hormone-related protein. P-value comes from analysing the correlation 
between the staining intensity of PTHR1 using H-score (Aperio ImageScope) with each variable.  
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Figure 4.10 The correlation between staining intensity of PTHR1 and PTHrP in canine 
OS. The scatter chart shows that the staining intensity of PTHR1 is proportionally associated 
with the staining intensity of PTHrP in canine OS (Pearson’s Chi-Square test, P= 0.004, n= 
50). 
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Figure 4.11 Representative immunohistochemical staining for PTHrP in canine OS. (A) Case number: V14-5195, osteoblastic OS, neoplastic 
cells display weak cytoplasmic positive staining for PTHrP; (B) case number: V15-2536, fibroblastic OS, neoplastic cells display moderate 
cytoplasmic plus nuclear positive immunolabelling for PTHrP; (C) case number: V16-918, osteoblastic OS, neoplastic cells display strong 
cytoplasmic plus nuclear positive immunostaining for PTHrP; (D, E and F) non-immune control for the above cases. IHC. Mayer’s haematoxylin 
counterstaining. ASAP-50 group, n= 50. Scale bar, 100 μm (small box, magnification 200X).
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Table 4.4 Correlation between PTHrP immunostaining and clinical and pathological 
features in dogs with OS (ASAP-50). 
Variable All cases, n= 50 (%) Strong PTHrP 
immunostaining, 
n= 9 (%) 
Moderate PTHrP 
immunostaining, 
n= 31 (%) 
Weak PTHrP 
immunostaining, 
n= 10 (%) 
P-value*  
Breed size     0.298 
Large 42 (84.0) 7 (16.7) 25 (59.5) 10 (23.8)  
Small 8 (16.0) 2 (25.0) 6 (75.0) 0 (0.0)  
Sex     0.898 
Male 30 (60.0) 6 (20.0) 18 (60.0) 6 (20.0)  
Female 20 (40.0) 3 (15.0) 13 (65.0) 4 (20.0)  
**Age (years)     0.931 
<9 25 (50.0) 4 (16.0) 16 (64.0) 5 (20.0)  
>9 25 (50.0) 5 (20.0) 15 (60.0) 5 (20.0)  
Affected 
skeleton 
    0.302 
Appendicular 35 (70.0) 6 (17.1) 20 (57.1) 9 (25.8)  
Axial 15 (30.0) 3 (20.0) 11 (73.3) 1 (6.7)  
Subtype of OS     0.202 
Osteoblastic 33 (66.0) 9 (27.3) 18 (54.5) 6 (18.2)  
Chondroblastic 11 (22.0) 0 (0.0) 8 (72.7) 3 (27.3)  
Fibroblastic 6 (12.0) 0 (0.0) 5 (83.3) 1 (16.7)  
Metastasis     0.872 
Yes 4 (8.0) 1 (25.0) 2 (50.0) 1 (25.0)  
No 46 (92.0) 8 (17.4) 29 (63.0) 9 (19.6)  
Tumour grade     0.489 
Low grade (G1) 27 (54.0) 4 (14.8) 16 (59.3) 7 (25.9)  
High grade (G2) 23 (46.0) 5 (21.8) 15 (65.2) 3 (13.0)  
PTHR1 
staining 
intensity 
    0.004*** 
Strong 9 (18.0) 7 (77.8) 2 (22.2) 0 (0.0)  
Moderate 31 (62.0) 13 (41.9) 18 (58.1) 0 (0.0)  
Weak 10 (20.0) 1 (10.0) 7 (70.0) 2 (20.0)  
*Pearson’s Chi-Square test; **Dogs were divided according to the median age; ***P < 0.05; PTHR1, parathyroid 
hormone receptor 1; PTHrP, parathyroid hormone-related protein. 
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4.2.8 Strong staining of PTHR1 in canine OS correlates with decreased survival time 
4.2.8.1 The relationship of strong PTHR1 staining intensity with poor survival in ASAP-
50 group of dogs with OS 
The relationship between staining intensity of PTHR1 in canine OS and the survival 
rates of 50 dogs was analysed using the Kaplan-Meier analysis and the log-rank test (see Figure 
4.12). The log-rank test showed that survival rate was significantly different between groups 
of dogs with OS showing weak, moderate and strong immunostaining of PTHR1 (log-rank test, 
P= 0.000023) (see Figure 4.12). Dogs with OS showing strong PTHR1 staining had shorter 
average survival rates (mean= 61 ± 11 days; 95% CI: 39-84) than that for those with moderate 
(mean= 227 ± 36 days; 95% CI: 156-298) or weak staining (mean= 580 ± 122 days; 95% CI: 
341-819) (see Figure 4.13)  
Furthermore, multivariate Cox regression analysis (Bradburn, et al. 2003) was used to 
analyse the prognostic value of breed size, sex, age, affected skeleton, metastasis, tumour 
grade, subtype of OS, chemotherapy, surgery (tumour removal), PTHR1 and PTHrP staining 
intensity for overall survival rates in the ASAP-50 group of dogs with OS. The analysis showed 
that staining intensity of PTHR1 (multivariate Cox regression analysis, P= 0.000195) (see 
Table 4.5) and the subtype of OS (as discussed below, Chapter 5) were the only parameters 
that were found to influence survival rates and act as an independent prognostic indicators for 
overall survival (see Table 4.5). Thus, the findings suggest that the staining intensity of PTHR1 
is significantly correlated with the prognosis of canine OS. 
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Figure 4.12 Kaplan-Meier survival analysis of canine OS with different immunostaining 
intensity of PTHR1. Dogs with OS tumours showing strong immunostaining of PTHR1 
(mean= 61 ± 11 days, n= 21) had shorter survival times compared to those with tumours 
showing moderate (mean= 227 ± 36 days, n= 27) or weak staining (mean= 580 ± 122 days, n= 
2) (log-rank test, P= 0.000023) (ASAP-50). Censored data were considered for dogs who were 
still alive at the date of data collection or that had died because of post-surgical complications. 
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Figure 4.13 Comparison between the average survival times for dogs with OS tumours 
showing weak, moderate and strong immunostaining of PTHR1, ASAP-50 group (n= 50). 
Data is presented as mean ± standard error of the mean. Dogs with weakly staining tumours 
had longer survival times compared with the dogs that had moderate or strongly staining OS 
tumours, P < 0.05, one-way ANOVA.   
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Table 4.5 Multivariate Cox regression analysis of prognostic factors in 50 dogs (ASAP-
50) with OS for overall survival. 
Variable Hazard ratio 95% 
confidence 
interval 
P-value* 
Breed size  
large vs. small 0.680 0.181-2.552 0.568 
Sex  
male vs. female 1.376 0.545-3.472 0.500 
**Age (years)  
<9 vs. >9 1.380 0.607-3.136 0.442 
Affected skeleton  
appendicular vs. axial 0.521 0.363-2.249 0.828 
Metastasis  
yes vs. no 3.452 0.496-24.038 0.211 
Tumour grade  
low vs. high 0.862 0.377-1.975 0.726 
Subtype of OS****  
Osteoblastic vs. 
chondroblastic vs. fibroblastic 
0.087 0.014-0.533 0.031*** 
Chemotherapy  
yes vs. no 0.371 0.052-2.657 0.324 
Surgery (Tumour removal)  
yes vs. no 0.866 0.136-5.520 0.879 
PTHR1 staining intensity  
strong vs. moderate vs. 
weak 
0.007 0.000-0.130 0.000195*** 
PTHrP staining intensity  
strong vs. moderate vs. 
weak 
3.475 0.785-15.391 0.089 
* Multivariate Cox regression analysis; **Dogs were divided according to the median age; ***P < 0.05; PTHR1, 
parathyroid hormone receptor 1; PTHrP, parathyroid hormone-related protein; ****This will be discussed in 
Chapter 5. 
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4.2.8.2 The relationship of strong PTHR1 staining intensity with poor survival in ASAP-
20 group of dogs with OS 
In order to minimise variation in the population and to analyse the survival times for 
the ASAP-20 group, dogs that had no surgical (24 dogs) or no chemotherapy treatments (26 
dogs), or had pulmonary metastasis at presentation (four dogs), or presented with OS localised 
in axial parts (15 dogs), or were still alive at the date of data collection (three dogs), or died 
because of post-surgical complications (four dogs) were excluded from survival analyses (see 
Table 4.1) (see Appendix 2). The remaining 20 dogs (40%) with appendicular OS had limb 
amputation and then went through adjuvant chemotherapy using cisplatin or carboplatin as a 
single or multiple dose, had no pulmonary metastasis and died due to OS (see Table 4.6). 
The association between PTHR1staining intensity and the survival times of these 20 
dogs was investigated using the Kaplan-Meier analysis with the log-rank test (see Figure 4.14). 
The log-rank test revealed that there was a significant difference in the survival time between 
groups of dogs with appendicular OS showing different staining intensity of PTHR1 (log-rank 
test, P= 0.00007) (see Figure 4.14). Dogs with appendicular OS showing strong PTHR1 
staining had shorter average survival times (mean= 86 ± 21 days; 95% CI: 45-126) compared 
with those with moderate (mean= 318 ± 51 days; 95% CI: 218-418) or weak staining (mean= 
580 ± 122 days; 95% CI: 340-819) (see Figure 4.15). 
In addition, the univariate Cox regression analysis (Clark, et al. 2003) on different 
clinicopathological parameters, such as breed size, sex, age, tumour grade and PTHrP staining 
intensity was used to analyse the prognostic value of PTHR1 staining intensity for overall 
survival in the ASAP-20 group of dogs with OS (see Table 4.7). In this analysis, 
PTHR1staining intensity was found to be the only parameter that is associated with survival 
(P= 0.002, univariate Cox regression) (see Table 4.7). Other variables including breed size, 
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sex, age, tumour grade and PTHrP staining intensity did not show any significant prognostic 
value. 
The prognostic value of PTHR1staining intensity in canine OS was further evaluated 
using a multivariate Cox regression analysis (see Table 4.7). PTHR1 staining intensity was an 
independent prognostic indicator for overall survival (P= 0.002, multivariate Cox regression 
analysis) (see Table 4.7). Therefore, similar to the results for analysing survival times of the 
ASAP-50 group of dogs with OS (n= 50) (see Section 4.2.8.1), the current results suggest that 
the PTHR1 staining intensity was inversely correlated with survival time and therefore 
significantly associated with the prognosis of canine OS (see Figure 4.16). 
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Table 4.6 Studied 20 dogs (ASAP-20) with appendicular OS and their clinicopathological and immunohistochemical data. 
Case 
number 
Breed Sex Age at 
diagnosis 
(years) 
Survival 
time 
(days) 
Grade PTHR1 
H-score 
PTHR1 
staining 
intensity 
PTHrP  
H-score 
PTHrP 
staining 
intensity 
1 Greyhound M 10 90 1 192 +2 180 +2 
2 Rottweiler M 1 114 1 183 +2 107 +2 
3 Boxer Mix M 11 420 1 71 +1 86 +1 
4 Bulldog M 10 193 1 127 +2 93 +1 
5 Labrador Retriever M 8 390 1 57 +1 78 +1 
6 Giant Schnauzer M 7 380 2 177 +2 229 +3 
7 German Shepherd F 11 330 2 183 +2 183 +2 
8 Dobermann F 10 240 1 161 +2 100 +1 
9 Labrador Retriever F 7 187 2 109 +2 91 +1 
10 Rottweiler F 4 96 2 175 +2 122 +2 
11 Mastiff Mix M 6 150 2 113 +2 92 +1 
12 Cairn Terrier F 12 150 1 203 +3 174 +2 
13 Labrador Retriever M 11 578 1 167 +2 158 +2 
14 Cavalier cross M 10 26 2 240 +3 160 +2 
15 Rottweiler Cross F 9 270 2 165 +2 140 +2 
16 Staffy cross F 9 76 2 245 +3 179 +2 
17 Alaskan Malamute M 6 82 1 278 +3 148 +2 
18 Rottweiler F 11 288 2 169 +2 273 +3 
19 Curly Coated 
Retriever 
F 11 90 1 240 +3 255 +3 
20 Greyhound M 11 196 1 145 +2 164 +2 
F, female; M, male; H-score from 0-2:   negative; H-score from 3-100: weak; H-score from 101-200: moderate; H-score from 201-300: strong; +1, weak expression; +2, 
moderate expression; +3, strong; PTHR1, parathyroid hormone receptor 1; PTHrP, parathyroid hormone-related protein. 
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Table 4.7 Univariate and multivariate Cox regression analysis of prognostic factors in 
20 dogs (ASAP-20) with OS for overall survival. 
Covariate Univariate analysis Multivariate analysis 
 HR 95% CI P-value*  HR 95% CI P-value* 
Breed size   
large vs. small 0.216 0.043-1.076 0.061    
Sex   
male vs. female 0.498 0.185-1.337 0.166    
**Age (years)   
<10 vs. >10 1.777 0.682-4.629 0.239    
Tumour grade   
low vs. high 0.704 0.268-1.849 0.476    
PTHR1 staining 
intensity 
  
strong vs. moderate 
vs. weak 
0.021 0.002-0.248 0.002*** 0.003 0.000-0.116 0.002*** 
PTHrP staining 
intensity 
  
strong vs. moderate 
vs. weak 
0.531 0.123-2.299 0.498    
* Multivariate Cox regression analysis; **Dogs were divided according to the median age; ***P<0.05; HR, hazard 
ratio; CI, confidence interval; PTHR1, parathyroid hormone receptor 1; PTHrP, parathyroid hormone-related 
protein. 
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Figure 4.14 Kaplan-Meier survival analysis of canine appendicular OS with different 
immunostaining intensity of PTHR1. Dogs with tumours showing strong immunostaining of 
PTHR1 (mean= 86 ± 21 days, n= 5) had shorter survival times compared to dogs with tumours 
showing moderate (mean= 318 ± 51 days, n= 13) and weak staining (mean= 580 ± 122 days, 
n= 2) (P= 0.00007, log-rank test) (ASAP-20). 
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Figure 4.15 Comparison between the average survival times for dogs with appendicular 
OS tumours showing weak, moderate and strong immunostaining of PTHR1, ASAP-20 
group (n= 20). Data is presented as mean ± standard error of the mean. Dogs with strong 
positive tumours for PTHR1 had shorter survival times compared with those dogs with 
moderate or weakly staining OS tumours, P < 0.05, one-way ANOVA. 
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Figure 4.16 The association between PTHR1 staining intensity and survival times for dogs 
with OS. The scatter chart shows that the increase in staining intensity of PTHR1 in canine OS 
tumours correlated with a decrease in survival times for the ASAP-20 group, n= 20. Pearson 
test, R score= −0.55, where −1 indicates a perfect negative linear relationship between the two 
variables; 0 indicates no linear relationship between the two variables and 1 indicates a perfect 
positive linear relationship between the two variables.  
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4.2.8.3 The relationship between high and low PTHR1 staining intensity with survival 
time in ASAP-20 group of dogs with OS 
To validate the findings presented in the previous two sections, the survival times for 
dogs with OS showing the highest seven H-scores (high PTHR1 staining intensity) and for 
those with OS showing the lowest seven H-scores (low PTHR1 staining intensity) were 
compared using the log-rank test, univariate and multivariate Cox regression analysis (see 
Figure 4.17; Table 4.8). 
The Kaplan-Meier analysis with the log-rank test was used to investigate the 
relationship between PTHR1staining intensity and the survival times for the selected 14 dogs 
(see Figure 4.17). The log-rank test showed that there was a significant difference in the 
survival time between groups of dogs with OS showing high and low staining intensity of 
PTHR1 (log-rank test, P= 0.022) (see Figure 4.18). Dogs with appendicular OS showing high 
PTHR1 staining intensity had shorter average survival times (mean= 143 ± 59 days; 95% CI: 
28-258) compared with those with low staining intensity (mean= 428 ± 76 days; 95% CI: 279-
577) (see Figure 4.19). 
Moreover, the prognostic value of PTHR1 staining intensity for overall survival in the 
group of 14 dogs with OS was analysed using the univariate Cox regression analysis on 
different clinicopathological parameters, such as breed size, sex, age, tumour grade and PTHrP 
staining intensity (see Table 4.9). In this analysis, PTHR1 staining intensity was the only 
parameter that influenced survival rates (P= 0.032, univariate Cox regression) (see Table 4.9). 
Other variables including breed size, sex, age, tumour grade and PTHrP staining intensity did 
not show any significant prognostic value. 
A multivariate Cox regression analysis was used to further evaluate the prognostic 
value of PTHR1 staining intensity in canine OS prognosis (see Table 4.9). The analysis showed 
that PTHR1 staining intensity was an independent prognostic factor for overall survival (P= 
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0.018, multivariate Cox regression analysis) (see Table 4.9). Thus, the findings also suggest 
that the staining intensity of PTHR1 is significantly linked with the prognosis of canine OS. 
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Figure 4.17 The distribution of H-score of PTHR1 for ASAP-20 group of dogs with OS. 
Samples located in the left third (low PTHR1 staining intensity, n= 7) and in the right third 
(high PTHR1 staining intensity, n= 7) of the scatter chart were selected for the survival 
analysis. Samples located in the middle third were not included in this analysis, n= 6.  
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Figure 4.18 Kaplan-Meier survival analysis of 14 cases of canine appendicular OS with 
only high and low immunostaining intensity of PTHR1. Dogs with tumours showing high 
staining intensity of PTHR1 (mean= 143 ± 59 days, n= 7) had shorter survival times compared 
to those with tumours showing low staining intensity (mean= 428 ± 76 days, n= 7) (P= 0.022, 
log-rank test). 
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Figure 4.19 Comparison between the average survival times for dogs with appendicular 
OS tumours showing high and low staining intensity of PTHR1, ASAP-20 group (n= 14). 
Data is presented as mean ± standard error of the mean. Dogs with strongly positive PTHR1 
OS tumours had shorter survival times compared to dogs with OS tumours showing low 
staining intensity, P= 0.033, one-way ANOVA. 
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Table 4.8 The clinicopathological and immunohistochemical data for 14 dogs with 
appendicular OS showing low and high PTHR1 staining intensity. 
Case 
number 
Breed Sex Age at 
diagnosis 
(years) 
Survival 
time 
(days) 
Grade PTHR1 
H-score 
PTHR1 
staining 
intensity 
1 Labrador 
Retriever 
M 8 390 1 57 Low 
2 Boxer Mix M 11 420 1 71 Low 
3 Labrador 
Retriever 
F 7 187 2 109 Low 
4 Mastiff Mix M 6 150 2 113 Low 
5 Bulldog M 10 193 1 127 Low 
6 Greyhound M 11 196 1 145 Low 
7 Dobermann F 10 240 1 161 Low 
8 German 
Shepherd 
F 11 330 2 183 High 
9 Greyhound M 10 90 1 192 High 
10 Cairn 
Terrier 
F 12 150 1 203 High 
11 Cavalier 
cross 
M 10 26 2 240 High 
12 Curly 
Coated 
Retriever 
F 11 90 1 240 High 
13 Staffy cross F 9 76 2 245 High 
14 Alaskan 
Malamute 
M 6 82 1 278 High 
 F, female; M, male; PTHR1, parathyroid hormone receptor 1. 
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Table 4.9 Univariate and multivariate Cox regression analysis of prognostic factors in 
14 dogs with OS for overall survival. 
Covariate Univariate analysis Multivariate analysis 
 HR 95% CI P-value*  HR 95% CI P-value* 
Breed size   
large vs. small 4.596 0.833-25 0.080    
Sex   
male vs. female 0.608 0.192-1.922 0.397    
**Age (years)   
<10 vs. >10 0.704 0.226-2.187 0.544    
Tumour grade   
low vs. high 0.785 0.245-2.516 0.684    
PTHR1 staining 
intensity 
  
high vs. low 0.268 0.081-0.891 0.032*** 0.114 0.019-0.693 0.018*** 
PTHrP staining 
intensity 
  
strong vs. moderate 
vs. weak 
0.251 0.025-2.536 0.369    
* Multivariate Cox regression analysis; **Dogs were divided according to the median age; ***P < 0.05; HR, 
hazard ratio; CI, confidence interval; PTHR1, parathyroid hormone receptor 1; PTHrP, parathyroid hormone-
related protein. 
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4.2.9 No significant correlation observed between PTHrP staining intensity and survival 
times in ASAP-50 and ASAP-20 groups of dogs with OS 
The association between PTHrP staining intensity in canine OS and the survival times 
for both the ASAP-50 and ASAP-20 groups of dogs was investigated using the Kaplan-Meier 
analysis with the log-rank test (see Figures 4.20 and 4.21). The log-rank test showed that there 
was no significant difference in the survival times between groups of dogs with OS showing 
weak, moderate or strong immunostaining of PTHrP (ASAP-50 group: log-rank test, P= 0.116) 
(see Figures 4.20), (ASAP-20 group: log-rank test, P= 0.485) (see Figure 4.21). 
 
  
 172 
 
 
Figure 4.20 Kaplan-Meier survival analysis of canine OS with different expression levels 
of PTHrP. Canine OS patients with PTHrP strongly stained tumours survived for (189 ± 60 
days, n= 9), compared with moderately stained (146 ± 34 days, n= 31) and finally those with 
weakly stained tumours that survived for 306 ± 68 days (n= 10) (log-rank test, P= 0.116) 
(ASAP-50). Censored data were considered for dogs who were still alive at the date of data 
collection or that had died because of post-surgical complications. 
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Figure 4.21 Kaplan-Meier survival analysis of canine appendicular OS with different 
expression levels of PTHrP. Dogs with OS showing strong staining of PTHrP survived for 
252 ± 85 days (n= 3), while those with OS showing moderate staining survived for 238 ± 68 
days (n= 11) and with weak staining survived for 390 ± 77 days (n= 6) (log-rank test, P= 0.485) 
(ASAP-20). 
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4.3 Discussion 
Despite the current treatments (consisting of surgery and adjuvant chemotherapy), OS 
has a poor prognosis (Hagleitner, et al. 2011). Identification and characterisation of novel 
markers that could assess possible survival time might allow for better categorisation of 
patients for treatment informed by predicted risk of progression. PTHR1 and PTHrP have not 
been investigated as prognostic indicators in either canine or human OS and until now the 
presence of PTHR1 and PTHrP has not been investigated in naturally occurring canine OS. 
The aim of this chapter was to investigate the expression of PTHR1 and PTHrP in 
canine OS tissues at the cellular level and whether staining intensity had prognostic value. 
PTHR1 was detected in 100% of canine OS tumours. To evaluate the prognostic value of 
PTHR1 and PTHrP, the survival times of dogs with tumours showing strong expression of 
these markers was compared with those that had moderately and weakly stained tumours. 
Univariate and multivariate analyses revealed that PTHR1 staining is a significant prognostic 
indicator in dogs with OS. Dogs with OS tumours that stained strongly for PTHR1 had a 
significantly shorter survival time than those with moderately or weakly stained tumours. In 
addition, no significant correlation was observed between expression of PTHrP and survival 
times for dogs with OS. To the best of our knowledge, this is the first study to show the 
correlation between PTHR1 staining intensity in canine OS and survival time. 
4.3.1 The significance of PTHR1 localisation in OS 
PTHR1 was first localised at the cellular level in human OS and 17 other tumours and 
their tissues of origin using western blot and IHC (Lupp, et al. 2010). Lupp and others found 
that PTHR1 was present in 50% (n= 4) of human OS (Lupp, et al. 2010). In addition, a recent 
study showed that PTHR1 was expressed in mouse OS cells (Ho, et al. 2015). In the same 
study, Ho and colleagues (2015) found that a knockdown of PTHR1 in murine OS cells 
increased tumour differentiation and reduced cell growth and invasion. Furthermore, previous 
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research revealed that overexpression of PTHR1 in human OS xenografts was correlated with 
increased proliferation, cell migration and invasion forming a more aggressive phenotype of 
OS (Yang, et al. 2007). However, expression of PTHR1 was also detected in human OS cell 
lines (OS160, OS164, OS166, OS187 and OS191) derived from patients, but at a low level 
(Yang, et al. 2007). Moreover, the authors found that tissue of metastatic human OS had high 
expression of PTHR1 mRNA compared to the primary tumour (Yang, et al. 2007). Collectively, 
these studies support our hypothesis that increased amounts of PTHR1 in OS may be correlated 
with poor prognosis. 
4.3.2 The significance of PTHrP localisation in OS 
The current findings also demonstrated that similar to PTHR1, PTHrP was detected in 
100% of canine OS tumours. The present study found that dogs with tumours that stained 
strongly for PTHrP did not have a significantly shorter survival time when compared with dogs 
that had weakly or moderately stained tumours. 
Several studies using rat and mouse OS cell lines have investigated the expression of 
PTHrP (Suda, et al. 1996; Ho, et al. 2015). Yang and colleagues found that PTHrP mRNA was 
not detected in aggressive human OS xenografts (Yang, et al. 2007). Although the current study 
did not examine gene expression, one could extrapolate that the increase in protein might be a 
result of increased gene expression. Pasquini and others (2002) found that overexpression of 
the PTHrP gene is correlated with reduced cell proliferation in UMR 106-01 murine OS cell 
line. This was supported by the overexpression of PTHrP in rat ROS cell line and this increased 
expression is associated with decreased tumour cell growth rate (Motomura, et al. 1996). 
On the other hand, a study was conducted using the Saos-2 human OS cell line 
(Gagiannis, et al. 2009), where PTHrP-induced tumour cells developed resistance to 
chemotherapy via the inhibition of major apoptosis signalling pathways. This may be due to 
blocking the death receptor and mitochondria-mediated apoptosis signalling. In addition, 
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Berdiaki and colleagues (2010) found that PTHrP stimulates the migration of MG-63 and Saos 
2 human OS cell lines. The last two studies suggest that increased amounts of PTHrP may be 
associated with shorter survival times. Recently, Walia and others (2016) found that PTHrP is 
crucial to initiate OS in murine p53-deficient primary osteoblasts. They showed that PTHrP 
binds to PTHR1, which stimulates the production of cAMP, resulting in the phosphorylation 
of CREB1 and the activation of transcription in p53-deficient OS (Walia, et al. 2016). This 
may explain detection of strong and moderate staining of PTHrP and PTHR1 in the majority 
of the canine OS tissues studied in the present project. In addition, this may support the findings 
of the present study in regards to the significant correlation between staining intensity of 
PTHR1 and PTHrP in canine OS. The findings showed that canine OS tumours with high 
PTHR1 staining intensity also showed high staining intensity of PTHrP and vice versa. 
 4.3.3 Cytoplasmic and nuclear localisation of PTHR1 and PTHrP in OS 
This current study demonstrated cytoplasmic and nuclear localisation of both PTHR1 
and PTHrP. It has been shown that PTHR1 is transported to the nucleus after binding to the 
transport regulatory proteins importin α1 and importin β (Pickard, et al. 2006), while PTHrP 
binds to importin β (Lam, et al. 1999). Pickard, et al. (2006) found that PTHR1 was 
overexpressed in the nucleus during early interphase stage (G0/G1, S, and G2 phases) of the 
cell cycle using MC3T3-E1 mouse non-transformed osteoblasts, SaOS-2 human OS and ROS 
17/2.8 rat OS cell lines. In these early stages, DNA is known to be open to transcriptional 
activity compared to the late stages where DNA is compact and transcriptional activities are 
very low and the localisation of PTHR1 is weak (Pickard, et al. 2006). The abundant nuclear 
localisation of PTHR1 in neoplastic cells could be explained by the increased rate of cell 
mitosis. Moreover, the majority of these cells are at stage G0 and G1. 
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4.3.4 Suggested pathways for PTHrP and PTHR1 in OS  
Recently, it was suggested that PTHrP stimulates matrix mineralisation and 
proliferation of osteoblasts through three mechanisms: an autocrine/paracrine signal-
peptide/PTHR1-dependent mechanism, an intracrine nuclear localisation signal-dependent 
mechanism and a mixed mechanism (Garcia-Martin, et al. 2014). Though it is associated with 
proliferation and reduction of apoptosis in certain cell types, the exact role of PTHrP in the 
nucleus/nucleolus is still unclear (Martin 2016). 
Furthermore, Walkley, et al. (2014) suggested the pathway by which PTHR1 stimulates 
OS carcinogenesis. Normally, the PTHR1 that is located on the surface of normal osteoblasts 
is activated via binding to PTHrP. Activation of PTHR1 results in the synthesis of cAMP from 
ATP by adenylyl cyclase. Cyclic AMP induces release of cAMP-dependent PKA from its α 
regulatory subunit of PKA type 1 (PRKAR1A) causing PKA to translocate the nucleus where 
it phosphorylates and activates CREB1. This leads to transcription of target genes downstream 
of PTHR1 (Walkley, et al. 2014). In OS, numerous defects in the PTHrP-PTHR1-PKA pathway 
raise the activity of PKA pathway including the first, increased expression of the Prkaca gene 
that encodes the catalytic component of PKA and amplifies the number of PTHR1 on the cell 
surface. Second, mutations in the PRKAR1A gene lead to increase activity of PKA. This then, 
leads to increased production of PTHrP, which can bind to PTHR1 and stimulate the formation 
of cAMP (Walkley, et al. 2014). Recently, Li, et al. (2017) proposed that the effects of PTHR1 
could be mediated by angiogenesis, inflammation and the Wnt pathway through altering the 
expression of the crucial enriched genes (Dkk1, Lef1, Agt-CCR3, and Agt-CCL9) using mouse 
OS cells. 
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4.3.5 Suggested mechanism for the association of PTHR1 expression and survival time 
in patients with OS 
The obvious question that may arise from the current study is, why increased 
immunostaining of PTHR1 is correlated with reduced survival time, even though dogs had no 
clear evidence of metastasis at presentation in the ASAP-20 group. The present work suggests 
that increased amounts of PTHR1 may activate tumour cells to detach and metastasize to the 
lung, which leads to a reduced survival time (see Figure 4.22). The increase in PTHR1 in OS 
could be correlated with increasing the capability of tumour cells to metastasize and this was 
supported by a recent study (Ho, et al. 2015). Knockdown of PTHR1 in OS reduced invasion 
of tumour cells in vitro (Ho, et al. 2015). In addition, Yang, et al. (2007) revealed that 
overexpression of PTHR1 increased invasion, and showed that metastatic OS had increased 
expression of PTHR1 mRNA compared to the primary tumour. 
PTHR1 may be involved in down-regulation or up-regulation of cell-cell or cell-
extracellular matrix adhesion molecules. For instance, several studies found that integrin 
adhesion molecules play a role in the migration of OS cells (Scotlandi, et al. 1993; Miura, et 
al. 2005; Tome, et al. 2013). Up-regulation of integrins such as αvβ3 (Tome, et al. 2013), β1 
(Miura, et al. 2005), α2β1 (Scotlandi, et al. 1993), α5β1 (Scotlandi, et al. 1993), and α6β1 
(Scotlandi, et al. 1993) were found to be correlated with metastasis in OS. The current study 
suggests that integrins may be up-regulated by PTHR1. In order to validate the current 
hypothesis and to further understand OS, future studies should investigate the correlation 
between PTHR1 and integrins in OS. 
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Figure 4.22 Possible outcomes for dogs with osteosarcoma. Dogs with strong PTHR1 
staining tumours had shorter overall survival times compared to those with moderate or weak 
staining. Overabundance of PTHR1 could activate neoplastic osteoblasts to detach via up-
regulation of integrin adhesion molecules (αvβ3, β1, α2β1, α5β1, α6β1), resulting in pulmonary 
metastases. Other possible mechanisms which could explain the effects of PTHR1 expression 
including increased chemoresistance, increased tumour growth and decreased apoptosis. This 
might result in shorter survival time. 
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4.3.6 Breed size, sex, age and tumour grade were not prognostic indicators in canine OS  
The current study did not detect any other significant prognostic value for other 
variables, such as breed size, sex, age and tumour grade. Similar findings were reported by 
previous studies (Spodnick, et al. 1992; Bergman, et al. 1996; Cavalcanti, et al. 2004; 
Loukopoulos and Robinson 2007; Schott, et al. 2018). This work also did not detect any 
significant correlation between staining intensity of PTHR1 or PTHrP and age at diagnosis, 
sex, breed size, tumour grade and OS subtype. In contrast, it has been previously shown that 
expression of PTHR1 and PTHrP was higher in cells of the osteoblastic subtype compared to 
fibroblastic OS in vivo (Ho, et al. 2015).  The differences between the findings in the current 
work and other study (Ho, et al. 2015) could be due to the use of a murine OS model. 
4.3.7 Analysis of clinical and epidemiological data for dogs with OS (ASAP-50) 
The present work showed that the mean and median age of onset for dogs with OS was 
nine years, which is in line with previous findings (Spodnick, et al. 1992; Boston, et al. 2006). 
The present data did not show a clear bimodal age distribution for canine OS and this is in 
accordance with one previous study in dogs (Cohen, et al. 1974). In line with previous studies 
in dogs (Spodnick, et al. 1992) and in humans (Price 1958; Stark, et al. 1990), OS was found 
to occur more frequently in male dogs compared to females. The current study also revealed 
that large dogs breeds, such as the Labrador, Rottweiler and Golden Retriever were more likely 
to be affected by OS compared to small dogs and this is similar to previous findings (Cohen, 
et al. 1974; Norrdin, et al. 1989; Spodnick, et al. 1992; Cooley and Waters 1997). It also showed 
that canine OS localised predominantly in the appendicular skeleton for example, the humerus, 
radius, femur and tibia (Liptak, et al. 2004; Sapierzynski and Czopowicz 2017). Osteoblastic 
OS was the most common subtype in dogs compared to chondroblastic and fibroblastic OS and 
this is consistent with previous findings (Trost, et al. 2012; Nagamine, et al. 2015). These 
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similarities showed that this population of dogs with OS was similar to previous studied 
populations. 
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4.4 Conclusions 
In conclusion, this study localised PTHR1 and PTHrP in canine OS. Moreover, it 
demonstrated that weak PTHR1 staining in canine OS was related to a better prognosis, while 
strong staining of PTHR1 was correlated with decreased survival time. This indicates that the 
presence of PTHR1 protein may be a prognostic indicator. 
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Chapter 5 
5.0 The fibroblastic subtype has a favourable prognosis in osteosarcoma of dogs 
5.1 Introduction 
In both dogs and humans, OS can be classified based on histological features or cell 
types, affected site or tumour grade (Kirpensteijn, et al. 2002; Klein and Siegal 2006). 
According to the World Health Organisation (WHO) Classification of Soft Tissue and Bone 
Tumours in humans (Rosenberg, et al. 2013) OS is classified into low-grade central OS, 
conventional OS, telangiectatic OS, small cell OS, secondary OS, parosteal OS, periosteal OS 
and high-grade surface OS. According to the veterinary classifications of bone tumours in 
domestic animals it is classified into central OS and surface OS (peripheral OS) (Thompson 
and Dittmer 2017).  This chapter focuses on the most common subtypes of human conventional 
OS and veterinary central OS. OS sub-classification is based on the presence of malignant 
stroma and the predominant extracellular matrix into three different subtypes: osteoblastic 
(osteoid and/or bone matrix), chondroblastic (chondroid matrix) and fibroblastic (none, 
minimal or focal production of osteoid) OS (Fletcher, et al. 1994; Kirpensteijn, et al. 2002; 
Rosenberg, et al. 2013; Thompson and Dittmer 2017). There are great variations in the 
histological characteristics of OS between tumours and even within the same tumour 
(Kirpensteijn, et al. 2002). In addition, different types of undifferentiated cells and matrix are 
frequently seen in a single OS tumour (Kirpensteijn, et al. 2002). 
The diagnosis of OS is based on microscopic findings of malignant sarcomatous stroma 
along with the formation of osteoid (Rosenberg 2010). Usually, routine H & E staining is used 
for diagnosis but IHC may be required for confirmation (Dorfman, et al. 2002). Several tumour 
markers have been investigated in human OS, although these markers lack diagnostic or 
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prognostic specificity (Trihia and Valavanis 2012). The most commonly expressed tumour 
markers in human OS include vimentin, osteonectin, osteocalcin, neuron-specific enolase 
(NSE), CD99, S100 and smooth muscle actin (SMA) (Trihia and Valavanis 2012). In addition, 
very few markers have been identified for determining the specific subtypes of OS. For 
example, in humans, galectin-1 is expressed in 92% of chondroblastic OS (Gomez-Brouchet, 
et al. 2010) and SATB2 is expressed in 100% of osteoblastic OS (Conner and Hornick 2013). 
It has been suggested that the histological subtypes of human OS may have similar 
prognoses and responses to chemotherapy (Gorlick 2009; Kruse, et al. 2013). Consistent with 
this, Nagamine, et al. (2015) and Schott, et al. (2018) found that no significant difference in 
survival times of dogs with different subtypes of OS. All human and canine patients receive 
treatment regardless of the histological subtype of OS and this suggests that these different 
histological characteristics could be reflective of one clinical disease (Bielack, et al. 2002; 
Morello, et al. 2011). This justifies the notion that human OS is seen by surgeons and 
oncologists as one disease regardless of its histological subtype (Bielack, et al. 2002; Gorlick 
2009; Morello, et al. 2011). 
In contrast, Ho, et al. (2015) found that expression of PTHrP and PTHR1 genes was 
higher in the osteoblastic subtype compared to the fibroblastic subtype using murine OS cell 
lines derived from fibroblastic (494H, OS80, Osx-Cre) and osteoblastic (Osx-Cre TRE-
p53.1224 pRb) OS models, suggesting that the histological subtypes of OS could have different 
genetic backgrounds. In addition, Paparella, et al. (2013) found that the chondroblastic subtype 
was associated with a poorer prognosis than the other subtypes in humans. Similarly, Hammer, 
et al. (1995) reported that dogs with the fibroblastic subtype had increased survival time in 
contrast to dogs with other subtypes.  
Recently, Walia, et al. (2016) observed that a knockdown of CREB1 had different 
effects on cells of different OS subtypes in vitro. Loss of CREB1 in normal osteoblasts had no 
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effect on cell proliferation or survival, while knockdown of CREB1 in fibroblastic cells 
reduced cell proliferation but had no significant effect on apoptosis. Furthermore, CREB1 
knockdown in cells of the osteoblastic subtype resulted in an arrest of cell proliferation and a 
significant decrease in cell survival (Walia, et al. 2016). This suggests that the OS subtypes 
could be rely on different pathways for survival and proliferation and have distinct proteomes 
(Walia, et al. 2016). Moreover, there is still a need for a low cost, simple and reliable 
assessment for prognosis prediction in OS. 
The aim of this study was to investigate if each canine OS histological subtype has a 
distinct prognosis. Immunohistochemically, we found in the previous chapter that localisation 
of established markers of OS including desmin, S100 and NSE was 24%, 15% and 56% of 
canine OS tissues, respectively (Al-Khan, et al. 2017). These were chosen because of their 
variable expression in canine OS as was seen in Chapter 3 (Al-Khan, et al. 2017). In order to 
investigate whether these differences in expression were related to histological subtypes of 
canine OS, this study investigated whether there is a significant correlation between the 
subtypes of canine OS and immunohistochemical localisation of desmin, S100 and NSE. 
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5.2 Results 
5.2.1 Analysis of epidemiological and clinical data of dogs with OS 
Data were collected from 106 cases of OS tumours (ASAP-50 and Bristol-56 groups) 
(see Table 5.1) surgically removed from dogs with an average and median age of nine years 
(see Figure 5.1). Tumours were more frequently removed from males (54%, 57 dogs). Forty-
six breeds were represented, 62 dogs were of pure breed and 44 dogs were of mixed breed. The 
number of dogs that were large breeds was 98 and eight dogs were of a small breed. The most 
common breeds were Rottweiler (14%, 15 dogs), Labrador (10%, 11 dogs), Golden Retriever 
(8%, eight dogs) and Doberman (6%, six dogs) (see Figure 5.2). Tumours were mostly located 
in the humerus (19%, 20 dogs), radius (16%, 17 dogs), tibia (14%, 15 dogs), jaw (13%, 14 
dogs), rib (10%, 11 dogs), femur (10%, 11 dogs), skull (6%, six dogs) or scapula (4%, four 
dogs) (see Figure 5.3). 
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Table 5.1 Clinicopathological and histological data for canine OS tumours collected from 
the Bristol University Veterinary Pathology Department (Bristol-56) and ASAP 
laboratory (ASAP-50). 
Case 
number 
Breed Sex Age Body part Tumour 
grade 
OS subtype 
1 Retriever F 6 Jaw 2 Osteoblastic 
2 Rottweiler M 9 Tibia 2 Osteoblastic 
3 Old English sheepdog F 5 Femur  1 Osteoblastic 
4 Rottweiler F 10 Tibia 2 Osteoblastic 
5 Rottweiler F 7 Radius 2 Fibroblastic 
6 Doberman F 9 Femur 1 Osteoblastic 
7 Great Dane M 7 Radius 1 Chondroblastic 
8 St Bernard F 7 Radius 1 Fibroblastic 
9 Golden Retriever F 6 Jaw  1 Fibroblastic 
10 German Shepherd Dog F 8 Jaw 1 Chondroblastic 
11 Border Collie M 11 Tibia 2 Chondroblastic 
12 Border Collie M 7 Rib 2 Chondroblastic 
13 Border Collie M 6 Femur 2 Chondroblastic 
14 Flat Coated Retriever M 1 Tibia 1 Chondroblastic 
15 Rottweiler F 6 Radius 2 Osteoblastic 
16 Rottweiler F 2 Rib 2 Osteoblastic 
17 Labrador M 10 Humerus  2 Osteoblastic 
18 Rottweiler M 8 Rib 1 Fibroblastic 
19 Spaniel M 11 Humerus  1 Osteoblastic 
20 Mastiff M 8 Scapula  1 Osteoblastic 
21 German Shepherd Dog 
Cross 
F 10 Humerus 
1 
Osteoblastic 
22 Great Dane M 5 Radius 2 Chondroblastic 
23 Boxer F 11 Femur  2 Osteoblastic 
24 Rottweiler F 5 Jaw 1 Fibroblastic 
25 Golden Retriever M 12 Ulna  2 Osteoblastic 
26 Rottweiler M 3 Radius 2 Osteoblastic 
27 Lurcher M 8 Radius 2 Osteoblastic 
28 Rottweiler F 7 Tibia 2 Osteoblastic 
29 Rottweiler F 6 Tibia 2 Osteoblastic 
30 German SH Pointer F 4 Radius 2 Chondroblastic 
31 Bull Mastiff M 4 Rib 2 Chondroblastic 
32 German Shepherd Dog 
Cross 
F 3 Humerus 
2 
Osteoblastic 
33 Greyhound M 11 Radius 1 Fibroblastic 
34 Labrador F 11 Rib 2 Chondroblastic 
35 Staffordshire Bull Terrier M 8 Skull 1 Osteoblastic 
36 Doberman F 7 Jaw  2 Osteoblastic 
37 Labrador M 10 Rib 1 Fibroblastic 
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38 Golden Retriever F 6 Vertebrae 2 Osteoblastic 
39 Golden Retriever F 9 Vertebrae 2 Osteoblastic 
40 Golden Retriever F 9 Ilium  2 Osteoblastic 
41 Irish Red Setter M 1 Tibia 2 Chondroblastic 
42 German Shepherd Dog 
Cross 
F 9 Humerus 
2 
Fibroblastic 
43 Border Collie M 11 Humerus 2 Fibroblastic 
44 Lurcher M 10 Radius 2 Fibroblastic 
45 Lurcher M 10 Scapula  2 Osteoblastic 
46 Labrador M 7 Tibia 2 Fibroblastic 
47 Labrador F 10 Tibia 2 Osteoblastic 
48 Boxer Cross F 11 Jaw 2 Fibroblastic 
49 Greyhound F 8 Tibia  1 Fibroblastic 
50 Collie Cross M 13 Toe 1 Osteoblastic 
51 Retriever F 9 Skull 1 Fibroblastic 
52 Border Collie cross M 8 Skull 1 Osteoblastic 
53 Labrador M 13 Humerus 2 Osteoblastic 
54 Doberman M 8 Skull 2 Chondroblastic 
55 Doberman F 9 Femur  2 Fibroblastic 
56 German Shepherd Dog F 5 Skull 2 Chondroblastic  
57 Staffordshire Bull Terrier F 12 Humerus 1 Osteoblastic 
58 Greyhound M 10 Tibia 1 Osteoblastic 
59 Rottweiler M 1 Humerus 1 Osteoblastic 
60 Boxer Cross M 11 Femur 1 Osteoblastic 
61 Mastiff F 7 Rib 1 Chondroblastic 
62 Bulldog M 10 Tibia 1 Osteoblastic 
63 Labrador Retriever M 8 Radius 1 Osteoblastic 
64 Giant Schnauzer M 7 Radius 2 Osteoblastic 
65 Boxer   F 10 Rib 2 Chondroblastic 
66 German Shepherd Dog F 11 Radius 2 Osteoblastic 
67 Rottweiler Cross F 8 Jaw 1 Osteoblastic 
68 Spoodle M 10 Rib 2 Osteoblastic 
69 Schnauzer Cross M 11 Rib 2 Fibroblastic 
70 Doberman F 10 Tibia 1 Osteoblastic 
71 Rottweiler M 8 Humerus 1 Chondroblastic 
72 Rottweiler F 9 Jaw 1 Osteoblastic 
73 Golden Retriever M 8 Humerus 1 Chondroblastic 
74 Golden Retriever M 14 Femur 2 Osteoblastic 
75 Rottweiler Cross M 9 Ilium  1 Chondroblastic 
76 Doberman M 9 Radius 1 Chondroblastic 
77 Labrador F 7 Radius 2 Osteoblastic 
78 Jack Russell Terrier M 8 Jaw 2 Osteoblastic 
79 Rottweiler F 4 Humerus 2 Chondroblastic 
80 Blue Heeler M 12 Tibia 1 Chondroblastic 
81 Golden Retriever M 13 Jaw 1 Fibroblastic 
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82 Mastiff Cross M 6 Femur 2 Fibroblastic 
83 Cairn Terrier F 12 Humerus 1 Osteoblastic 
84 Boxer Cross F 15 Jaw 1 Fibroblastic 
85 Jack Russell Terrier F 9 Scapula 2 Osteoblastic 
86 Labrador M 11 Humerus 1 Fibroblastic 
87 Cavalier Cross M 10 Humerus 2 Osteoblastic 
88 Labrador M 13 Jaw 2 Osteoblastic 
89 Border Collie M 6 Femur 2 Osteoblastic 
90 Labradoodle M 3 Rib 2 Chondroblastic 
91 Pointer Cross F 9 Radius 1 Osteoblastic 
92 Rottweiler Cross F 9 Humerus 2 Osteoblastic 
93 Border Collie Cross F 13 Scapula 2 Chondroblastic 
94 American Staffordshire Bull 
Terrier 
M 12 Vertebrae  1 Osteoblastic 
95 White Swiss Shepherd Dog F 9 Ilium  2 Osteoblastic 
96 Maltese Cross M 13 Jaw 2 Osteoblastic 
97 SBT Cross F 9 Humerus 2 Chondroblastic 
98 Alaskan Malamute M 6 Radius 1 Osteoblastic 
99 Rottweiler F 11 Tibia 2 Osteoblastic 
100 Curly Coated Retriever F 11 Humerus 1 Osteoblastic 
101 Boxer F 7 Skull 1 Osteoblastic 
102 Labrador M 8 Humerus 2 Osteoblastic 
103 Jack Russell Terrier M 14 Jaw 2 Osteoblastic 
104 Labrador M 7 Femur 1 Osteoblastic 
105 Greyhound M 11 Femur 1 Fibroblastic 
106 Labradoodle M 7 Humerus 1 Osteoblastic 
      SBT, Staffordshire Bull Terrier; F, female; M, male. 
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Figure 5.1 Pattern of age at diagnosis for dogs with OS, ASAP-50 group and Bristol-56 
group (n= 106). The age distribution of the larger population shows a single peak at the age 
range of 7-10 years, which is similar to the findings in the two component populations.   
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Figure 5.2 Comparison between the number of dogs with OS and their breeds for the 
most common 18 breeds, ASAP-50 group and Bristol-56 group (n= 79). The analysis of the 
larger population shows similar findings to what have been found in the two component 
populations. Canine OS is predominantly found in large breeds such as Rottweiler, Labrador, 
Golden Retriever and Doberman. 
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Figure 5.3 The most commonly affected sites by OS in dogs, the picture of the dog skeleton 
without the sited percentages was taken with permission from (Yesko 1999), ASAP-50 group 
and Bristol-56 group (n= 106). The analysis of the larger population shows that canine OS 
more frequently affects long bones such as humerus, radius and tibia which is similar to the 
findings in the two component populations. 
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5.2.2 Histopathological findings of the dogs with OS 
A histopathological analysis was carried out to count the proportion of each subtype 
and grade of the canine OS tumours. In the total group of 106, osteoblastic OS was classified 
as the most common subtype (57%, 61/106 dogs) (see Figure 5.4 and Figure 5.5a). 
Chondroblastic (23%, 24/106 dogs) (see Figure 5.6a) and fibroblastic (20%, 21/106 dogs) (see 
Figure 5.7a) OS were less common. The number of dogs with a grade G1 tumour was 46/106 
(43%), while the number of dogs with a grade G2 tumour was 60/106 (57%) (see Table 5.1). 
The proportions of each canine OS subtype for the clinical, epidemiological and 
histopathological factors of dogs with OS are summarised in Table 5.2. 
5.2.3 The association between canine OS subtypes and clinicopathological parameters 
The association between canine OS subtypes and clinicopathological characteristics 
was investigated in 106 dogs with OS using Pearson’s Chi-Square test. The analyses showed 
that there were no statistically significant correlations between subtypes of canine OS and the 
tested clinicopathological features including breed size, sex, age, affected skeleton and tumour 
grade (P > 0.05) (see Table 5.2). 
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Figure 5.4 Comparison between the number of dogs diagnosed with osteoblastic, 
chondroblastic or fibroblastic OS, ASAP-50 group and Bristol-56 group (n= 106). The 
frequency of osteoblastic subtype is significantly higher than chondroblastic and fibroblastic 
subtypes and this is similar to what has been shown in the two component populations. P < 
0.05, one-way ANOVA. 
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Table 5.2 Correlation between subtypes of OS and clinical and pathological characters 
in dogs with OS (n= 106). 
Variable All cases, 
n= 106 (%) 
Osteoblastic 
OS, n= 61 (%) 
Chondroblastic 
OS, n= 24 (%) 
Fibroblastic 
OS, n= 21 (%) 
P-value*  
Breed size     0.170 
Large 98 (92.5) 54 (55.1) 24 (24.5) 20 (20.4)  
Small 8 (7.5) 7 (87.5) 0 (0) 1 (12.5)  
Sex     0.617 
Male 57 (53.8) 31 (54.4) 15 (26.3) 11 (19.3)  
Female 49 (46.2) 30 (61.2) 9 (18.4) 10 (20.4)  
**Age (years)     0.098 
<9 64 (60.4) 34 (53.1) 19 (29.7) 11 (17.2)  
>9 42 (39.6) 27 (64.3) 5 (11.9) 10 (23.8)  
Affected 
skeleton 
    0.301 
Appendicular 72 (67.9) 45 (62.5) 15 (20.8) 12 (16.7)  
Axial 34 (32.1) 16 (47.0) 9 (26.5) 9 (26.5)  
Tumour grade     0.350 
Low grade (G1) 46 (43.4) 25 (54.3) 9 (19.6) 12 (26.1)  
High grade (G2) 60 (56.6) 36 (60.0) 15 (25.0) 9 (15.0)  
*Pearson’s Chi-Square test; **Dogs were divided according to the median age. 
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5.2.4 Optimisation of desmin, S100 and NSE for immunostaining  
Staining conditions for the localisation of desmin, S100 and NSE using IHC were 
optimised using different reagents, concentrations and incubation times (see Tables 2.9a and 
2.9b). 
5.2.4.1 Optimisation of conditions for localisation of desmin 
The optimal conditions for detection of desmin occurred when the desmin antigen was 
retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was incubated in the 
mouse monoclonal primary antibody for 45 minutes at room temperature, then the section was 
incubated in the goat anti-mouse polyclonal secondary antibody for 30 minutes at room 
temperature and in DAB for 10 minutes (see Section 3.2.2.3; Table 3.2; Figure 3.6A). 
5.2.4.2 Optimisation of conditions for localisation of S100 
The optimal conditions for the localisation of S100 occurred when the S100 antigen 
was retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was incubated in 
the rabbit polyclonal primary antibody for 30 minutes at room temperature, then it was 
incubated in the mouse anti-rabbit monoclonal secondary antibody that was diluted 1:50 for 30 
minutes at room temperature in DAB for 10 minutes (see Section 3.2.2.4; Table 3.2; Figure 
3.7A). 
5.2.4.3 Optimisation of conditions for localisation of NSE 
The optimal conditions for the detection of NSE occurred when the NSE antigen was 
retrieved using solution 2 (pH 8.0) for 20 minutes at 97 °C, the section was incubated in the 
mouse monoclonal primary antibody for 30 minutes at room temperature, then the section was 
incubated in the goat anti-mouse polyclonal secondary antibody for 30 minutes at room 
temperature and in DAB for 10 minutes (see Section 3.2.2.5; Table 3.2; Figure 3.8A). 
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5.2.5 Immunohistochemical localisation of desmin, S100 and NSE in different subtypes 
of canine OS 
IHC was carried out to investigate the localisation of desmin, S100 and NSE in 56 
canine OS tumours (Bristol-56 group). The three histological subtypes of canine OS showed 
varied immunostaining of desmin, S100 and NSE (see Table 5.3). Desmin was detected in 
13/56 (23%), S100 in 9/56 (16%) and NSE in 31/56 (55%) tumours (see Figures. 5.5, 5.6 and 
5.7). Desmin demonstrated cytoplasmic localisation, whereas S100 and NSE demonstrated 
nuclear plus cytoplasmic labelling of tumour cells. 
Thirty-two percent (9/28) of osteoblastic tumours (see Figures. 5.5b-5.5d) were triple 
negative for desmin, S100 and NSE and 7% (2/28) were triple positive. Thirty-one percent 
(4/13) of chondroblastic tumours (see Figures. 5.6b-5.6d) were triple negative for desmin, S100 
and NSE and 8% (1/13) were triple positive. Thirty-three percent (5/15) of fibroblastic tumours 
(see Figures 5.7b-5.7d) were triple negative for desmin, S100 and NSE and no triple positive 
fibroblastic tumours were identified. Immunohistochemical findings of the three histological 
subtypes are summarised in Table 5.4. 
5.2.6 No correlation was observed between immunohistochemical localisation of desmin, 
S100 and NSE and subtypes of canine OS 
A Mann-Whitney U test was performed to assess the correlation between the 
localisation of desmin, S100 and NSE and the subtypes of 56 canine OS tumours (Bristol-56 
group). The current analyses showed that there was no statistically significant association 
between the localisation of these three protein tumour markers and the subtypes of canine OS 
(P > 0.05) (see Table 5.4). 
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Table 5.3 Subtypes of canine OS tumours (Brisrol-56 group) and the detection of 
desmin, S100 and NSE (n= 56). 
Case 
number 
Breed OS subtype Desmin 
staining 
S100 staining NSE staining 
1 Retriever Osteoblastic Negative Positive Negative 
2 Rottweiler Osteoblastic Positive Negative Positive 
3 Old English 
sheepdog 
Osteoblastic Positive Positive Positive 
4 Rottweiler Osteoblastic Negative Negative Positive 
5 Rottweiler Fibroblastic Negative Negative Positive 
6 Doberman Osteoblastic Negative Negative Positive 
7 Great Dane Chondroblastic Negative Negative Positive 
8 St Bernard Fibroblastic Negative Positive Positive 
9 Golden Retriever Fibroblastic Negative Negative Negative 
10 German Shepherd 
Dog 
Chondroblastic Negative Negative Negative 
11 Border Collie Chondroblastic Positive Positive Positive 
12 Border Collie Chondroblastic Negative Negative Positive 
13 Border Collie Chondroblastic Negative Negative Negative 
14 Flat Coated 
Retriever 
Chondroblastic Negative Negative Positive 
15 Rottweiler Osteoblastic Negative Negative Negative 
16 Rottweiler Osteoblastic Positive Negative Negative 
17 Labrador Osteoblastic Negative Negative Positive 
18 Rottweiler Fibroblastic Negative Negative Negative 
19 Spaniel Osteoblastic Negative Negative Positive 
20 Mastiff Osteoblastic Positive Negative Positive 
21 German Shepherd 
Dog Cross 
Osteoblastic Positive Negative Positive 
22 Great Dane Chondroblastic Negative Negative Positive 
23 Boxer Osteoblastic Negative Negative Positive 
24 Rottweiler Fibroblastic Negative Negative Negative 
25 Golden Retriever Osteoblastic Negative Negative Positive 
26 Rottweiler Osteoblastic Positive Negative Negative 
27 Lurcher Osteoblastic Negative Negative Positive 
28 Rottweiler Osteoblastic Negative Negative Negative 
29 Rottweiler Osteoblastic Negative Negative Negative 
30 German SH 
Pointer 
Chondroblastic Negative Negative Positive 
31 Bull Mastiff Chondroblastic Negative Negative Positive 
32 German Shepherd 
Dog Cross 
Osteoblastic Negative Positive Negative 
33 Greyhound Fibroblastic Negative Negative Positive 
34 Labrador Chondroblastic Positive Negative Negative 
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35 Staffordshire Bull 
Terrier 
Osteoblastic Negative Negative Negative 
36 Doberman Osteoblastic Negative Positive Negative 
37 Labrador Fibroblastic Positive Positive Negative 
38 Golden Retriever Osteoblastic Negative Negative Positive 
39 Golden Retriever Osteoblastic Negative Negative Positive 
40 Golden Retriever Osteoblastic Positive Positive Positive 
41 Irish Red Setter Chondroblastic Negative Negative Negative 
42 German Shepherd 
Dog Cross 
Fibroblastic Negative Negative Positive 
43 Border Collie Fibroblastic Negative Negative Positive 
44 Lurcher Fibroblastic Negative Negative Positive 
45 Lurcher Osteoblastic Negative Negative Negative 
46 Labrador Fibroblastic Negative Positive Positive 
47 Labrador Osteoblastic Negative Negative Negative 
48 Boxer Cross Fibroblastic Negative Negative Negative 
49 Greyhound Fibroblastic Negative Negative Negative 
50 Collie Cross Osteoblastic Negative Negative Negative 
51 Retriever Fibroblastic Positive Negative Positive 
52 Border Collie 
cross 
Osteoblastic Negative Negative Positive 
53 Labrador Osteoblastic Positive Negative Positive 
54 Doberman Chondroblastic Negative Negative Negative 
55 Doberman Fibroblastic Positive Negative Negative 
56 German Shepherd 
Dog 
Chondroblastic  Negative Negative Positive 
NSE, neuron-specific enolase. 
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Figure 5.5 Comparison of histology and immunoreactivity for desmin, S100 and NSE in 
osteoblastic canine OS, group Bristol-56, n= 56. (A) Poorly differentiated spindle neoplastic 
cells produce osteoid (arrow) extracellular matrix. H & E; (B) neoplastic cells are negative with 
no cytoplasmic immunoreactivity for desmin (negative); (C) neoplastic cells are characterised 
by no cytoplasmic immunoreactivity for S100 (negative); (D) neoplastic cells have weak 
cytoplasmic immunoreactivity for NSE (low NSE labelling intensity). IHC. Scale bar, 100 µm. 
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Figure 5.6 Comparison of histology and immunoreactivity for desmin, S100 and NSE in 
chondroblastic canine OS, group Bristol-56, n= 56. (A) Spindle neoplastic cells produce 
chondroid (arrow) extracellular matrix. (H&E); (B) neoplastic cells are weakly positive in the 
cytoplasm and nucleus for desmin (low desmin labelling intensity); (C) neoplastic cells are 
characterised by moderate cytoplasmic and nuclear immunoreactivity for S100 (moderate S100 
staining intensity); (D) neoplastic cells are characterised by no cytoplasmic immunoreactivity 
for NSE (negative). IHC. Scale bar, 100 µm. 
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Figure 5.7 Comparison of histology and immunoreactivity for desmin, S100 and NSE in 
fibroblastic canine OS, group Bristol-56, n= 56. (A) Spindle neoplastic cells (arrows) have 
elongated or oval nuclei and produce no or minimal amounts of osteoid or chondroid 
extracellular matrix. H&E; (B) neoplastic cells are characterised by no cytoplasmic staining 
for desmin (negative); (C) neoplastic cells are negative with no cytoplasmic staining for S100 
(negative); (D) neoplastic cells are characterised by strong cytoplasmic and nuclear staining 
for NSE (high NSE labelling intensity). IHC. Scale bar, 100 µm. 
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Table 5.4 Correlation between desmin, S100 and NSE immunostaining and OS subtypes 
in Bristol-56 group of dogs with OS (n= 56). 
Variable All cases, n=56 (%) Osteoblastic OS, 
n= 28 (%) 
Chondroblastic 
OS, n= 13 (%) 
Fibroblastic OS, 
n= 15 (%) 
P-value*  
Desmin     0.428 
Positive 13 (23.2) 8 (28.6) 2 (15.4) 3 (20.0)  
Negative 43 (76.8) 20 (71.4) 11 (84.6) 12 (80.0)  
S100     0.961 
Positive 9 (16.1) 5 (17.9) 1 (8.0) 3 (20.0)  
Negative 47 (83.9) 23 (82.1) 12 (92.0) 12 (80.0)  
NSE     0.885 
Positive 32 (57.1) 15 (53.6) 8 (61.5) 8 (53.3)  
Negative 24 (42.9) 13 (46.4) 5 (38.5) 7 (46.7)  
*Mann-Whitney U test; NSE, neuron-specific enolase. 
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5.2.7 Dogs with fibroblastic OS had longer survival times than those with osteoblastic or 
chondroblastic subtypes  
5.2.7.1 The association between subtypes of OS and survival time in ASAP-50 group of 
dogs with OS 
Kaplan-Meier analysis with the log-rank test was used to analyse the relationship 
between the subtypes of OS and survival times for 50 dogs with OS (ASAP-50) (see Figure 
5.8). The analysis showed that the survival time was significantly different between groups 
with different subtypes (log-rank test, P= 0.037) (see Figure 5.8). Dogs with chondroblastic 
OS had a shorter average survival time (mean= 104 ± 22 days; 95% CI: 61-147) than that for 
dogs with osteoblastic (mean= 168 ± 33 days; 95% CI: 104-232) or fibroblastic OS (mean= 
463 ± 116 days; 95% CI: 236-690) (see Figure 5.9). 
Multivariate Cox regression analysis (Bradburn, et al. 2003) was used to investigate the 
prognostic value of breed size, sex, age, affected skeleton, metastasis, tumour grade, subtype 
of OS, chemotherapy, surgery (tumour removal), PTHR1 and PTHrP staining intensity  for 
overall survival in the ASAP-50 group of dogs with OS. Based on the analysis, subtype of OS 
(multivariate Cox regression analysis, P= 0.031) (see Table 5.5) and staining intensity of 
PTHR1 (already discussed in Chapter 4) were the only parameters that appeared to impact 
survival and act as independent prognostic factors for overall survival (see Table 5.5). 
Therefore, the results suggest that the subtype of OS is significantly linked with the prognosis 
of dogs with OS. 
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Figure 5.8 Kaplan-Meier survival analysis of dogs with different subtypes of OS. Dogs 
with fibroblastic OS (mean= 463 ± 116 days, n= 6) had longer survival times compared with 
those with chondroblastic (mean= 104 ± 22 days, n= 11) or osteoblastic OS (mean= 168 ± 33 
days, n= 33) (log-rank test, P= 0.037) (ASAP-50). Censored data were considered for dogs 
who were still alive at the date of data collection or that had died because of post-surgical 
complications. 
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Figure 5.9 Comparison between the average survival times for dogs diagnosed with 
osteoblastic, chondroblastic or fibroblastic OS, ASAP-50, n= 50. Data is presented as mean 
± standard error of the mean. Dogs with fibroblastic subtype had significantly longer survival 
times compared to those dogs with chondroblastic or osteoblastic subtypes, P= 0.031, one-way 
ANOVA. 
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Table 5.5 Multivariate Cox regression analysis of prognostic factors in 50 dogs with OS 
for overall survival (ASAP-50)*. 
Variable Hazard ratio 95% 
confidence 
interval 
P-value** 
Breed size  
large vs. small 0.680 0.181-2.552 0.568 
Sex  
male vs. female 1.376 0.545-3.472 0.500 
***Age (years)  
<9 vs. >9 1.380 0.607-3.136 0.442 
Affected skeleton  
appendicular vs. axial 0.521 0.363-2.249 0.828 
Metastasis  
yes vs. no 3.452 0.496-24.038 0.211 
Tumour grade  
low vs. high 0.862 0.377-1.975 0.726 
Subtype of OS  
Osteoblastic vs. 
chondroblastic vs. fibroblastic 
0.087 0.014-0.533 0.031**** 
Chemotherapy  
yes vs. no 0.371 0.052-2.657 0.324 
Surgery (Tumour removal)  
yes vs. no 0.866 0.136-5.520 0.879 
PTHR1 staining intensity  
strong vs. moderate vs. 
weak***** 
0.007 0.000-0.130 0.000195**** 
PTHrP staining intensity  
strong vs. moderate vs. 
weak 
3.475 0.785-15.391 0.089 
*Same data presented in Chapter 4 (Table 4.5); ** Multivariate Cox regression analysis; ***Dogs were divided 
according to the median age; ****P < 0.05; *****Discussed previously in Chapter 4. 
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5.2.7.2 The relationship of subtypes of OS with poor survival in ASAP-20 group of dogs 
with OS 
Dogs in the following categories were excluded from the survival analysis to minimise 
variation in the ASAP-20 group of dogs with OS: (1) did not receive surgical treatment; (2) did 
not receive chemotherapy treatment; (3) had pulmonary metastasis at presentation; (4) 
presented with OS localised in the axial region (5) were still alive at the date of data collection 
(6) died because of post-surgical complications (n= 30) (see Appendix 2). The number of dogs 
that satisfied the inclusion criteria was 20 (ASAP-20) (had limb amputation and then went 
through adjuvant chemotherapy using cisplatin or carboplatin as a single or multiple dose, had 
no pulmonary metastasis at presentation, presented with OS localised in the appendicular 
skeleton and died due to OS) and survival times ranged from 26 to 702 days (see Table 5.6). 
The relationship between the subtypes of appendicular OS and the survival times of the 
20 dogs was analysed using the Kaplan-Meier analysis with the log-rank test (see Figure 5.10). 
The log-rank test showed that the survival time was different amongst the groups of dogs with 
different subtypes of appendicular OS (log-rank test, P= 0.016) (see Figure 5.10). Dogs with 
appendicular chondroblastic OS had shorter average survival times (mean= 86 ± 10 days; 95% 
CI: 66-106) compared with those with appendicular osteoblastic (mean= 257 ± 48 days; 95% 
CI: 163-351) or appendicular fibroblastic OS (mean= 568 ± 54 days; 95% CI: 463-672) (see 
Figure 5.11). A comparison can be seen in Figure 5.10 of the survival estimations over time 
for those dogs diagnosed with different subtypes of appendicular OS, while Figure 5.11 
illustrates a comparison of the average survival times for dogs diagnosed with appendicular 
chondroblastic, appendicular osteoblastic or appendicular fibroblastic OS. 
Furthermore, the univariate Cox regression analysis (Clark, et al. 2003) on different 
clinicopathological parameters including breed size, sex, age and tumour grade was used to 
evaluate the prognostic value of the histological subtype of OS for overall survival rates in the 
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ASAP-20 group of dogs with OS (see Table 5.6). Based on this analysis, subtype of OS was 
found to influence survival (P= 0.037, univariate Cox regression) (see Table 5.7). Other 
parameters including breed size, sex, age and tumour grade did not show any significant 
prognostic value. 
The prognostic value of canine OS subtype was further examined using a multivariate 
Cox regression analysis (see Table 5.7). It was observed that the subtype of OS was an 
independent prognostic factor for overall survival (P= 0.030, multivariate Cox regression 
analysis) (see Table 5.7). Thus, in line with the findings of the ASAP-50 group of dogs with 
OS (n= 50) (see Section 5.2.7.1), the results suggest that the histological subtype of OS is 
significantly linked with the prognosis of canine OS. 
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Table 5.6 Clinicopathological data for dogs with appendicular OS included in the survival 
analysis (ASAP-20). 
Case 
number 
Breed Sex Age at 
diagnosis 
(year) 
Body 
part 
Survival 
time  
(days) 
Subtype Tumour 
grade 
Chemotherapy 
1 Cavalier Cross M 10 Humerus 26 O 2 Carboplatin (5 
doses) 
2 SBT Cross F 9 Humerus 76 C 2 Carboplatin (5 
doses) 
3 Alaskan 
Malamute 
M 6 Radius 82 O 1 Cisplatin (1 dose) 
4 Greyhound M 10 Tibia 90 O 1 Carboplatin (5 
doses) 
5 Curly Coated 
Retriever 
F 11 Humerus 90 O 1 Carboplatin (5 
doses) 
6 Rottweiler F 4 Humerus 96 C 2 Carboplatin (5 
doses) 
7 Rottweiler M 1 Humerus 114 O 1 Carboplatin (5 
doses) 
8 Cairn Terrier F 12 Humerus 155 O 1 Carboplatin (5 
doses) 
9 Bulldog M 10 Tibia 193 O 1 Carboplatin (1 
dose) 
10 Dobermann F 10 Tibia 240 O 1 Carboplatin (1 
dose) 
11 Rottweiler 
Cross 
F 9 Humerus 270 O 2 Carboplatin (5 
doses) 
12 Labrador 
Retriever 
F 7 Radius 277 O 2 Carboplatin (1 
dose) 
13 Rottweiler F 11 Tibia 288 O 2 Carboplatin (1 
dose) 
14 Giant 
Schnauzer 
M 7 Radius 380 O 2 Carboplatin (5 
doses) 
15 Boxer Cross M 11 Femur 458 O 1 Carboplatin (6 
doses) 
16 Mastiff Cross M 6 Femur 470 F 2 Carboplatin (5 
doses) 
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17 German 
Shepherd Dog 
F 11 Radius 485 O 2 Cisplatin (one 
dose) 
18 Labrador 
Retriever 
M 11 Humerus 578 F 1 Carboplatin (5 
doses) 
19 Greyhound M 11 Femur 655 F 1 Carboplatin (5 
doses) 
20 Labrador 
Retriever 
M 8 Radius 702 O 1 Carboplatin (4 
doses) 
SBT, Staffordshire Bull Terrier; F, female; M, male; O, osteoblastic OS; C, chondroblastic OS; F, fibroblastic OS. 
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Table 5.7 Univariate and multivariate Cox regression analysis of prognostic factors in 
ASAP-20 group of dogs with OS for overall survival. 
Covariate Univariate analysis Multivariate analysis 
 HR 95% CI P-value*  HR 95% CI P-value* 
Breed size   
large vs. small 0.216 0.043-1.076 0.061    
Sex   
male vs. female 0.498 0.185-1.337 0.166    
**Age (years)   
<10 vs. >10 1.777 0.682-4.629 0.239    
Tumour grade   
low vs. high 0.704 0.268-1.849 0.476    
Subtype of OS   
strong vs. moderate 
vs. weak 
0.065 0.008-0.526 0.037*** 0.002 0.000-0.238 0.030*** 
* Multivariate Cox regression analysis; **Dogs were divided according to the median age; ***P<0.05; HR, hazard 
ratio; CI, confidence interval. 
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Figure 5.10 Kaplan-Meier survival analysis of dogs with different subtypes of 
appendicular OS. Dogs with appendicular fibroblastic (mean= 568 ± 54 days, n= 3) had longer 
survival times compared with those with appendicular osteoblastic (mean= 257 ± 48 days, n= 
15) or appendicular chondroblastic (mean= 86 ± 10 days, n= 2) OS (log-rank test, P= 0.016) 
(ASAP-20). 
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Figure 5.11 Comparison between the average survival times for dogs diagnosed with 
appendicular osteoblastic, appendicular chondroblastic or appendicular fibroblastic OS, 
ASAP-20, n= 20. Data is presented as mean ± standard error of the mean. Dogs with 
fibroblastic subtype had significantly longer survival times compared to those dogs with 
chondroblastic or osteoblastic subtypes, P= 0.013, one-way ANOVA. 
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5.3 Discussion 
The histological classification of OS is necessary for accurate diagnosis (Rosenberg 
2010). This classification can help in categorising human patients for risk-based assessment 
(Rosenberg 2010). Despite multiple studies that have attempted to evaluate the prognostic 
significance of human and canine OS sub-classification (Kruse, et al. 2013; Paparella, et al. 
2013; Nagamine, et al. 2015; Walia, et al. 2016), such classification still remains controversial 
because of contradictory findings. Furthermore, Chapter 3 showed that immunostaining of 
established tumour markers of OS including desmin (24%), S100 (15%) and NSE (56%) was 
variable in canine OS tissues. The current study investigated whether specific histological 
subtypes of canine OS have significantly different survival times and whether there was a 
significant difference in the immunostaining of desmin, S100 and NSE among the three 
histological subtypes. 
To investigate the correlation between histological subtypes of canine OS and survival, 
the survival times of dogs with osteoblastic, chondroblastic and fibroblastic subtypes of 
appendicular OS were compared. Statistical analyses showed that dogs with the appendicular 
fibroblastic subtype had significantly longer overall survival times compared to dogs with 
appendicular osteoblastic or chondroblastic subtypes. In addition, dogs with appendicular 
chondroblastic OS had shorter survival times and this subtype was a significant indicator for a 
poor prognosis of OS in dogs. 
5.3.1 Histological subtypes of canine osteosarcoma influence prognosis 
In line with the results reported by previous studies on canine OS (Misdorp and Hart 
1979; Hammer, et al. 1995; Straw 2000; Loukopoulos and Robinson 2007; Thompson and 
Dittmer 2017), the present work also revealed that dogs with a fibroblastic subtype had a more 
favorable prognosis compared with those that had other the subtypes. Kirpensteijn, et al. (2002) 
reported that dogs with an osteoblastic subtype had early metastasis compared with the other 
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subtypes. In addition, a study by Loukopoulos and Robinson (2007) showed that high grade 
OS was associated with specific subtypes in dogs. For example, dogs with high grade OS were 
mostly sub-classified as osteoblastic or chondroblastic. Loukopoulos and Robinson (2007) also 
reported that fibroblastic OS cells were less pleomorphic compared with those in other 
subtypes. In humans, numerous studies have revealed that chondroblastic OS is more 
aggressive (Bentzen, et al. 1988; Szendroi, et al. 2000; Ferrari, et al. 2001; Paparella, et al. 
2013). This was substantiated by Hauben, et al. (2002) and Bacci, et al. (2006) who found that 
humans with chondroblastic OS had a poorer response to chemotherapy compared to patients 
with the fibroblastic subtype. Furthermore, pulmonary metastases were detected more 
commonly in humans with osteoblastic OS followed by those with chondroblastic OS (Kaste, 
et al. 1999). The above findings in dogs and humans in regards to the different responses to 
chemotherapy, metastatic potential and tumour grade among the three histological subtypes of 
OS could explain the significantly increased survival times for dogs with the fibroblastic 
subtype in contrast with dogs with the other subtypes. In line with the present data, this suggests 
that the subtypes of OS may have different behaviors and therefore could be genetically 
different. 
Beckwith, et al. (2010) showed that although canine OS of the head (maxilla, mandible 
and skull) is locally aggressive, it has a lower metastasis rate than canine appendicular OS. In 
addition, it has been found that dogs with OS of the mandible treated with mandibulectomy 
alone had a one-year survival rate of 71% (Straw, et al. 1996). In the present study of the ASAP-
50 group, 33% (2/6 dogs) of fibroblastic OS tumours were localised in the jaw and one could 
suggest that relative survival times of dogs with fibroblastic subtypes could be cofounded by a 
higher percentage of fibroblastic subtypes in the cases of OS of the jaw. Nevertheless, we found 
that the fibroblastic tumour group (ASAP-20) which have OS in the appendicular skeleton had 
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longer survival times. We understand that the size of the group limits interpretation, but these 
data will lead to a more extensive research project in the future addressing this issue. 
In contrast, other studies (Kirpensteijn, et al. 2002; Cavalcanti, et al. 2004; Schott, et 
al. 2018) reported that no significant differences were found between the histological subtypes 
of canine OS and survival times. Straw, et al. (1996) and Kruse, et al. (2013) also revealed 
similar findings but these two studies only analysed canine OS that was localised in the axial 
skeleton, which could explain the dissimilarity in findings between these studies and the current 
study. 
No association was observed between survival times and other clinicopathological 
factors investigated including tumour grade, age, sex or breed. Although researches has shown 
that a high grade OS (Kirpensteijn, et al. 2002) and being male (Petrilli, et al. 1991) were 
correlated with lower survival times, the data presented agreed with other studies (Misdorp and 
Hart 1979; Spodnick, et al. 1992; Loukopoulos and Robinson 2007; Bispo Junior and Camargo 
2009; Schott, et al. 2018) that these factors are not correlated with survival outcomes. A study 
in different geographic areas with a larger sample size and a diversity of breeds could be 
warranted to evaluate and confirm the correlation between the survival outcome and previous 
clinicopathological factors. 
5.3.2 Histological subtypes of OS had no correlation with the immunostaining of 
desmin, S100 and NSE 
5.3.2.1 Localisation of desmin in different subtypes of canine OS 
The localisation of desmin in canine OS showed variable immunostaining (Al-Khan, et 
al. 2017) but the correlation between its localisation and histological subtypes was not 
investigated. Therefore, immunostaining of desmin was analysed to examine whether there was 
a link between its expression and subtypes of canine OS. In the present work, 23% of all canine 
OS studied showed immunoreactivity for desmin. Analysis of IHC did not reveal a significant 
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correlation between desmin immunoreactivity and OS histological subtypes. Recently, 
Nagamine, et al. (2015) reported similar results. Only a few canine OS cells were positive for 
desmin in the different histological subtypes (Nagamine, et al. 2015). In humans, Hasegawa, 
et al. (1997) showed that there was no significant correlation between patterns of expression of 
desmin and OS subtypes. In contrast, Hemingway, et al. (2012) did not detect desmin 
expression in 17 human OS. Collectively, the current findings suggest that desmin-positive OS 
cells, may have characteristics of smooth muscle cells or myofibroblasts, and the staining for 
desmin may not depend on the histological subtype. 
5.3.2.2 Localisation of S100 in different subtypes of canine OS 
Previous findings showed that the localisation of S100 in canine OS was variable (Al-
Khan, et al. 2017). Thus, S100 localisation was analysed to investigate whether there was a 
correlation between its localisation and the subtypes of canine OS. In the current study, 16% 
of canine OS showed S100 immunoreactivity, but no significant association between the 
immunoreactivity of S100 and the OS histological subtypes. These findings are supported by 
studies in humans (Okajima, et al. 1988; Chano, et al. 1996; Hasegawa, et al. 1997). In which 
S100 immunoreactivity was found in all three subtypes of human OS (Okajima, et al. 1988). 
Furthermore, Chano, et al. (1996) showed that S100 was only expressed by few human OS 
tumours and was not correlated with histological subtypes. In addition, Hasegawa, et al. (1997) 
found that S100 was localised in the human chondroblastic OS subtype and other histological 
subtypes including fibroblastic and osteoblastic OS. This may suggest that S100 is not only 
expressed by chondroblasts, but also could be expressed by osteoblasts and fibroblasts. 
5.3.2.3 Localisation of NSE in different subtypes of canine OS 
It has been shown that expression of NSE in canine OS is variable (Al-Khan, et al. 
2017). Therefore, NSE immunostaining was analysed to examine whether there was an 
association between the histological subtypes and immunostaining. NSE-positive neoplastic 
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cells were observed in all subtypes and there was no significant difference in immunoreactivity 
of NSE between the three canine OS subtypes. To our knowledge, the present study is the first 
to investigate the correlation between immunoreactivity of NSE and subtypes of canine OS. 
Several studies reported that NSE was expressed in some human OS (Rosenberg 1995; Trihia 
and Valavanis 2012), but the histological subtypes were not reported. The present study 
suggests that OS cells of different subtypes could have some properties of neural cells such as 
the expression of NSE. 
Together, these results suggest that the localisation of desmin, S100 and NSE is not 
dependant on canine OS subtypes. 
5.3.3 Epidemiological and clinical data of the studied dogs with OS (ASAP-50 and 
Bristol-56 groups)  
Analysis of the epidemiological and clinical data for dogs with OS revealed that most 
of the population characteristics are compatible with previous findings. The current results 
showed that canine OS occurred more frequently at the age of nine years (Spodnick, et al. 1992; 
Boston, et al. 2006), in males (Spodnick, et al. 1992; Trost, et al. 2012), in pure breeds (Gomes 
and Rocha 2016), in large dog breeds (Norrdin, et al. 1989; Spodnick, et al. 1992; Cooley and 
Waters 1997; McNeill, et al. 2007) and in the appendicular skeleton (Liptak, et al. 2004; 
Rosenberger, et al. 2007). Development of canine OS predominantly in males and middle aged 
could be due to sex hormones (Cooley, et al. 2002; Simpson, et al. 2017). In addition, 
development of canine OS in specific breeds could be related to the differences in the genomes 
(Phillips, et al. 2007; Simpson, et al. 2017). The localisation of canine OS most commonly in 
appendicular skeleton, especially in the humerus, radius and tibia could be a result of weight 
bearing (Liptak, et al. 2004; Simpson, et al. 2017). The current findings also showed that 
osteoblastic OS is the most predominant histological subtype compared to fibroblastic and 
chondroblastic subtypes (Trost, et al. 2012; Nagamine, et al. 2015). In line with a veterinary 
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study (Cohen, et al. 1974), the current work did not show a bimodal age distribution for dogs 
with OS but a previous study in humans did (Mirabello, et al. 2009b). 
5.4 Conclusion 
In conclusion, this chapter has revealed that dogs with fibroblastic OS have longer 
survival times compared to dogs with osteoblastic and chondroblastic subtypes. In addition, 
this current study revealed that the chondroblastic subtype may be an indicator for poor 
prognosis. The histological subtypes of OS could be used in categorising patients for risk-based 
assessment. This supports the hypothesis that the histological subtypes of OS have diverse 
behaviours and may be genetically different. In addition, this study has also shown that there 
is no significant difference in the localisation of desmin, S100 and NSE among the subtypes of 
canine OS. 
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Chapter 6 
6.0 General discussion and conclusion 
6.1 General discussion 
The aim of this present project was to improve our understanding of OS by validating 
canine OS as an appropriate natural animal model for the study of human OS and the 
identification of novel prognostic indicators that may help predict patient outcomes. 
By comparing novel data on canine OS with published studies of human OS, this 
comparative histopathological study has shown similarities in the localisation of tumour 
marker proteins in OS of both dogs and humans, which will improve our understanding of this 
disease. The current study is the first demonstration of the localisation of the tumour marker 
proteins panel including vimentin, ALP, desmin, S100, NSE, Runx2 and BMP4 in canine OS. 
This pattern is similar to that seen in human OS (Rosenberg 1995; Andela, et al. 2005; Coffin 
and Belchis 2006; Rosier and Bukata 2007). This demonstrates that canine and human OS share 
a similar tumour marker profile. It also demonstrates that canine OS may be a suitable animal 
model for the study of human OS.  
In the last three decades, there has been no improvement in the treatment of human OS, 
especially for those patients with metastases (Chou, et al. 2009). Thus, there is a need to find 
new prognostic indicators and novel therapeutic targets, which could assist in improving 
treatments and quality of life for OS patients. Before this study, PTHR1 had not been localised 
in canine OS and its value as a prognostic marker had not yet been assessed. This study 
demonstrated that dogs with OS that stained strongly for PTHR1 survived for a shorter time 
compared to those with OS showing moderate or weak staining. Overexpression of PTHR1 is 
a significant factor for a poor prognosis in canine OS. This study supports the view that dogs 
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with OS tumours with strong positive for PTHR1 are at a high risk for cancer-related mortality, 
those with OS tumours with moderate staining are at a lesser risk for cancer-related mortality 
and those with OS tumours with weak staining are at an even lower risk for cancer-related 
mortality. This study has shown that an increased amount of PTHR1 in OS is correlated with 
poor prognosis. 
OS is sub-classified based on predominance of extracellular matrix and malignant 
stroma into three subtypes: osteoblastic, chondroblastic and fibroblastic OS (Fletcher, et al. 
1994; Kirpensteijn, et al. 2002; Rosenberg, et al. 2013; Thompson and Dittmer 2017). In 
osteoblastic OS, the neoplastic cells produce large amounts of osteoid and/or bone (Dorfman, 
et al. 2002; Trihia and Valavanis 2012). The mineralisation may spread to the surrounding soft 
tissue. The major malignant cells in osteoblastic OS are spindle in shape but some can be 
epithelioid (Schajowicz, et al. 1995). The malignant cells of chondroblastic OS produce 
cartilage and the major feature of this tumour is the presence of chondroid material 
(Schajowicz, et al. 1995). Fibroblastic tumours produce focal and minimal amounts of osteoid 
and have a high cellular fibroblastic proliferation (Raymond, et al. 2002). 
The histological sub-classification of OS is important to diagnose this disease precisely 
and might be useful for human risk-adapted therapy (Rosenberg 2010). Several previous 
studies suggested that subtyping of OS histologically has no prognostic value in either humans 
or dogs (Straw, et al. 1996; Gorlick 2009; Kruse, et al. 2013; Nagamine, et al. 2015). 
Experiments that have been described in the current study are the first to demonstrate that dogs 
with appendicular fibroblastic OS may survive longer compared to those with appendicular 
osteoblastic or appendicular chondroblastic OS. Furthermore, this small study indicates that 
appendicular chondroblastic OS maybe a possible significant indicator for poor prognosis in 
dogs. The present findings demonstrate that patients affected with appendicular chondroblastic 
or appendicular osteoblastic OS might be at a higher risk for cancer-related mortality compared 
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to those affected with appendicular fibroblastic OS. This preliminary work supports the 
hypothesis that the histological subtype of OS might have prognostic value.  
OS is an aggressive primary bone tumour in both humans and dogs (Brodey and Riser 
1969; Mirabello, Pfeiffer, et al. 2011). Using suitable animals as models to study the biology 
of human OS is required to improve our understanding of this disease and to increase the quality 
of life for patients by discovering novel treatments (Guijarro, et al. 2014). Canine OS is an 
important model for comparative studies of cancer. Using a canine model helps to answer some 
non-clinical research questions more simply compared to mouse models (Khanna, et al. 2006). 
The normal immune interactions between the tumour and the surrounding tissue in canine 
spontaneously occurring tumours such as OS allows the tumour to grow and progress naturally. 
Therefore, using canine models for the study of human tumours may provide more accurate 
and reliable results compared to rodent models. Canine tumours are similar to those in humans 
with regards to their genetic instability and heterogeneity (Riccardo, et al. 2015). The treatment 
of human OS and prognosis after current therapy with surgery and adjuvant chemotherapy has 
not improved, particularly for patients with metastases (Chou, et al. 2009; Hagleitner, et al. 
2011). Therefore, using canine models to identify protein markers that can predict prognosis 
and allow early diagnosis may provide better treatment options for both humans and dogs  
(Paoloni and Khanna 2008; Riccardo, et al. 2015). In addition, using canine models to test new 
therapies may provide novel treatments that may lead to improve the quality of life for both 
dog and human patients (Paoloni and Khanna 2008; Riccardo, et al. 2015).  
Furthermore, using dogs as a model is potentially less expensive than mouse models as 
dogs may be sourced as outpatients and animal housing facilities are not required. In addition 
to chemotherapy, immunotherapy and radiotherapy trials, dogs provide a good model to test 
different surgical procedures such as limb sparing surgery and amputation (LaRue, et al. 1989; 
Lascelles, et al. 2005; Jeys, et al. 2007; Fenger, et al. 2014) . Surgical removal of canine OS 
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could also help in management of bone post-operative infections, which may occur in humans 
(Fenger, et al. 2014). 
6.1.1 Canine OS is a comparative model for the study of human OS 
Previously, there have been some studies showing that there might be a similarity 
between canine and human OS. These similarities include global gene expression signatures 
(Paoloni, et al. 2009), histological appearance of OS, tumour progression, response to 
conventional OS therapies, molecular targets (Guil-Luna, et al. 2015) and OS biological 
behaviours (Owen 1969).  
Other researchers have investigated the characteristics that support the use of dogs as 
models to study a number of tumour types. The reasons for this include the fact that humans 
and dogs share similar physiological gross anatomy features (Gordon and Khanna 2010) and 
live in the same environmental conditions (Owen, et al. 1975; Guil-Luna, et al. 2015). Canine 
OS is about 27 times more common than human OS (Simpson, et al. 2017) and this offers the 
opportunity to collect large sample sizes for experiments. Apart from humans, the dog is the 
only other large mammal that naturally develops OS with high incidence (Brodey 1979; Vail 
and MacEwen 2000; Fan 2010). In other animal models such as mice and rats, OS needs be 
chemically or genetically induced and this produces artifacts, which do not occur naturally in 
human cancers (Hewitt 1978; Donehower, et al. 1992). Canine OS also metastasizes earlier 
than it does in humans (Owen 1967; Withrow, et al. 1991). Dogs have shorter lifespans (Owen 
1967), which may provide better opportunities to examine the effects of potential treatments 
that target the migration of tumour cells (Mirabello, et al. 2009b). Moreover, canine OS has a 
quicker progression than human OS (Owen 1967; Gordon and Khanna 2010) which offers an 
opportunity to study the response to different treatments (Guil-Luna, et al. 2015). 
The localisation of protein tumour markers in OS is significant for accurate diagnosis, 
prediction of prognosis, response to chemotherapy and metastases (Trieb, et al. 2003; Won, et 
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al. 2009). This project investigated the immunostaining of vimentin, ALP, desmin, S100, NSE, 
Runx2 and BMP4 in canine OS. Vimentin is important to distinguish OS from non-
mesenchymal tumours (Loning, et al. 1985; Leader, et al. 1987; Poradowski, et al. 2016), while 
ALP is used to differentiate OS from other mesenchymal tumours such as synovial cell sarcoma 
fibrosarcoma and chondrosarcoma (Barger, et al. 2005). Localisation of desmin, S100 and NSE 
are linked with OS (Hasegawa, et al. 1997; Trihia and Valavanis 2012; Mandal, et al. 2014) 
but with low specificity and sensitivity as they are also expressed by other cancers such as 
rhabdomyosarcomas, chondroblastoma and Ewing's sarcoma respectively. (Dias, et al. 1987; 
Fanburg-Smith and Miettinen 1999; Gao and Kahn 2005). The overexpression of both Runx2 
and BMP4 is correlated with a poor prognosis in OS (Yoshikawa, et al. 1988; Yoshikawa, 
Rettig, et al. 1994; Andela, et al. 2005; Won, et al. 2009). This panel of protein markers might 
help in differential diagnosis of both canine and human OS. 
In addition to OS, previous studies have found that dog models might be good animal 
models to study many types of human cancers including lymphoma, leukemia, transitional cell 
carcinoma (TCC) and mammary cancer. For instance, human and canine non-Hodgkin 
lymphoma (NHL) share similar biologic behaviours such as drug resistance and response to 
standard chemotherapy (Hansen and Khanna 2004). Use of canine lymphoma models in 
clinical trials supports this assertion (Rowell, et al. 2011). Due to the similarities between 
canine and human B-cell NHL, including response to chemotherapy and diagnostic features, 
dogs were enrolled in a clinical study to investigate the effect of Bruton’s tyrosine kinase 
(BTK) inhibitor on B-cell activation (Honigberg, et al. 2010). The data collected from the eight 
dogs enrolled in this study showed that canine NHL is a valid model to test this inhibitor (PCI-
33380) (Honigberg, et al. 2010). 
Moreover, studies showed that human and canine chronic lymphocytic leukemia (CLL) 
share a similar genetic abnormality in Rb1 gene (Dohner, et al. 2000; Breen and Modiano 
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2008). Analogous to human acute lymphocytic leukemia (ALL), canine ALL has feline 
McDonough sarcoma (fms)-like tyrosine kinase 3 (FLT3) point mutations that are associated 
with a poor prognosis (Gilliland and Griffin 2002; Usher, et al. 2009). A further study showed 
that the mutation of FLT3 was involved in the regulation of MAP and JAK/STAT kinase 
signalling pathways in canine ALL (Suter, et al. 2011).  
Human invasive high-grade TCC and canine TCC share similar clinical, biological and 
histological features (Knapp, et al. 2014). It has been also shown that overexpression of 
cyclooxygenase (COX)-2 was detected in both human and canine invasive TCC and carcinoma 
in situ and this suggests that canine TCC might be a good model for the study of human disease 
(Mohammed, et al. 2002; Knapp, et al. 2014).  
Similar to humans, mutations in BRCA1 and BRCA2 and decreased expression of Her-
2 protein with negative estrogen receptor (ER) and positive basal cell markers (cytokeratin 5, 
P-cadherin and p63) are present in canine mammary tumours (Gama, et al. 2008; Rivera, et al. 
2009). Given the similarities in mammary cancer and the other above-mentioned cancers 
between humans and dogs, dogs might be a suitable animal model to study the biology of 
human cancers in general and to possibly identify novel therapies. 
6.1.2 PTHR1 is a prognostic indicator for poor prognosis in canine OS 
Previous studies have shown differences in cell proliferation, migration and invasion 
associated with knockdown or overexpression of PTHR1 in OS (Yang, et al. 2007; Ho, et al. 
2015) . It has been demonstrated that knockdown of PTHR1 in murine OS cells decreased cell 
growth and invasion and increased tumour differentiation (Ho, et al. 2015). Yang, et al. (2007) 
also noted that increased expression of PTHR1 in human OS xenografts was linked with the 
formation of a more aggressive phenotype of OS that had increased cell migration, invasion 
and proliferation. PTHR1 was more highly expressed in clinical samples of metastatic human 
OS compared to the primary tumours (Yang, et al. 2007). 
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PTHR1 may predict the aggressiveness of OS related to metastasis or rapid tumour 
growth and hence have value as a prognostic indicator. Based on risk, PTHR1 immunostaining 
may be used to categorise OS patients into different groups. It might also assist oncologists in 
assessing whether the patient has an OS tumour that is rapidly growing and to identify patients 
with a high risk for pulmonary metastases. This assessment could allow those OS patients with 
a higher risk to receive specific chemotherapy and/or more intensive treatments. Moreover, 
this evaluation might aid in personalising treatment, which would improve the quality of life 
for each OS patient. Patients with OS tumours exhibiting strong staining for PTHR1 may 
receive a more aggressive chemotherapy regimen than those with moderately staining OS 
tumours who may receive a different regimen. Patients with weak staining for PTHR1 in their 
OS tumours may receive a less aggressive regimen of chemotherapy. Risk-adapted 
categorisation would improve the quality of life for both dogs and possibly humans. Future 
new therapeutic chemotherapy that targets PTHR1 in OS tumour tissue may reduce the tumour 
growth, decreasing the possibility for metastases and therefore prolong the survival time of 
those patients. 
6.1.3 Histological sub-classification of canine OS might influence prognosis 
Previous studies on humans (Bentzen, et al. 1988; Kaste, et al. 1999; Szendroi, et al. 
2000; Ferrari, et al. 2001; Hauben, et al. 2002; Bacci, et al. 2006; Paparella, et al. 2013) and 
dogs (Kirpensteijn, et al. 2002; Loukopoulos and Robinson 2007) have shown that the three 
histological subtypes of OS might be different with regards to metastatic capacities, responses 
to chemotherapy and tumour grade. In dogs, it was reported that osteoblastic OS developed 
metastases earlier than other subtypes (Kirpensteijn, et al. 2002). Canine osteoblastic and 
chondroblastic OS frequently show features of high grade tumours, while fibroblastic OS 
shows less pleomorphy (low grade) (Loukopoulos and Robinson 2007). Evidence from some 
studies have shown that humans with fibroblastic OS had better survival rates compared to 
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those with osteoblastic or chondroblastic OS (Bentzen, et al. 1988; Ferrari, et al. 2001; 
Paparella, et al. 2013).  Szendroi, et al. (2000) also noted that an increase in the amount of 
chondroid tissue in human OS correlated with decreased survival rates. Moreover, it has been 
shown that  human chondroblastic OS is more chemoresistant when compared to fibroblastic 
OS (Hauben, et al. 2002; Bacci, et al. 2006). In humans, Kaste, et al. (1999) showed that 
pulmonary metastases were commonly seen in patients with osteoblastic OS followed by those 
with chondroblastic OS. 
In both species, prognostic indicators would help in predicting survival and overall 
outcome (Selvarajah and Kirpensteijn 2010). The histological subtype of OS might be a useful 
prognostic marker if it can be correlated with specific responses to chemotherapy, histological 
features and metastatic potential. It may also help in categorising patients into various groups 
based on risk. In addition, the histological subtype of OS might be a useful predictive factor 
because it could guide clinicians to evaluate whether the patient will respond to specific 
therapies. The ability of the histological subtype of OS to identify patients with higher risk for 
pulmonary metastasis or those with a poorer response to chemotherapy may be crucial, as novel 
or more intensive treatment protocols become available for such patients in the future. 
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6.2 Study limitations 
Despite the novel findings presented in this dissertation, there were limitations. The 
small sample size was a limitation, especially for the smaller population of dogs (ASAP-20 
group) with similar inclusion criteria (diagnosed with appendicular OS, had limb amputation, 
went through adjuvant chemotherapy, had no pulmonary metastasis at presentation and died 
because of OS). Also, there were small numbers with uncommon subtypes of canine OS 
(chondroblastic and fibroblastic OS) and with OS tumours that were weakly positive for 
PTHR1. 
One reason behind the small number of dogs included in the survival rate analysis could 
be the inability or unwillingness of some owners to cover the cost for treatment resulting in an 
increased number of dogs with no surgical treatment or chemotherapy. As a prospective sample 
collection, there was no positive selection for specific subtypes of canine OS or for canine OS 
tumours that would be weakly positive for PTHR1. Due to the difficulty in obtaining sufficient 
clinical samples and time limitations, it was not possible to analyse human OS samples in 
parallel with the canine OS samples in this study. So, comparisons between canine OS were 
restricted to published information on human OS. Another limitation of the current study was 
the limited availability of canine OS tissue material for protein extraction that would have been 
needed to carry out quantitative analysis of PTHR1 protein expression using techniques such 
as western blotting. Follow up of dogs through intermittent visits to the treating veterinarians 
but not via radiographs or routine blood tests was a barrier for collecting data in regards to the 
pulmonary and lymph node metastases and tumour recurrence. In addition, some important 
data such as the measurements of serum ALP, radiograph reports, body weight and tumour size 
were not always available from most of the veterinary clinics and it was impossible to get these 
data when the dogs had died.  
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6.3 Future directions 
Comparative studies that investigate the localisation of important protein tumour 
markers in canine and human OS using a larger size and a larger panel of tumour markers 
would help in validating canine OS as a suitable model to study human OS. Future studies 
could use modern molecular sequencing techniques such as single cell sequencing to study the 
expression of these proteins in canine and human OS in biopsy material. 
The current study showed that overexpression of PTHR1 is correlated with decreased 
survival times in canine OS. Hence, future experiments using larger sample sizes would be 
useful to investigate the association between the expression of the PTHR1 protein and gene, 
expression of adhesion molecules, metastasis, angiogenesis, tumour grade and size in canine 
and human OS in vivo and in vitro. This will give a clearer picture of the role of PTHR1 in OS 
and it would help to better understand this disease. In addition, a long-term treatment clinical 
study using small molecules that target PTHR1 in dogs would confirm the findings of the 
current study and could lead to novel therapies, which would improve the quality of life for 
patients. 
Future studies should seek to increase the sample number in the groups of rare canine 
OS subtypes such as fibroblastic and chondroblastic OS to evaluate and confirm the prognostic 
value of the histological sub-classification. In addition, investigating gene mutations that may 
occur in specific histological subtypes of OS would improve our understanding of this disease. 
This may lead to each subtype having a specific treatment regimen. It would be better to follow 
dogs with OS until death via blood tests and radiographs. This would allow the collection of 
more information in regards to the progression and prognosis of the disease. 
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6.4 Conclusions   
Taken together, the series of experiments carried out in the current study have 
contributed to a better understanding of canine OS. It is demonstrated that localisation of 
vimentin, ALP, desmin, S100, NSE Runx2 and BMP4 in canine OS is similar to the profile 
reported for human OS. This indicates that humans and dogs share a comparable protein profile 
of tumour markers in OS. This study therefore supports the view that the dog model of OS is a 
suitable natural animal model for the study of human OS. 
Furthermore, the study has demonstrated that dogs with OS tumours displaying strongly 
expression of PTHR1 had shorter survival times compared with those with moderate or weak 
expression. Dogs with strongly positive OS tumours could be categorised as high risk, while 
those showing moderate immunostaining could be categorised as moderate risk and those with 
weak immunostaining could be categorised as low risk. This suggests that PTHR1 might play 
a critical role in the development of an aggressive phenotype in OS and it could be a promising 
target for therapy. 
It has been shown that dogs with fibroblastic OS might have longer survival times 
compared with those with other subtypes. Dogs with fibroblastic OS could be categorised as 
low risk, whereas those with chondroblastic or osteoblastic OS could be categorised as at higher 
risk. This could link the subtype of OS with the prognosis as well. These subtypes could have 
different genetic profiles and this could lead to potential new treatments. 
Overall, the study demonstrated that patients with OS tumours that show strong or 
moderate immunostaining of PTHR1 or those affected with chondroblastic or osteoblastic OS 
might be at a higher risk for cancer-related mortality compared with patients who have OS 
tumours that show weak immunostaining of PTHR1 or are affected with fibroblastic OS. 
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Appendix 1 
An electronic communication from Dr. Brad Hayward, Coordinator, Animal Ethics and 
Gene Modification Research Integrity, Governance & Systems, RMIT University, in regards 
to the approval request for an animal ethics application submitted for this thesis. 
 
 290 
 
Appendix 2 
Appendix Table 1. Clinicopathological data for the 50 dogs with OS included in the survival analysis (ASAP-50). 
# Sample 
number 
Breed 
size 
Sex Age Affected 
skeleton 
Body part Subtype of OS Metastasis Tumour 
grade 
Surgical 
treatment 
Chemotherapy Number 
of doses 
Survival 
time 
Cause of 
death cause  
PTHR1 
H-score 
PTHR1 
staining 
intensity 
PTHrP 
H-score 
PTHrP 
staining 
intensity 
ALP 
(U/L) 
1 14-
037753 
Large Female 12 Appendicular Humerus Osteoblastic No 1 No No 0 28 Euthanized 
because of OS 
102 Moderate 89 Weak N/A 
2 15-
002122 
Large Male 10 Appendicular Tibia Osteoblastic No 1 Yes Yes 5 90 Euthanized 
because of OS 
192 Moderate 180 Moderate 122 
3 15-
000337 
Large Male 1 Appendicular Humerus Osteoblastic No 1 Yes Yes 5 114 Euthanized 
because of OS 
183 Moderate 107 Moderate N/A 
4 15-
004566 
Large Male 11 Appendicular Femur Osteoblastic No 1 Yes Yes 6 458 OS 71 Weak 86 Weak N/A 
5 15-
007284 
Large Female 7 Axial Rib Chondroblastic No 1 No No 0 14 OS 118 Moderate 102 Moderate N/A 
6 15-
008150 
Large Male 10 Appendicular Tibia Osteoblastic No 1 Yes Yes 1 193 Euthanized 
because of OS 
127 Moderate 93 Weak 132 
7 15-
008475 
Large Male 8 Appendicular Radius Osteoblastic No 1 Yes Yes 4 702 OS 57 Weak 78 Weak N/A 
8 15-
010816 
Large Male 7 Appendicular Radius Osteoblastic No 2 Yes Yes 5 380 Euthanized 
because of OS 
177 Moderate 229 Strong 149 
9 15-
012826 
Large Female 10 Axial Rib Chondroblastic No 2 Yes Yes 4 240 OS 102 Moderate 77 Weak 48 
10 15-
013046 
Large Female 11 Appendicular Radius Osteoblastic No 2 Yes Yes 1 485 OS 183 Moderate 183 Moderate 35 
11 15-
013389 
Large Female 8 Axial Jaw Osteoblastic No 1 No No 0 83 OS 270 Strong 165 Moderate N/A 
12 15-
017138 
Small Male 10 Axial Rib Osteoblastic Yes 2 Yes Yes 5 71 Euthanized 
because of OS 
251 Strong 125 Moderate 163 
13 15-
018237 
Small Male 11 Axial Rib Fibroblastic Yes 2 No No 0 4 Post-surgical 
complication 
141 Moderate 130 Moderate N/A 
14 15-
018398 
Large Female 10 Appendicular Tibia Osteoblastic No 1 Yes Yes 1 240 Euthanized 
because of OS 
161 Moderate 100 Weak N/A 
15 15-
021281 
Large Male 8 Appendicular Humerus Chondroblastic No 1 No No 0 150 OS 168 Moderate 100 Weak N/A 
16 15-
027771 
Large Female 9 Axial Jaw Osteoblastic No 1 No No 0 157 Euthanized 
because of OS 
161 Moderate 143 Moderate N/A 
17 15-
029120 
Large Male 8 Appendicular Humerus Chondroblastic No 1 No No 0 65 OS 125 Moderate 107 Moderate N/A 
18 15-
031333 
Large Male 14 Appendicular Femur Osteoblastic No 2 Yes No 0 115 Euthanized 
because of OS 
156 Moderate 171 Moderate 168 
19 15-
031920 
Large Male 9 Appendicular Ilium  Chondroblastic Yes 1 No No 0 1 Post-surgical 
complication 
256 Strong 100 Weak N/A 
20 15-
033659 
Large Male 9 Appendicular Radius Chondroblastic No 1 No No 0 104 Euthanized 
because of OS 
131 Moderate 119 Moderate N/A 
21 15-
035311 
Large Female 7 Appendicular Radius Osteoblastic No 2 Yes Yes 1 277 OS 109 Moderate 91 Weak N/A 
22 15-
037769 
Small Male 8 Axial Jaw Osteoblastic No 2 No No 0 21 OS 191 Moderate 117 Moderate N/A 
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23 15-
038132 
Large Female 4 Appendicular Humerus Chondroblastic No 2 Yes Yes 5 96 Euthanized 
because of OS 
175 Moderate 122 Moderate 83 
24 15-
038424 
Large Male 12 Appendicular Tibia Chondroblastic No 1 No No 0 150 OS 183 Moderate 178 Moderate N/A 
25 15-
040082 
Large Male 13 Axial Jaw Fibroblastic No 1 Yes Yes 5 180 Still alive 135 Moderate 175 Moderate 125 
26 15-
040499 
Large Male 6 Appendicular Femur Fibroblastic No 2 Yes Yes 5 470 OS 113 Moderate 92 Weak N/A 
27 15-
041042 
Small Female 12 Appendicular Humerus Osteoblastic No 1 Yes Yes 5 155 OS 203 Strong 174 Moderate N/A 
28 14-
004994 
Large Female 15 Axial Jaw Fibroblastic No 1 Yes Yes 5 43 OS 213 Strong 175 Moderate N/A 
29 14-
008304 
Small Female 9 Appendicular Scapula Osteoblastic No 2 No No 0 27 Euthanized 
because of OS 
238 Strong 164 Moderate N/A 
30 14-
008343 
Large Male 11 Appendicular Humerus Fibroblastic No 1 Yes Yes 5 578 OS 167 Moderate 158 Moderate N/A 
31 14-
010496 
Small Male 10 Appendicular Humerus Osteoblastic No 2 Yes Yes 5 26 OS 240 Strong 160 Moderate N/A 
32 14-
012229 
Large Male 13 Axial Jaw Osteoblastic No 2 No No 0 21 Euthanized 
because of OS 
228 Strong 187 Moderate N/A 
33 14-
017342 
Large Male 6 Appendicular Femur Osteoblastic No 2 No No 0 17 Euthanized 
because of OS 
204 Strong 136 Moderate N/A 
34 14-
024545 
Large Male 3 Axial Rib Chondroblastic No 2 No No 0 11 Euthanized 
because of OS 
213 Strong 172 Moderate N/A 
35 14-
024898 
Large Female 9 Appendicular Radius Osteoblastic No 1 No No 0 17 Euthanized 
because of OS 
210 Strong 139 Moderate N/A 
36 14-
025291 
Large Female 9 Appendicular Humerus Osteoblastic No 2 Yes Yes 5 270 OS 165 Moderate 140 Moderate N/A 
37 14-
026101 
Large Female 13 Appendicular Scapula Chondroblastic No 2 No No 0 135 OS 143 Moderate 102 Moderate N/A 
38 14-
027000 
Large Male 12 Axial Vertebrae  Osteoblastic No 1 Yes No 0 54 OS 218 Strong 112 Moderate N/A 
39 14-
027310 
Large Female 9 Appendicular Ilium  Osteoblastic No 2 No No 0 3 Post-surgical 
complication 
194 Moderate 150 Moderate N/A 
40 14-
029531 
Small Male 13 Axial Jaw Osteoblastic No 2 No No 0 47 Euthanized 
because of OS 
298 Strong 270 Strong N/A 
41 14-
033242 
Large Female 9 Appendicular Humerus Chondroblastic No 2 Yes Yes 5 76 OS 245 Strong 179 Moderate 107 
42 14-
037120 
Large Male 6 Appendicular Radius Osteoblastic No 1 Yes Yes 1 82 Euthanized 
because of OS 
278 Strong 148 Moderate N/A 
43 16-01259 Large Female 11 Appendicular Tibia Osteoblastic No 2 Yes Yes 1 288 Euthanized 
because of OS 
169 Moderate 273 Strong N/A 
44 16-06044 Large Female 11 Appendicular Humerus Osteoblastic No 1 Yes Yes 5 90 Euthanized 
because of OS 
240 Strong 255 Strong N/A 
45 16-07903 Large Female 7 Axial Skull Osteoblastic No 1 No No 0 24 Euthanized 
because of OS 
254 Strong 214 Strong N/A 
46 16-09653 Large Male 8 Appendicular Humerus Osteoblastic Yes 2 No No 0 14 Euthanized 
because of OS 
262 Strong 222 Strong 100 
47 16-09960 Small Male 14 Axial Jaw Osteoblastic No 2 No No 0 154 Still alive 248 Strong 228 Strong N/A 
48 16-
99752360 
Large Male 7 Appendicular Femur Osteoblastic No 1 No No 0 7 Post-surgical 
complication 
278 Strong 283 Strong N/A 
49 16-02417 Large Male 11 Appendicular Femur Fibroblastic No 1 Yes Yes 5 655 OS 145 Moderate 164 Moderate 50 
50 16-
99760256 
Large Male 7 Appendicular Humerus Osteoblastic No 1 No No 0 142 Still alive 229 Strong 220 Strong 56 
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Appendix 3 
Appendix Table 2. The immunostaining evaluation and image scoring for vimentin, ALP, 
desmin, S100, NSE, Runx2 and BMP4 using CellSens Dimension Microscope Imaging 
Software (Bristol-56). 
Case 
number 
Percentage of neoplastic cells stained positively using IHC (%)* 
 Vimentin ALP Desmin S100 NSE Runx2 BMP4 
1 100 98 0 45 0 100 100 
2 98 100 50 0 20 88 100 
3 100 100 55 70 44 100 100 
4 100 100 0 0 24 80 98 
5 75 100 0 0 50 55 100 
6 100 96 0 0 35 70 100 
7 100 100 0 0 30 85 100 
8 100 98 0 54 54 55 100 
9 100 100 0 0 0 50 100 
10 100 100 0 0 0 100 100 
11 100 100 44 22 26 100 100 
12 100 100 0 0 50 54 100 
13 100 100 0 0 0 100 95 
14 95 100 0 0 70 75 100 
15 80 98 0 0 0 54 98 
16 100 100 50 0 0 100 98 
17 100 100 0 0 48 50 100 
18 100 100 0 0 0 78 88 
19 100 100 0 0 26 76 100 
20 100 100 60 0 42 80 100 
21 100 98 35 0 40 100 100 
22 85 100 0 0 22 100 100 
23 100 96 0 0 35 100 100 
24 90 85 0 0 0 70 100 
25 95 100 0 0 48 88 80 
26 88 100 34 0 0 98 100 
27 100 100 0 0 52 100 100 
28 80 98 0 0 0 46 98 
29 94 98 0 0 0 78 100 
30 100 100 0 0 50 76 100 
31 100 96 0 0 35 100 96 
32 100 100 0 20 0 80 85 
33 100 88 0 0 44 100 100 
34 98 90 44 0 0 55 100 
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35 90 100 0 0 0 98 100 
36 100 100 0 55 0 90 100 
37 96 100 60 48 0 98 100 
38 100 98 0 0 68 100 100 
39 100 98 0 0 46 58 95 
40 100 100 45 34 35 65 100 
41 100 100 0 0 0 60 98 
42 88 98 0 0 40 78 96 
43 90 100 0 0 22 90 100 
44 98 96 0 0 50 98 100 
45 98 100 0 0 0 100 100 
46 100 100 0 15 32 55 95 
47 96 100 0 0 0 100 100 
48 100 100 0 0 0 100 100 
49 100 100 0 0 0 78 95 
50 88 100 0 0 0 96 100 
51 98 100 50 0 20 100 98 
52 100 100 0 0 45 58 98 
53 96 98 22 0 48 68 100 
54 98 100 0 0 0 100 100 
55 100 96 20 0 0 98 100 
56 100 100 0 0 30 96 100 
ALP, alkaline phosphatase; NSE, neuron-specific enolase; Runx2, Runt-related protein 2; BMP4, Bone 
morphogenetic protein 4. *Negative staining, percentage of positive stained cells < 1%; positive staining, 
percentage of positive stained cells >1%.  
 
